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ABSTRACT
Cell-based therapies, which rely on transplanted cells to restore function to damaged
tissues, are currently under investigation in clinical trials. Stem and progenitor cells, including
mesenchymal stem cells (MSCs), have shown potential in pre-clinical models to treat diseases
ranging from connective tissue defects, through differentiating into bone or cartilage forming
cells, to inflammatory conditions, through suppressing activated immune cells. While the ability
of stem cells to differentiate into multiple lineages, secrete trophic factors, and modulate
inflammatory processes has made them applicable to many diseases, these diverse functions also
pose challenges in controlling their phenotype. In this thesis a new platform technology to
influence the phenotype of cells is described and used to solve three critical challenges in MSC-
based therapies, controlling MSC differentiation, tracking cells, and enhancing MSC's
immunomodulatory potency. MSCs were found to efficiently and stably internalize micron-sized
biodegradable particles. The platform can be tuned to specific applications through incorporation
of phenotype altering drugs or other payloads into particles. In the first study, particles were
loaded with a small molecule drug, dexamethasone (DEX), that induces MSC osteogenic
differentiation. Modification of MSCs with DEX-particles resulted in differentiation of particle-
laden cells to the same extent as those grown in osteogenic media. Furthermore, DEX was
released from the cells in sufficient quantities to influence neighboring and distant cells
demonstrating the particle platform can influence both the modified cell and its
microenvironment. Next, the platform was adapted to address the need for longitudinal tracking
of MSCs. Loading iron oxide nanoparticles in the microparticles resulted in enhanced tracking of
MSCs by MRI from 6 days with nanoparticles alone to beyond 12 days with iron oxide
microparticles. Finally, the novel discovery that glucocorticoid steroids significantly increase the
immunomodulatory potency of MSCs by up-regulating expression of indoleamine-2,3-
dioxygenase (IDO) is reported. Loading MSCs with particles containing the glucocorticoid
steroid, budesonide, doubled their potency in suppressing activated peripheral blood
mononuclear cell co-cultures in an IDO dependent manner. While the platform presented here
was used to control, track, and augment MSCs, it can easily be tailored to control the function of
other therapeutically relevant cells to develop next-generation cell-based therapies.
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Chapter 1 Preface
The purpose of this chapter is to introduce the reader to mesenchymal stem cells
(MSCs), the state of MSC based therapies at the beginning of my thesis research.
Included is a thorough introduction to MSC phenotype including cell surface markers,
differentiation potential, and expression of therapeutic factors, as well as citations to
seminal papers in the field. Data regarding when, where, and how MSCs are being used
in clinical trials is also included to orient the reader to the context in which MSC therapy
is in use. The chapter closes with a list of outstanding questions regarding MSC therapy
that have served as a driving force for my research during my PhD.
This article is an adaptation of a peer-reviewed article published on March 23, 2010 in
Trends and Molecular Medicine. Reprinted with permission.
Ankrum J, Karp J. (2010). Mesenchymal stem cell therapy: Two steps forward, one step
back. Trends Mol Med, 16(5), 203-9.
Glossary of Terms
Allogeneic: Cells originate from a donor of the same species as the recipient
Autologous: Donor cells originate from the recipient
Xenograft: Cells originate from a donor of a different species than the recipient
Alu Sequences: A repetitive sequence of several hundred base pairs that occur
frequently in primate genomes
Endocrine Signaling: Secreted factors exert effect on distant cells
Paracrine Signaling: Secreted factors exert effect on neighboring cells
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Chapter 1: Mesenchymal Stem Cell Therapy: Two steps
forward, one step back
Abstract
Mesenchymal stem cell (MSC) therapy is poised to establish a new clinical
paradigm, however, recent trials have produced mixed results. While MSC were
originally considered to treat connective tissue defects, preclinical studies revealed
potent immunomodulatory properties that prompted the use of MSC to treat numerous
inflammatory conditions. Unfortunately, while clinical trials have met safety endpoints,
efficacy has not been demonstrated. We believe the challenge to demonstrate efficacy
can be attributed in part to an incomplete understanding of the fate of MSC following
infusion. Here, we highlight the clinical status of MSC therapy and discuss the
importance of cell-tracking techniques, which have advanced our understanding of the
fate and function of systemically infused MSC and might improve clinical application.
Introduction to MSC Therapy
Imagine a simple intravenous cell therapy that can restore function to damaged
or diseased tissue, avoid host rejection and reduce inflammation throughout the body
without the use of immunosuppressive drugs. Such a breakthrough would revolutionize
medicine. Fortunately, pending regulatory approval, this approach might not be far off.
Specifically, cell therapy utilizing adult mesenchymal stem cells (MSC), multipotent cells
with the capacity to promote angiogenesis, differentiate to produce multiple types of
connective tissue and downregulate an inflammatory response, are the focus of a
multitude of clinical studies currently underway. MSC are being explored to regenerate
damaged tissue and treat inflammation, resulting from cardiovascular disease and
myocardial infarction (MI), brain and spinal cord injury, stroke, diabetes, cartilage and
bone injury, Crohn's disease and graft versus host disease (GvHD) (1). The problems,
however, are that some recent late stage clinical trials have failed to meet primary
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endpoints, and the fate of MSC following systemic infusion as well as the mechanisms
through which they impact host biology are largely unknown(2).
In this chapter, we will highlight the recent paradigm shift that has occurred in
therapeutic use of MSC based on their immunomodulatory properties as opposed to
their multilineage differentiation capacity. We discuss the clinical state of MSC therapy
in addition to cell-tracking techniques that have been developed with in vivo models to
elucidate the mechanisms through which MSC provide a therapeutic effect.
MSC Phenotype
While they have donned many names, i.e. mesenchymal stem cells,
mesenchymal stromal cells, multipotent stromal cells, marrow stromal cells, and colony-
forming unit-fibroblastic, MSC were originally described as adherent cells from bone
marrow that form colonies(3). Later these cells were found to have multilineage
differentiation potential as they could form connective tissue cell types capable of
producing bone, adipose and cartilage (4). The International Society for Cellular
Therapy (ISCT) defines human MSC as tissue culture plastic adherent cells capable of
osteogenesis, adipogenesis and chondrogenesis that are positive for CD73, CD90, and
CD105 but negative for CD11b, CD14, CD34, CD45, CD79a, and HLA-DR surface
markers (5). Despite these guidelines, characterizing and defining the MSC phenotype
represents an ongoing challenge (2, 6, 7). Bone marrow-derived MSC are a
heterogeneous population of cells and MSC characteristics such as surface marker
expression, proliferation rate and differentiation potential are dependent on passage,
cell density and the cell culture media(7). The discovery of MSC in fat and virtually all
other mature tissues(8) has introduced additional nuances in that MSC properties seem
to depend on the tissue from which they are isolated (7). Although MSC were initially
considered for therapy based on their multi-lineage differentiation capacity, their ability
to secrete cytokines and growth factors that are anti-apoptotic, pro-angiogenic and have
the potential to reduce scarring and inflammation have positioned MSC for a broader
spectrum of clinical applications (9). In particular, the use of MSC to down-regulate
inflammation offers significant therapeutic potential for treating inflammatory diseases.
Specifically, MSC possess the ability to reduce B-cell proliferation, monocyte maturation
I I
and secretion of interferon (INF)-y and TNF-a while promoting T-regulatory cell
induction and secretion of IL-10 (10, 11). Table 1 presents a summary of MSC traits and
properties.
Table 1. Reported MSC Characteristics (Adapted from (12))
Surface Differentiation Therapeutic
Markers Potential Factors
CD44+ Osteogenic VEGF, Ang-1, SDF-
CD73 + Adipogenic 1, PDGF, TSG-6,
CD90 + Chondrogenic bFGF, FGF-7, IL-1ra,
CD105 + Myogenic IL-6, PIGF, MCP-1,
CD11b- Endothelial TGFP, PGE-2, IDO,
CD14 - Epithelail M-CSF, HGF, MMP-
CD34 - Neuronal 9, Sfrp, Thymosin P4,
CD45 - (1, 4, 7) Plasminogen
CD79a - activator, Tenacin C,
HLA-DR - Thrombospondin 1
(5, 13) (9-11, 14, 15)
Paradigm shift in the use of MSC for therapy
While the initial applications conceived for MSC therapy focused on their
multilineage differentiation capacity, and more specifically on the potential of MSC to
differentiate into osteogenic cells that produce bone tissue as a treatment for fractures,
osteogenesis imperfecta or spinal fusion, recent clinical trials have focused almost
entirely on the ability of MSC to exert their biological function through trophic
mechanisms, including the secretion of cytokines that might serve both paracrine and
endocrine functions (14-17). This shift stemmed from observations that MSC therapy
resulted in reduction of inflammation, apoptosis and fibrosis in numerous disease
models despite a lack of MSC differentiation and engraftment in the injured tissue. Thus
it was hypothesized that regeneration must be due to trophic factors rather than
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differentiation as reviewed by van Poll et al (18). This paradigm shift towards utilizing
trophic properties of MSC for therapy also included a shift from local delivery of MSC to
systemic administration, which is less invasive and more convenient, especially for
multiple dosing regimens. However, similar to bone marrow transplantation, where a
small percentage of the total hematopoietic stem cells that are infused reach the bone
marrow (19, 20), only a small percentage of the infused MSC (often <1%) reach the
target tissue with cell entrapment commonly observed in capillaries within the liver,
spleen and lung (1).
Clinical State of MSC Therapy
Mixed results from recent clinical trials have evoked promise and
discouragement from both the scientific and clinical communities. Early studies
demonstrating that MSC modulate immune function in human (21) and mouse (22) in
vitro cultures and within rodent models generated optimism for the prospect of treating
some of the most chronic and elusive inflammatory conditions in the developed world.
For example, numerous groups have shown reduced scarring and increased cardiac
output following MSC therapy in animal models of MI (23-25). A recently completed
phase I trial, using a single infusion of allogeneic MSC (Osiris Therapeutics, Inc.
Prochymal"'N' product) in patients within 10 days of acute MI corroborates these findings
(26). In the randomized placebo-controlled, dose-escalating trial, patients receiving
MSC experienced a 4-fold decrease in arrythmias and premature ventricular
contractions (PVC), and showed improved overall health compared to patients receiving
placebo. Magnetic resonance imaging of a subset of patients one year post-treatment
revealed a significant increase in left ventricular ejection fraction (LVEF). Interestingly,
an increase in the dose of MSC reduced the rate of PVC but not any of the other
metrics. Importantly, there were no significant adverse events, and thus, this trial
validated the safety of allogeneic MSC; however, the viability of MSC post-treatment
and the role of MSC in the recovery of cardiac function remain to be elucidated. These
results should be considered with cautious optimism; the BOOST trial, which assessed
intracoronary delivery of MSC, initially showed significant improvement in LVEF over
control, but this difference was not significant after 18 months (27), thus long-term follow
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up of intravenous MSC therapy is needed. A phase 11 trial using MSC to treat GvHD
reported a reduced 2-year mortality rate (28). These promising results provided
significant motivation for large-scale, placebo-controlled clinical trials. While phase I and
11 safety trials progressed without severe adverse events, the phase Ill randomized,
placebo-controlled trials failed to reach their primary endpoints. These trials utilized
MSC as a first- and second-line therapy to treat GvHD and steroid-refractory GvHD,
respectively (29). Interestingly, these trials illuminated the significant placebo effect that
is common with stem cell-based therapies. It is important to consider that the placebo
effect has the potential to mask modest therapeutic efficacy. Treatment resulted in a
statistically significant improvement over those receiving placebo in patients with
steroid-refractory liver or gastrointestinal GvHD and a clinically significant improvement
over controls among pediatric patients(29). Further analysis of the data is ongoing. A
trial targeting Chronic Obstructive Pulmonary Disease (COPD) with Prochymal" is
underway and preliminary data (gathered 6 months after treatment) showed reduced
systemic inflammation compared to controls as measured by C-reactive protein, but
there was no significant improvement in pulmonary function (30). Although the mixed
clinical data could be considered a major setback to the entire MSC field, these trials
extended initial phase I safety data to thousands of patients, and we believe this should
be considered a critical milestone, especially given that typical doses include hundreds
of millions of allogenic MSC. It is also important to consider that it took several decades
to optimize bone marrow transplantation before it became a standard of care. Thus, we
need to focus on reaching the challenges that were highlighted by these clinical trials,
which likely stem from our lack of understanding of the fate of MSC following systemic
infusion. Enhanced understanding of fundamental MSC biology should allow more
systematic engineering approaches to reduce variability and achieve higher efficacy.
It is possible that the inability to meet primary clinical endpoints resulted from a
low efficiency of engrafted cells, which is often described in animal models(2), that
reduces the potential for long-term availability of immunomodulatory cytokines.
Intriguingly, positive data have emerged from clinical trials despite the lack of data
supporting long-term survival and engraftment of systemically delivered MSC. This
could result from the dominant use of allogenic MSC in animal studies and human trials
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(see Table 2 for the source of MSC used in clinical trials), which may be recognized and
quickly disposed of by the host immune system. Hare and colleagues (University of
Miami, FL) are currently recruiting patients to determine if autologous MSC exhibit
enhanced therapeutic efficacy compared to allogeneic MSC in a National Institutes of
Health-funded study for heart failure. In addition to these considerations, it is also
possible that once introduced into the body, MSC do not secrete the same repertoire or
concentration of cytokines that have been observed in vitro. The lack of data supporting
long-term engraftment and the limited knowledge of cell fate for systemically
administered MSC could be due to a lack of sufficient technologies to monitor MSC fate
in vivo, an area we believe deserves attention.
Monitoring MSC fate in vivo
A large fraction of systemically infused MSC typically become trapped within the
lungs as emboli due to their large size and their repertoire of cell-surface adhesion
receptors (31-34). Alternatively, they arrest and interrupt blood flow during the first pass
through the precapillary level (35). Such passive arrest prevents the majority of infused
MSC from homing to damaged or diseased tissues. Despite these complications,
numerous animal studies and some clinical trials have reported favorable outcomes
following systemic infusion of MSC (23, 28, 36-38). The lack of specific homing is
perhaps why high dosing is used in clinical trials; 150-300 million MSC are typically
administered with each infusion (39). This prompts the questions: can entrapped MSC
transmigrate through the endothelium; how long do the entrapped MSC survive; and
can they provide benefit to distant organs? Several recent publications have attempted
to address these questions.
Lee and colleagues used a cross-species experimental design and real-
time PCR (rtPCR) to track the fate of systemically administered human MSC in a mouse
model(15). rtPCR analysis for human-specific Alu sequences in blood samples showed
that within 5 minutes of MSC infusion through the tail vein, 99% of MSC were cleared
from the circulation. Within 10-30 minutes, a resurgence of -2-3% of the infused MSC
was observed within the blood stream. Tissue samples from various organs revealed
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that the majority of cells were initially found in the lung, which was consistent with
previous studies(31, 33). Fifteen minutes after infusion, 83% of the human DNA was
Table 2. State of Clinical Trials Using Exogenous MSCs (Adapted from (12))
Condition bv Orman Svstem
Multiple System.
GvHD
S*gren's Syndrome
SLE(Lupus)
BonWCartilage
Arthritis-Foot Fusion
Bone Fracture
Bone Neoplasms
Cartilage Defects
Meniscoctomy
Osteodysplasia
Osteogenesis imperfecta
Osteonecrosrs
Penodontitis
Spinal Fusion
Cardioveascular
Dilated Cardomyopath y
Heart Failure
Ischemic Heart Disease
Myocardial Infarcti on
Limb Ischemia
Gartrointesinal
Crohn's
*0dney
Acute Kidney Inlury
Kidney Transplant
Lupus Nephrifis
Liver
orthosis
Fam. Hypercholesterolemia
Lung
CoPD
Nervous
Multiple System Atrophy
Neuroblastoma
Spinal Cord Injury
Multiple Sclerosis
Parkinson's Disease
ALS
Stroke
Pancreas
Type I Diabetes
Type 2 Diabetes
Sidn
Diabetic Wounds
Systemic Sclerosis
Epidermolysis Bullosa
Total
Trials'(Patientil ANogeneic Autooermie TroohkI' Differentate" IVo Local
18 1wi7
16 (1027)
1(20)
1(20)
26(14871
1(100)
2 (210)
1(50)
4 (185)
2 (110)
2 (58)
3(35)
2 (51)
1 (10)
8(678)
191961)
2(80)
3(200)
3 (160)
7(428)
4 (83)
31400)
3 (480)
61136)
1 (15)
4 (107)
1 (20)
7(204)
6(203)
1 (1)
11601
1 (60)
1212941
I (NA)
T (15)
2 (103)
4 (84)
1(5)
1(24)
2 (63)
4 (210)
3 (10)
1(100)
6 (466)
3(360)
1 (20)
1 (75)
101 (5,344)
15 16
T
I
1
2
1
4
2
2
3
2
8
2
2
59 13.385)
2
2
2
6
4
3
1
4
T
2
6
1
2
3
2
IA'
16
1
3
1
7
2
4
2
8
2
3
3
3 4
3
3
4
3 3
2
4
11
3
11
3 2
42 11.959) 65 13,588) 36 11,756)
2 4
7
2
3 7
2
3
48 12.495)
Completed trials (n=21)
2005 2006 2007 2008 2009
2 8 8
Scheduled for completion In = 63)
2010 2011 2012
21 20 13
2013 2014 Not specified/other
5 1 17:4
16
3 1
49 (2.6831 5 1166)
11
1
1
1
7
Colors indicate number of studies with locations in that region
Least Most
Labels give exact study count
*Studies with multiple locations are reported in each region containing a location.
aData collected from ClinicalTrials.gov registry on 13 March, 2010. Searches for
'Mesenchymal Stem Cells', 'Mesenchymal Stromal Cells', 'Multipotent stromal cells',
'bone marrow stromal cells', 'Stem cells for Spinal Fusion', 'Prochymal', and 'connective
tissue progenitor' returned 142 unique results, and of those the 101 reported here used
exogenous delivery of MSCs. Based on information provided in the trial summary, it is
estimated that approximately 85% of trials utilize culture expanded cells. Excluded trials
involved expanded access to existing trials, recruitment of endogenous MSCs to sites of
injury, and others that did not pertain to MSC therapy.
bTrials were categorized as Trophic, if the rationale for the study was dependent on
MSC's pro-angiogenic, anti-apoptotic, or immune modulating properties. Trials were
categorized as Differentiate if the rationale depended on the differentiation of delivered
MSCs.
CIV, intravenous; IA, intra-arterial; Local, delivered in scaffold or injected directly into
target tissue.
dMap above displays global distribution of MSC clinical trials
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detected in the lung while only trace amounts were detected in other tissues. The
authors attempted to reduce lung entrapment by decreasing the number of infused
cells, blocking key adhesion integrins and pretreating the MSC with rat white-blood cells
(to sensitize them to Stromal Cell-Derived Factor-1); however, the fraction of trapped
MSC remained unchanged. Histological analysis revealed that the MSC formed emboli
in the afferent blood vessels of the lung, a common finding for systemic infusion of other
cell types including hematopoietic stem cells and endothelial progenitor cells (20, 40).
No MSC were found in the bone marrow, which contradicted other studies(32, 41) and
highlighted a potential shortcoming of PCR-based techniques, which could be
approximately 10-fold less sensitive than radiolabeling techniques (42-44).
Despite mass entrapment of systemically administered MSC within the lung and
other tissues, tail vein injection in rodent models of MI still provides a functional
improvement that is typically evidenced by decreased scar size and increased cardiac
output. In the seminal paper by Lee et al., a paracrine factor that is released by
embolized MSC was identified; this factor promotes tissue regeneration through a
systemic effect, similar to the action of a conventionally administered drug (15). A
transcriptome analysis of embolized MSC from the lungs generated a list of 451
upregulated transcripts with rtPCR analysis showing that TSG-6, a known anti-
inflammatory protein, had the largest increase in mRNA levels(15). TSG-6, which was
originally discovered by secretome analysis of skin fibroblasts following incubation with
tumor necrosis factor (TNF)-u (45), is a 30 kDa protein that inhibits neutrophil migration
and the production and activity of both plasmin and matrix-metalloproteinases
(MMPs)(46). Interestingly, MSC secretion of TSG-6 was 120-fold greater than that of
fibroblasts obtained from the same human donor (15). Two infusions of recombinant
TSG-6 following MI (without administration of MSC) decreased infarct size, reduced
scaring and improved cardiac function, yet not to the same extent as MSC. MSC with
TSG-6 knock down by RNA interference did not impact infarct size. The authors
hypothesized that the embolism of the MSC in the lung creates a local injury that
activates the MSC to secrete TSG-6, which enters circulation and downregulates the
inflammatory process at the site of MI. MI is characterized by invasion of neutrophils,
monocytes, and macrophages that secrete MMPs, breaking down the dead myocardium
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to replace it with a fibrous scar (23). MSC secretion of TSG-6 and infusion of
recombinant TSG-6 interrupted this process during the initial 48 hours of wound healing,
resulting in a reduced inflammatory process and improved regeneration of the infarcted
tissue. This study utilized xenografts; human MSC were injected into a murine model.
Xenografts have different distribution kinetics than allogeneic MSC in murine models
(43) (allogenic MSC are the standard for human clinical trials). Because Lee et al.'s
proposed mechanism for enhanced therapeutic efficacy depends on entrapment and
activation of xenogenic MSC in the lungs, allogeneic MSC, which have been shown in
mouse models to disperse from the lungs within hours of infusion, might produce
substantially different results.
In addition to PCR-based techniques for tracking the fate of systemically
administered MSC, alternative approaches leverage the advantages of light and
fluorescent microscopy that are well suited for small animal models. Lin's group has
characterized tumor-cell, hematopoietic stem cell, and MSC trafficking in the skull of
living mice using in vivo confocal and two-photon microscopy, which provide high-
resolution spatial delineation of a cell's location (32, 47, 48). Similarly, Toma and
colleagues utilized intravital microscopy, which permits detailed real-time and serial
imaging of in vivo phenomenon, to examine the entrapment of MSC within a
microvascular bed (35). In this model, the cremaster muscle of the rats was exposed
and fluorescently labeled MSC were injected into the iliac artery. The density of MSC in
varying depths of the vasculature was monitored over time using differential interference
contrast and fluorescence imaging. All MSC arrested within 5 minutes of injection with
92% of the injected MSC entrapped during the first pass within the cremaster muscle.
However, MSC were only trapped at the precapillary level, resulting in blockage of blood
flow to the capillary bed. The number of viable MSC in the cremaster muscle decreased
drastically over the next 72 hours; only 14% of those originally entrapped survived, as
determined by preserved nuclear morphology. As intravital microcopy is best suited for
monitoring cells within a pre-selected location, redistribution of the MSC to other tissues
is challenging to evaluate.
One method that can address this is bioluminescence imaging, which lacks
single-cell resolution, but enables whole-organism tracking of cell distribution. For
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example, Wang et al. used MSC expressing a firefly-luciferase reporter gene in
combination with bioluminescence imaging in a metastatic breast cancer model (49).
This allowed non-invasive whole-animal tracking of intravenously injected MSC and
their progeny over the course of several days. In healthy controls, MSC were initially
found in the pulmonary capillaries but quickly dispersed after one day. The reduction of
signal in the lungs can be attributed both to redistribution of MSC to other tissues as
well as to cell death. Bioluminescence can be extremely valuable in characterizing MSC
affinity and tropism for inflammatory and tumor microenvironments as has been
reviewed by Spaeth et al. (50).
Recent cell tracking studies have provided valuable insight into the distribution of
MSC following systemic infusion and have begun to help elucidate the process of cell
localization within specific tissues. However, it is critical to note that whole-animal
imaging techniques such as bioluminescence lack the resolution to determine if cells
remain in the vasculature or have undergone transendothelial migration. Aside from
passive cell entrapment, which appears to be a dominant mechanism through which
infused MSC reach their final destination, characterization of the host vasculature is
required to better understand active homing mechanisms. The vascular expression of
adhesion molecules and endothelial presentation of cytokines can vary substantial
within a vascular bed (48). Thus, future studies should aim to employ multiple methods,
summarized in Table 3, to assess the final destination of the infused cells through both
macroscopic distribution and microscopic spatial localization analysis.
Therapeutic implications and concluding remarks
The results from multiple clinical trials using systemically administered MSC
illuminate critical challenges that must be addressed; yet provide the young field of MSC
therapy with rationale for additional 'steps' forward. Importantly, work has already begun
to identify the fate and function of MSC following systemic infusion. With evidence for
massive cell entrapment in the lungs and in capillary beds of other tissues, approaches
are being developed to enhance cell homing to target tissues through genetic and
chemical engineering approaches(2, 54). It is possible that targeted delivery of cells is
unnecessary for certain applications, as the therapeutic effects of MSC are systemic,
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Table 3. Cell Monitoring Techniques (adapted from (12))
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Technique Detected Agent Detection Limit Temporal Whole Animal
Resolution
PCR(44) Sequence unique 50,000 cells Requires sacrifice Yes
to donor
Radiolabeling Isotope 5,000 cells 30 sec/projection Yes
(SPECT)(44)
Intravital Fluorescent Single Cell <1 sec No
Microscopy(13, marker, ie.
51) reporter gene,
antibody,
quantum dots
In vivo Fluorescent Single Cell <1 sec No
confocal(52) marker
Bioluminescence Luciferase gene 10 Cells <1 min Yes
Microscopy(53) + substrate
MRI(43) Magnetic 10-20 cells/voxel >10 min depending Yes
nanoparticles on size of region
however, enhanced delivery to specific tissues could increase the efficiency of cell
therapy and reduce the number of infused cells, potentially reducing the cost of
developing a therapeutic product. Conventional wisdom suggests that promoting
transmigration and longevity of MSC, perhaps even non-specifically, could increase
therapeutically relevant systemic effects (i.e. where engrafted cells continue to secrete
cytokines that are released into the circulation). Furthermore, extensive research is
needed to determine if the few MSC that have been reported to engraft in target
tissues(55) mediate regeneration through the alternate mechanism of differentiation and
whether or not these grafted cells integrate and coordinate with the native tissue to
restore function. With the discovery of secreted TSG-6 by MSC entrapped within the
lungs and knowledge of several other MSC-secreted immunomodulatory factors (Box
1), there is now evidence that the therapeutic effects could in part be due to systemic
(endocrine) effects in addition to previously described (local) paracrine signaling and
direct cell-cell interactions. For example, Nemeth et al. demonstrated that MSC in direct
contact with macrophages secrete prostaglandin E2 (PGE2), which reprograms
macrophages to increase production of the potent anti-inflammatory cytokine
interleukin-1 0 (IL-1 0) (10, 11).
The heterogeneity of the MSC population presents a challenge for generalizing
findings from different groups, as it is known that differences in culture conditions,
source, passage and cell density all impact MSC phenotype (56). Moving forward, it is
important to characterize the conditions needed to develop therapeutically relevant
cells, and in tandem, cell-tracking techniques that can be performed in large animal
models and in humans, which would enhance understanding of MSC engraftment, allow
long-term assessment of cell phenotype and ultimately increase therapeutic potential
(See Table 4 for outstanding questions in MSC therapy.). Furthermore, development of
such tracking technologies for animal models could make it possible to monitor cells
following systemic infusion into patients. Unlike conventional drugs, which are designed
to act through a known pathway, cell therapies are living therapeutics, which can
multiply, senesce, undergo necrosis or apoptosis, or alter their phenotype, and thereby
drastically change their therapeutic potential. The ability to track the location of cells and
monitor viability and functional characteristics (e.g. differentiation state) could provide
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Table 4. Outstanding Questions (Apapted from (12))
MSC Homing
- Which adhesion molecules mediate MSC homing?
MSC Monitoring
- What are the best approaches to monitor MSC therapy and how might
these approaches be connected to clinical interventions to improve the
therapeutic outcome?
- How should MSC distribution and phenotype be monitored in animals and
in humans?
MSC Fmnetion
* Iaddition to T34, ydtWQIC-lbagroWte akites havel systpmic, fects?
Therapy Optimization
- What are the optimal conditions to develop therapeutically relevant cells
(with increased homing potential and/or increased cytokine production)?
- Can MSC be replaced by MSC supernatant and how might the supernatant
be standardized?
- Can MSC therapy be improved by shifting the balance between systemic
(endocrine) and local (paracrine or cell-cell contact) activity? How might
this change for treatment of different diseases?
- How can patients be stratified to select those who would be most
responsive?
- What is the optimal dosing regimen?
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feedback for potential clinical interventions and for the development of a consistently
efficacious treatment. Despite an incomplete explanation of their role in regeneration,
there are multiple clinical trials being performed. As shown in Table 2, the
ClinicalTrials.gov registry currently lists 85 trials that are using exogenous MSC to treat
a wide range of damaged, diseased or inflammed tissues. Because only 20 of these
trials have been completed, we can anticipate an abundance of new human data in the
near future for a wide range of therapeutic applications (17 trials are scheduled to be
completed in 2010 and 17 trials in 2011). Through investigation of MSC biology,
discovery of their therapeutic mechanisms within animal models and testing their
therapeutic potential within human trials, we will hopefully achieve many more steps
forward to make MSC therapy a new clinical paradigm.
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Chapter 2 Preface
In this chapter a method of engineering MSCs with intracellular polymeric
microparticles in introduced. As highlighted in Chapter 1, cells used in cell therapy are
very responsive to their surroundings, and as such control of cell phenotype and
function is often relinquished following administration into patients. With this work, we
aimed to establish a method to influence cell phenotype even after injection into a
patient. In this chapter I present a summary of the development of particle-modified
MSCs and demonstrate the utility of the platform by controlling MSC differentiation into
bone forming cells in vitro.
This chapter is an adaptation of a peer-reviewed article published on April 1, 2011 in
Biomaterials. Reprinted with permission.
Sarkar D1, Ankrum J1, Teo GSL, Carman CV, Karp JM. (2011). Cellular and
extracellular programming of cell fate through engineered intracrine-, paracrine-, and
endocrine-like mechanisms. Biomaterials, 32(11), 3053-61.
1 Co-first authors
Figures 11, 12 and the section "Application of platform technology for enhanced MRI
imaging," have been adapted from a peer-reviewed article published on July 12 ,2012
in Nano Letters. Adapted with permission, Copyright 2012, American Chemical Society.
For a complete version of the manuscript, please see Appendix 1.
Xu C, Miranda-Nieves D, Ankrum J, Matthiesen ME, Phillips JA, Roes I, Wojtkiewicz
GR, Juneja V, Kultima JR, Zhao W, Vemula PK, Lin CP, Nahrendorf M, and Karp JM.
(2012). Tracking Mesenchymal Stem Cells with Iron Oxide Nanoparticle Loaded
Poly(lactide-co-glycolide) Microparticles. Nano Lett , 12(8), 4131-9.
Glossary of Terms
Microenvironment: Local environment around each individual cell
Osteogenesis: Generation of bone forming cells from immature progenitor cells
Intracrine Signaling: Soluble factors released within a cell that act within the same cell
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Chapter 2: Cellular and Extracellular Programming of Cell
Fate through Intracrine-, Paracrine-, and Endocrine-like
Mechanisms
Abstract
A cell's fate is tightly controlled by its microenvironment. Key factors contributing to this
microenvironment include physical contacts with the extracellular matrix and
neighboring cells, in addition to soluble factors produced locally or distally. Alterations to
these cues can drive homeostatic processes, such as tissue regeneration/wound
healing, or may lead to pathologic tissue dysfunction. In vitro models of cell and tissue
microenvironments are desirable for enhanced understanding of the biology and
ultimately for improved treatment. However, mechanisms to exert specific control over
cellular microenvironments remain a significant challenge. Genetic modification has
been used but is limited to products that can be manufactured by cells and release
kinetics of therapeutics cannot easily be controlled. Herein we describe a non-genetic
approach to engineer cells with an intracellular depot of phenotype altering agent/s that
can be used for altering cell fate via intracrine-, paracrine-, and endocrine-like
mechanisms. Specifically, we show that human mesenchymal stem cells (MSCs) can
be engineered with poly(lactic-co-glycolic acid) (PLGA) particles containing
dexamethasone, which acts on a cytoplasmic receptor. The controlled release
properties of these particles allowed for sustained intracellular and extracellular delivery
of agent to promote differentiation of particle carrying cells, as well as neighboring cells
and distant cells that do not contain particles.
Introduction
Control of cell fate and its extracellular environment is critical for tissue
regeneration and cell therapy. During development, for example, cells are instructed by
a complex set of microenvironmental cues, comprising soluble mediators and direct
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contacts with extracellular matrix and neighboring cells that are precisely regulated in
time and space (1). Consequently, when the microenvironmental balance is altered,
cells may be activated toward homeostatic responses, such as regeneration of
damaged tissues, or pathologic changes in cell phenotype leading to aberrant cell
growth or loss of function. To better understand these processes, engineer tissues,
develop in vitro tissue models, and develop cell therapies, one must be able to exert
localized control over the cell microenvironment.
Current methods to control cell fate in culture include: i) genetic manipulation of
cells to program a desired phenotype, ii) addition of drugs or growth factors to the
culture media, and iii) presentation of an engineered extracellular environment. Genetic
modification has been used to program cell fate in culture to promote expression of
specific cell surface receptors and to drive production of therapeutic peptides and
proteins (2-7). However, these modifications often exhibit a long-term impact on the
cells, are limited to agents that can be manufactured by cells, and aside from use of
genetic switches, there is an inability to finely tune the release kinetics of these agents.
Drugs or growth factors can be added to culture media to mimic a tissue
microenvironment, however all cells receive essentially the same signal, and application
of soluble factors for controlling the fate of transplanted cells is limited to pre-
conditioning regimens. Alternatively, scaffolds or 2D/3D micro/nano-engineered
substrates are useful to create multiple distinct microenvironments within a single
culture system. These types of substrates have been used extensively to study cell-cell
interactions, transplant cells, or mimic stem cell niches in vitro through support of cell
proliferation, differentiation, or migration via controlled presentation of soluble cues,
adhesive interactions, or surface stiffness and topology (8-12). In addition, cues such as
growth factors can be chemically immobilized to the substrate, providing specific
locations to modulate cell behavior (13-15). However, all of these strategies require
cells to be on, or in close proximity to the substrate. Engineering substrates to control
cell phenotype and function often involves a complex manufacturing methodology and
there are several circumstances under which it is desirable to infuse cells in vivo without
the use of a carrier or substrate (e.g. systemic cell infusion) (2-7, 16).
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Thus, there is a need to exert control over cells and their microenvironment
without genetic modification or the use of an engineered substrate. Such a strategy
would be useful to create in vitro models of regenerative or disease microenvironments
that recapitulate critical cell-cell signaling events in situ. This approach could also be
applied to control the fate of cells following transplantation or control specific in vivo
microenvironments without the need for a cell carrier.
Here we propose a method to control the cellular microenvironment through a
simple biomaterial-based cell modification approach independent of genetic
manipulation or the presence of an artificial substrate. Rather than immobilizing cells on
a biomaterial to control the cellular microenvironment, we present a strategy in which
readily internalized biodegradable particles containing phenotype altering agents can be
used to control cell fate (Fig. 1A). Upon modification of the cells, intracellular and
extracellular release of agents was characterized. Assays were developed to test
whether the released agents could promote osteogenic differentiation of particle-
carrying cells as well as neighboring and distant cells (Fig. 1B). Furthermore, in vitro
and in vivo applications of the cell modification approach are discussed.
Results and Discussion
To exert control over cells without genetic modification or engineered substrates,
we conceived of a strategy utilizing a controlled drug delivery approach. Specifically, we
envisioned that cells could be modified with a depot containing drugs or differentiation
factors that could impact the modified cells and their cellular microenvironment through
diffusion or transport of agents out of the carrier cell. Although strategies for modifying
the surface of cells with nanoparticles exist, achieving stability beyond minutes or hours
requires chemical modification of the cell surface (17, 18). To develop an approach that
does not require chemical modification of the cell, we considered utilizing biodegradable
particles which are readily internalized by multiple cell types. Particles formulated with
poly(lactic-co-glycolic acid) (PLGA) enable a nontoxic and efficient system for sustained
intracellular delivery of small molecles directly to the cytoplasm. While the efficiency is
particle formulation dependent, PLGA particles have been reported to undergo rapid
endo-lysosomal escape, further facilitating delivery to the cytoplasm(19). PLGA is a
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Figure 1. Controlling cell fate through internalized biodegradable particles. (A)
Schematic illustration of functionalizing cells with biodegradable particles to generate
cells with internalized particles. (B) The encapsulated agent can control the cell and
neighboring microenvironment in three distinct ways. The release of the agent can
control the fate of the (i) particle-carrying cell through intracrine-like signaling, (ii)
neighboring cell, through paracrine-like signaling, (iii) and distant cells through
endocrine-like signaling. (Adapted from (20))
35
polyester that hydrolyzes into biologically compatible and metabolizable moieties (lactic
acid and glycolic acid). While small molecules such as dexamethasone (DEX), a
commonly utilized osteogenic differentiation factor, can freely cross membranes of cells
such as MSCs to engage intracellular receptors (21, 22), many exogenously supplied
large or acidic molecules (i.e. added to the culture media) have limited ability to
transverse membranes unless the membranes are permeabilized (23, 24). For agents
that cannot passively transverse the cell membrane, active processes including gap
junctions and permeability glycoproteins can be utilized (25, 26). Thus, we hypothesized
that particle based carriers could be used to deliver high intracellular concentrations of
agents leading to either passive or active transport across the cell membrane to impact
the extracellular environment. For proof of concept of this approach, we focused on
small molecules that have been shown to freely cross cell membranes including
dexamethasone and rhodamine dye.
Engineering MSCs with PLGA particles
Although MSCs readily internalize nano-sized particles (27), small particles
(<1pm) that are typically endocytosed (28) have been shown in other cell types to be
rapidly exocytosed unless they are conjugated to the cell membrane (19, 29-31). To
reduce the potential for exocytosis, PLGA particles with a diameter of 1-2 pm were
fabricated (Fig. 2A & B) and found to be internalized irrespective of the surface
chemistry, likely via phagocytosis (28) (Fig. 2C). However, the kinetics of internalization
was increased by modifying the surface with a positive charge or with an antibody
directed towards an MSC surface antigen (e.g. CD90) (Fig. 2C). Thus positively
charged particles were selected for further experimentation. Confocal microscopy
demonstrated that -95% of the PLGA particles were internalized following a 12 hr
incubation (Fig. 2D). Importantly, in contrast to previous reports of nanoparticle
exocytosis, the 1-2pm particles were stable inside the cell for at least 7 days (Fig. 2E &
F). Additionally, internalization of particles was confirmed with transmission electron
microscopy (Fig. 3A). While MSCs were found to internalize numerous particles ranging
from 0.5-3 pm in diameter (Fig. 3B-C), the modification procedure did not significantly
impact cell phenotype including viability, adhesion, proliferation (Fig. 4) or multilineage
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Figure. 2. Particle morphology, size, uptake and stability. (A) Scanning electron
microscope image of PLGA particles reveals particles are spherical with a smooth pin-
hole free surface (Scale bar: 1 pm). (B) Representative distribution of particle diameter
as determined by dynamic light scattering. (C) Particle interaction/binding with cells was
moderately affected by changes in surface chemistry, yet after 12 hr the majority of cells
contained bound particles regardless of surface chemistry. (D) Kinetics of particle
internalization as a function of particle surface chemistry. (E,F) Stability of internalized
particles within DiD stained MSCs (red) as analyzed by confocal microscopy.
Representative orthogonal confocal images (E) 1 day, and (F) 7 days after incubation
with DiO loaded PLGA particles (green). (Scale bar: 10 pm) (Adapted from (20))
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[A
Figure 3. MSC internalization of polydisperse particles. MSCs were incubated with
polydisperse DiO loaded PLGA particles, 300 nm - 5 pm, for 24 hr, fixed and prepared
for transmission electron microscopy and confocal microscopy. (A) PLGA particles were
observed in the intracellular space next to the rough endoplasmic reticulum (Scale bar:
500 nm). (B-D) Three 3D projections of a single confocal z-stack reveals 500 nm to 3
pm sized particles were internalized by MSCs at 24 hr (Scale bar: 10 pm). (Adapted
from (20))
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Figure 4. Viability, proliferation, and adhesion of modified MSCs. (A) Viability of MSCs
engineered with PLGA particles immediately after modification and 48 hr after
modification. (B) Proliferation of MSCs engineered with PLGA particles and unmodified
MSCs. (C) Adhesion of MSCs engineered with PLGA particles on tissue culture plastic
at 10, 30, and 90 min. (Adapted from (20))
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Figure 5. Differentiation potential of PLGA modified MSCs. Osteogenesis and
adipogenesis 21 days after induction observed by alkaline phosphatase (ALP) and Oil
Red 0 (ORO) staining, respectively. Particle modified MSCs cultured in respective
differentiation media showed positive staining for both ORO and ALP. Particle modified
MSCs cultured in expansion media, without differentiation factors, showed no ORO or
ALP staining. (Adapted from (20))
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differentiation potential (Fig. 5)
.Following the development of particles that were readily and stably internalized
by MSCs, we sought to examine the potential for agents encapsulated within the
particles to be released into the intracellular and extracellular milieu using rhodamine
dye as a model small molecule (mol. wt. 479). Intracellular accumulation of rhodamine
dye was examined over a 10 day period through permeabilization of the cells at different
time points following rinsing to remove residual culture media. Dye was released in an
initial burst within the first 2 days followed by relatively constant release (Fig. 6A). To
examine the potential for rhodamine to be transported into the extracellular miliu, we
sampled the media throughout the culture period with a fluorescence spectrophotometer
and compared this result to a particle suspension without cells. Remarkably, we
detected increasing concentrations of rhodamine over time in the culture media
indicating transport from the intracellular to the extracellular milieu. Release of
rhodamine from particles without cells showed a characteristic initial burst release with
over 40% of encapsulated rhodamine being released within the first day followed by
steady sustained release (Fig. 6B). In contrast, rhodamine was released from
internalized PLGA depots at a constant rate, with 40% of entrapped rhodamine released
by day 5 and 100% by day 10 (Fig. 6B). Importantly the rate of rhodamine delivery was
easily tuned by changing the concentration of particles added to the cultures (Fig. 6C).
This demonstrates the potential of engineering cells with particles to achieve sustained
targeted release of membrane permeable agents to the carrier cell and its
microenvironment.
Controlling particle engineered cells, neighboring cells, and distant cells
MSCs are multipotent cells capable of self-renewal that can give rise to a number
of unique, differentiated mesenchymal cell types including osteoblasts, chondrocytes,
and adipocytes. To examine the potential to control MSC phenotype we utilized an
osteogenesis assay where differentiation of MSCs to osteoblasts can easily be detected
through the characteristic expression of alkaline phosphatase (ALP) (32). MSCs
differentiate into osteogenic cells in the presence of the glucocorticoid steroid,
dexamethasone (DEX) that passively diffuses across the cell membrane (21, 22), but
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Figure 6. Rhodamine intracellular accumulation and extracellular release from MSCs.(A) To quantify the intracellular accumulation of rhodamine over time, MSCs loaded with
0.1 mg/mL or 0.5 mg/mL of rhodamine-PLGA particles were permeabilized with 5
mg/mL of L-lysine at 4 hr, 2 days, 4 days, 7 days, or 10 days, the permeabilized cells
were discarded, and the dye concentration in the lysate was assessed with UV-
Spectrophotometry. (B) Kinetics of rhodamine dye released into the culture media from
MSCs modified particles versus a suspension of PLGA particles without cells. 200 pl of
a 0.1mg/mL rhodamine-PLGA particle solution was added to the MSCs leading to
internalization of -19 pg and release was examined in 500 pi of media. To examine
release of dye from particles without cells, conditions were normalized to the
experimental group with -19 pg of particles suspended in 500 pl of PBS. C.
Extracellular release of a model dye. Sustained and controlled release of dye from
MSCs modified with 200 pl of 0.1 mg/mL, 0.5 mg/mL and 1.0 mg/mL rhodamine-PLGA
particles into surrounding media at 37 0C over 10 days. (Adapted from (20))
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only produce mineralized extracellular matrix in the presence of ascorbic acid (A) and
phosphate ions (e.g. from P-glycerol-phosphate (G)) (32). Instead of placing DEX into
media, we incorporated DEX into PLGA microparticles that were internalized by MSCs
(Fig. 7A). Quantification of dexamethasone in media above modified cells demonstrated
that DEX was transported from the particle engineered MSCs to the extracellular
environment for up to 2 weeks (Fig. 7B). The media was supplemented with A and G
and after 21 days, osteogenic differentiation was detected via ALP staining (Fig. 7C).
MSCs with blank particles, and MSCs in the presence of A and G alone did not stain
positive for ALP (Fig. 7D). Approximately 80% of the MSCs engineered with DEX
containing particles in the presence of A and G stained positive for ALP, which was
comparable to the ALP staining of MSCs (without particles) in complete osteogenic
media. In addition, co-staining cultures with ALP and Von Kossa revealed the formation
of bone nodules in DEX-PLGA cultures (Fig. 7E). Since DEX binds to intracellular
glucocorticoid receptors (21, 22), these results demonstrate that DEX released from
PLGA microparticles induced osteogenic differentiation of particle modified MSCs as
previously shown with nanoparticles (33, 34). Thus microparticles that do not readily
undergo exocytosis, as nanoparticles do (19), can be used to deliver phenotype altering
agents such as dexamethasone to intracellularly control the fate of particle modified
cells.
Given that DEX can be transported across the MSC membrane into the
extracellular environment following internalization of DEX loaded microparticles, we
envisioned particle engineered cells could be used to control the phenotype of
neighboring cells in a paracrine-like manner. For an in vitro model, the previous
experiment was repeated, with only half of the MSCs containing DEX-PLGA particles
(Fig. 8A). Specifically, MSCs and DEX-PLGA modified MSCs were mixed in a 1:1 ratio
and plated in a 6-well plate. Strikingly, following differentiation conditions, the majority of
cells within the co-culture with DEX-PLGA particles stained positive for ALP (Fig. 8B).
Given that cell adhesion and proliferation properties of the PLGA modified and
unmodified cells were similar (Fig. 4), these results are likely not due to differences in
adhesion and proliferation between the two populations of cells. This data suggests that
DEX released from particle modified MSCs can control the fate of adjacent cells.
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Figure 7. Intracrine-like signaling leads to osteogenic differentiation of DEX-PLGA
particle modified MSCs. (A) Schematic of DEX release into culture media from adherent
MSCs modified with DEX-PLGA particles. (B) Release kinetics of DEX from MSCs
incubated with O.1mg/mL DEX-PLGA particles into media at 37 0C for 21 days. (C)
Osteogenic differentiation of DEX-PLGA modified MSCs and controls were assessed
via alkaline phosphatase staining (ALP, red), nuclei were counterstained with DAPI(blue). (D) Quantification of ALP staining. (E) Bone nodules were identified via positive
dual staining for Von Kossa and ALP in DEX and internalized DEX-PLGA particle
containing cultures supplemented with A and G but not in the absence of DEX or DEX-
PLGA particles. (Adapted from (20))
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Figure 8. Paracrine-like activity of modified MSCs. (A) Schematic illustration of DEX-
PLGA modified MSCs controlling the fate of neighboring MSCs without particles (black
arrows). (B) Osteogenic differentiation of DEX-PLGA modified MSCs and neighboring
MSCs seeded in a 1:1 ratio quantified through ALP staining. D=Dexamethasone,
A=Ascorbic Acid, G=D-Glycerolphosphate, CCM=MSC expansion media. (Adapted from(20))
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Next we examined the potential for extracellular release of DEX from particle-
modified cells to promote differentiation of unmodified MSCs in a different culture dish
(endocrine-like signaling). On every third day, conditioned media was transferred from
particle modified cells (supplemented with G and A) to the unmodified cells and after 21
days stained to detect ALP activity (Fig. 9A). ALP staining of the unmodified cells
incubated in conditioned media from DEX-PLGA modified cells was comparable to the
DEX-PLGA modified MSCs (Fig. 9B). Importantly, no detectable ALP staining was
observed when the media was transferred from MSCs engineered with blank PLGA
particles (supplemented with G and A) and from unmodified MSCs (supplemented with
G and A) to a separate dish containing unmodified MSCs. To ensure that the released
DEX was responsible for induction of osteogenic differentiation and that this was not
due to a factor released from the differentiating MSCs, additional experiments were
performed. Specifically, media transferred from unmodified MSC cultures following 21
days of osteogenic differentiation (supplemented with DEX, G, and A) resulted in no
detectable ALP staining (Fig. 9C). In a separate experiment, lung microvascular
fibroblasts with internalized DEX-PLGA particles were used in place of MSCs. Media
transferred from the DEX-PLGA modified fibroblast cultures to unmodified MSCs
(supplemented with G and A) induced osteogenic differentiation of the MSCs to the
same degree as media transferred from DEX-PLGA modified MSCs (Fig. 9D). These
two controls demonstrate that the DEX released from the particle modified cells was
responsible for inducing osteogenic differentiation of the unmodified MSCs in a different
culture dish in an endocrine-like manner.
To determine if engineered endocrine-like signaling could promote differentiation
in a more relevant assay, we investigated the ability of adhered DEX-PLGA modified
MSCs to impact the fate of cells on a distant transwell membrane in the same culture
environment. We incubated MSCs with DEX-PLGA particles on the bottom surface of a
transwell dish, and unmodified MSCs on a filter surface that was 2mm above in the
presence of A and G (Fig. 9E). Cells were stained to detect ALP activity after 21 days in
culture. DEX-PLGA modified MSCs were shown to induce the differentiation of -80% of
the unmodified MSCs on the transwell membrane (Fig. 9F). This demonstrates that
agents released from particle-modified cells can impact the fate of distant cells without
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Figure 9. Endocrine-like activity of modified MSCs. (A) Schematic illustration of
programming cell fate of distant cells (without particles in well 'ii') by transferring
conditioned media from well 'i', containing DEX-PLGA modified MSCs, differentiated
MSCs, or DEX-PLGA modified fibroblasts to well 'ii'. (B) Osteogenic differentiation of
DEX-PLGA modified MSCs and distant cells quantified through ALP staining. (C)
Osteogenic differentiation of MSCs treated with conditioned media from differentiated
MSCs without DEX-PLGA particles. (D) Osteogenic differentiation of MSCs treated with
conditioned media from DEX-PLGA modified fibroblasts. (E) Schematic illustration of
DEX-PLGA modified MSCs controlling the fate of MSCs (without particles) separated by
a transwell membrane 2 mm above the surface. (F) Osteogenic differentiation of
unmodified MSCs atop transwell membrane quantified through ALP staining. (Adapted
from (20))
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cell contact.
Controlling cell fate after cryopreservation
To assess the potential for particle modified MSCs to retain their DEX releasing
properties following cryopreservation, cells containing DEX-PLGA particles were stored
for 10 days at -140 C. Upon thawing and re-plating, particle modified MSCs
differentiated into osteogenic cells via intracellular release of DEX, as indicated by
positive alkaline phosphatase staining (Fig. 10 A,C) and induced osteogenic
differentiation of distant unmodified MSCs, comparable to non-cryopreserved DEX-
PLGA modified cells (Fig. 10 B,D) Thus particle engineered MSCs can be
cryopreserved without loss of activity.
Potential for a platform technology
While small molecules such as DEX and rhodamine can freely cross the
membrane of cells such as MSCs, it is well known that many exogenously supplied
molecules (i.e. added to the culture media) have limited ability to traverse membranes
unless the membranes are permeabilized (24). However, we do not anticipate this to be
a significant bottleneck to expanding our results to other agents including small
molecules, peptides, and proteins given that many cell types including MSCs possess
relevant machinery to facilitate transport of agents from the intracellular to the
extracellular environment. For example, MSCs and their subpopulations have been
shown to express the plasma membrane protein, P-glycoprotein otherwise known as
permeability glycoprotein (35-37), an ATP-dependent efflux pump responsible for
multidrug resistance in tumor cells that is also expressed in hematopoietic stem cells
and their progeny (25). Interestingly, P-glycoprotein has the ability to transport multiple
types of agents across the cell membrane including steroids, lipids, peptides, and drugs.
P-glycoprotein can also be modulated to alter drug efflux (38). In addition to P-
glycoprotein mediated transport of soluble agents, cell-cell communication via soluble
cues may occur through gap junctions that permit the movement of small molecules and
proteins between cells that are in direct cell contact. This pathway has been exploited
for double stranded shRNAs/siRNA delivery (26, 39). MSCs have been shown to
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Figure 10. Effect of cryopreservation on DEX-PLGA modified MSCs. MSCs modified
with DEX-PLGA particles were frozen at -140 *C for 10 days and then thawed to assess
their cell programming capability. (A) Schematic of DEX release into culture media from
adherent MSCs modified with DEX- PLGA particles. (B) Schematic illustration of
controlling the fate of distant cells (without particles) by transferring conditioned media
from well 'i', containing DEX-PLGA modified MSCs to well 'ii'. (C) Osteogenic
differentiation of DEX-PLGA modified MSCs quantified through ALP staining. (D)
Osteogenic differentiation of distant cells grown in conditioned media from DEX-PLGA
modified MSCs quantified through ALP staining. D=Dexamethasone, A=Ascorbic Acid,
G=P-Glycerolphosphate, CCM=MSC expansion media. (Adapted from (20))
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express gap junctions and it has been suggested that this could be used as a means to
mediate responses of cells that are in direct cell contact with MSCs(40, 41), however in
the current study only small molecule delivery was explored. Furthermore, MSCs have
been shown to use nanometer scale vesicles called exosomes (42, 43) for transport of
multiple intracellular agents to the extracellular environment, as has been shown for
other cell types (44, 45). Thus, the collective activity of these mechanisms theoretically
permits the delivery and extracellular transport of a large repertoire of therapeutic
agents via internalized biodegradable particles. For example, agents could be used to
impact cell survival, proliferation, differentiation, extracellular matrix production, cell
death, or expression of therapeutic peptides and proteins. We envision this intracellular
drug depot will be useful for developing cell-based therapies for tissue regeneration,
drug delivery and cancer therapeutics and potentially in combination with cell based
targeting strategies (46-49). In addition, stable microparticle internalization may enable
improved monitoring of cell therapies through the development of enhanced contrast
agents.
Application of platform technology for enhanced MRI imaging
Monitoring the location, distribution and long-term engraftment of administered
cells is critical for demonstrating the success of a cell therapy. Among available
imaging-based cell tracking tools, magnetic resonance imaging (MRI) is advantageous
due to its non-invasiveness, deep penetration, and high spatial resolution(50). While
tracking cells in pre-clinical models via internalized MRI contrast agents (iron oxide
nanoparticles, lO-NPs) is a widely used method(51, 52), IO-NPs suffer from low iron
content per particle, low uptake in non-phagocytotic cell types (e.g., mesenchymal stem
cells, MSCs), weak negative contrast, and decreased MRI signal due to cell proliferation
and cellular exocytosis(19). To examine if our particle-engineered approach could be
adapted to enhance MRI tracking of MSCs and provide an advantage over current
nanoparticle based approaches, we encapsulated iron oxide nanoparticles (lO:NP, 10
nm) in PLGA microparticles(O.4-1.5 pm).
As with DEX particles, IO:NP PLGA particles were formulated through a single
emulsion technique and found to be -1 pm in size with iron oxide particles clustered
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Figure 11. lO:PLGA-MPs preparation and internalization by MSCs: (A) Schematic
illustration of the preparation of lO:PLGA-MPs with single emulsion method. (B) SEM
image of lO:PLGA-MPs. (C) TEM image of a representative lO:PLGA-MP. (D) TEM
image of lO:PLGA-MPs internalized in an MSC. (Adapted from (53))
50
/
1'
/
/
/
in the core of particle (Fig. 11). Interestingly, clustering of iron oxide has previously
been shown to result in enhanced T2 signal of nanoparticles(54).
MSCs were modified with particles while maintaining a constant Fe concentration
(25, 50, 100 or 200 pg/mL) and the amount of Fe loaded into the cells was quantified.
MSCs were digested and Fe content was quantified via ICP-AES. The maximum Fe
loading/cell was attained at 100pg/mL initial concentration (Fig. 12A). Further increases
in the initial Fe concentration did not enhance the final quantity of Fe per cell.
Interestingly, maximal Fe loading per cell was 20 and 80 pg Fe/cell for lO-NPs and
lO:PLGA-MPs, respectively. A significant 4-fold increase for Fe loading per cell reveals
the advantage of using microparticles for internalization of iron oxide.
To assess changes in Fe content over time, following particle internalization and
subsequent purification from free particles, MSCs were plated in T25 plates for 28 days
(the labeling day was designated as day 1). The culture media was replaced every two
days for all samples and at each time point (day 1, 2, 4, 6, 12, and 28) MSCs were
collected for quantification of MSC proliferation, Fe concentration, and MRI analysis (by
dispersing 200,000 MSCs in 1 mL 3% agarose gel). As shown in Fig. 11B, when MSCs
were labeled with lO-NPs, the iron concentration per MSC decreased to -50% of the
initial value by day 4 and the iron concentration per cell approached background by 12
days. However, when MSCs were labeled with lO:PLGA-MPs, within 6 days the
concentration had decreased to half of its initial value and after 25 days, the iron
concentration per cell remained significantly higher than background. The combination
of contrast enhancement due, possibly due to iron oxide clustering, and increased
cellular loading in MSCs of IO:PLGA-MPs permitted us to visualize MSCs with MRI for
at least 12 days (Fig. 12C). While in the case of lO-NPs labeling there was minimal
detectable signal after only 6 days. To further confirm the MRI results and examine the
stability of internalized lO:PLGA-MPs, we labeled MSCs with fluorescent lO:PLGA-MPs
containing Dil and examined the fluorescent signal by fluorescent confocal microscopy.
18 days after labeling, lO:PLGA-MPs could still be found in 15±5% MSCs (Fig. 12D),
which reveals the potential of lO:PLGA-MPs for the long-term tracking of MSCs.
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Figure 12: Improved retention of 10 in MSCs after PLGA encapsulation: (A) Cellular Fe
content of MSCs after incubation with magnetic particles as a function of iron
concentration. (B) Change in cellular iron content per cell after initial labeling with 10-
NPs or lO:PLGA-MPs at the incubation concentration of 50pg Fe/mi. (C) R2-weightedMR images of 200,000 MSCs collected at different time points and suspended in 3%
agarose gels (4 x 4 mm 2 per square). (D) Fluorescent confocal image of MSCs 18 days
after labeling with l0:PLGA-MPs. The plasma membrane is stained green (DiO), the
nucleus is blue (DAPI) and the l0:PLGA-MPs are stained red (Dil). Scale bar is 10pm.(Adapted from (53))
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Conclusion
Herein we have developed a strategy to engineer cells with intracellular particles
to impart intracellular and extracellular control of cell fate. In our proof of concept
studies we have shown that primary human mesenchymal stem cells (MSCs) can
efficiently internalize 1-2 micron sized biodegradable particles containing differentiation
factors or iron oxide nanoparticles. Drug loaded particles remain localized within the cell
for at least 7 days while releasing biologically active agents such as dexamethasone.
The release kinetics to the extracellular environment can easily be controlled by tuning
the number of internalized particles. Remarkably, differentiation factors released from
the particles were shown to promote the differentiation of particle-carrying cells
(intracrine-like signaling), neighboring cells (paracrine-like signaling), and the
differentiation of distant cells (endocrine-like signaling). In addition to use as an in vitro
tool to create cell niches in culture where temporal and spatial control of cellular cues is
critical, intracellular depots may permit exquisite control over transplanted cells and their
microenvironment through impacting cellular phenotype and function. Finally, to
demonstrate the utility of this technology as a platform technology we demonstrated the
ability to engineer MSCs with iron oxide loaded microparticles, leading to enhanced MRI
contrast and prolonged detection of MSCs over existing nanoparticle based
approaches. We believe this technology can serve as a platform in which cells can be
influenced, tracked, and probed through through incorporation of novel phenotype
altering small molecules, modulation of particle formulation to control release kinetics, or
conjugation of chemical sensors onto the particle surface opening the door to a wide
array of potential applications.
Materials & Methods
Mesenchymal stem cell culture and characterization
Primary human MSCs were obtained from the Texas A&M Health Science
Center, College of Medicine, Institute for Regenerative Medicine at Scott & White
Hospital supported by NIH Grant # P40RR017447. MSCs were derived from healthy
consenting donors and thoroughly characterized as previously described (8-12, 55).
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MSCs were maintained in a-MEM expansion media (Invitrogen) supplemented with 15%
Fetal Bovine Serum (Atlanta Biologicals), 1% (v/v) L-Glutamine (Invitrogen), and 1%
penicillin:streptomycin solution (Invitrogen). Cells were cultured to 70-80% confluence
before passaging. All experiments were performed using MSCs at passage number 3-6
where cells expressed high levels of MSC markers CD90 and CD29 (>99% cells), and
did not express hematopoietic markers CD34 or CD45 (0% of cells) as observed from
flow cytometry analysis.
PLGA Microparticle Fabrication
Rhodamine 6G dye (Sigma) or the osteogenic differentiation agent,
dexamethasone (DEX), were encapsulated in poly (lactic-co-glycolic) acid (PLGA)
particles using a single emulsion encapsulation technique. Briefly, 100 mg of 50kDa
(0.55-0.75 dL/g inherent viscocity) 50:50 PLGA(carboxylic acid end group) was
dissolved in 2 mL dichloromethane. DEX or dye was then added to the PLGA solution
and mixed thoroughly. For complete dissolution of DEX, 10% methanol was added to
dichloromethane. The PLGA solution was then added to 20 mL of 1% (w/v)
polyvinylalcohol (80% hydrolyzed) solution in deionized water and emulsified using a
probe sonicator at 30 W for 60 seconds. The solution was then stirred overnight at room
temperature on a magnetic stirrer to allow extraction and evaporation of the organic
solvent. The remaining solution was centrifuged and rinsed with PBS to isolate particles
and lyophilized. Particle size was determined by dynamic light scattering and confirmed
by scanning electron microscopy. To determine the encapsulation efficiency, briefly, 10
mg of DEX-PLGA particles were dissolved in anhydrous dimethyl-solfoxide (DMSO)
followed by quantification of DEX with a UV-vis spectrophotometer at 251 nm. Blank
PLGA particles without any DEX served as control. DEX was reliably encapsulated in
DEX-PLGA particles with an efficiency of 71±13.5% (e.g. from an initial 10mg of DEX,
-7.1 mg ±1.35 was typically entrapped within the PLGA particles).
Modifying MSCs with PLGA microparticles.
To improve particle uptake, PLGA microparticles were incubated with 50 pg/mL
poly-L-lysine for 3 hrs before incubation with MSCs. PLGA particle suspensions with
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concentrations of 0.1 mg/mL and 0.5 mg/mL in PBS were added to 90% confluent
layers of MSCs in a 24 well plate for 10 min after which the PBS was removed and
complete media was added. The MSCs were allowed to internalize particles for 24 hrs
at 37 0C. To characterize particle internalization and stability of internalized particles,
MSCs were loaded with DiO containing PLGA particles and characterized with a Zeiss
LSM510 laser scanning confocal microscope equipped with a 63X water dipping
objective. After a 24 hr incubation, the cells were fixed with 3.7% formaldehyde at room
temperature and stained with 5 pg/mL of propidium iodide (PI) solution or 5 pl/mL Dil
Vybrant cell stain solution for 10 min to visualize the cells. The cells were visible through
the red fluorescence channel and the particles were visible through the green
fluorescence channel. Internalization of particles was examined from 3-D re-constructed
Z-stack confocal microscopy images and a particle was considered internalized if it was
localized within the plane of the nucleus, yet inside the borders of the cell membrane.
The percentage of internalized particles was calculated from the number of particles
present inside the cell compared to the total number of particles associated with cells in
the field of view for ten random fields. For transmission electron microscopy, particle
modified cells were prepared as described above, fixed, and analyzed by the W.M Keck
Microscopy Facility at the Whitehead Institute. Specifically, the cells were fixed in 2.5%
gluteraldehyde, 3% paraformaldehyde with 5% sucrose in 0.1M sodium cacodylate
buffer (pH 7.4), pelleted, and post fixed in 1% OsO4 in veronal-acetate buffer. The cell
pellet was stained in block overnight with 0.5% uranyl acetate in veronal-acetate buffer
(pH 6.0), then dehydrated and embedded in Spurrs resin. Sections were cut on a
Reichert Ultracut E microtome with a Diatome diamond knife at a thickness setting of 50
nm, stained with uranyl acetate, and lead citrate. The sections were examined using a
FEI Tecnai spirit at 80KV and photographed with an AMT CCD camera. The viability,
adhesion kinetics and proliferation of particle-modified MSCs and unmodified MSCs
were examined using our previously reported experimental methodology(46). Briefly,
the viability of the cells was examined immediately after modification (time 0) and after
the cells were incubated within 6-well plates for 48 hrs using a trypan blue exclusion
assay. Cell adhesion kinetics were quantified by measuring the number of adherent
cells on the tissue culture surface after 10, 30, and 90 min. Proliferation of modified and
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unmodified MSCs was quantified by plating cells in T25 flasks at low density and
counting the number of cells in the flask for an 8 day period with light microscopy at 1OX
for ten random fields. Multi-lineage differentiation potential of the particle modified
MSCs and unmodified MSCs was examined by incubating cells with osteogenic and
adipogenic induction media followed by respective colorimetric staining (46). Cells were
assayed for osteogenic differentiation and adipogenic differentiation using cell
membrane associated alkaline phosphatase activity and Oil Red 0 staining,
respectively.
In vitro release experiment from particle modified MSCs
0.1 mg/mL, 0.5mg/mL, or 1mg/mL PLGA microparticles with entrapped
rhodamine dye were incubated with MSCs for 24 hrs at 37 0C. The media was then
discarded and the cells were rinsed with PBS and supplied fresh media to create a
baseline for the dye release measurements. On days 2, 4, 7, 10 media was collected
and the quantity of dye released was measured using a fluorescence
spectrophotometer with excitation and emission wavelengths of 540 and 625 nm,
respectively. Preliminary characterization of the particle-modification approach showed
that 0.1mg/mL particles were efficiently internalized by cells and resulted in adequate
cell loading, therefore this concentration was used for the remainder of the experiments.
To quantify the amount of dexamethasone released, MSCs were incubated with 0.1
mg/mL DEX-PLGA particles for 24 hrs at 37 C. On day 2, 4, 6, 10, 14, 18, and 22, 1
mL of media was collected and replenished with fresh media. The released DEX was
determined using ultraviolet (UV) spectrophotometer at 251 nm. Cells with no particles
and cells with blank particles (no DEX) served as controls.
Examination of Osteogenic Differentiation
To evaluate osteogenic differentiation, cell membrane associated ALP activity
was examined after 21 days by aspirating the culture media and rinsing the cells
followed by fixation with 3.7% formaldehyde solution for 10 min at room temperature.
After 45 min incubation in 0.06% Red Violet LB salt solution in Tris HCl, DMF and
Naphthol AS MX-P0 4 , the wells were rinsed 3 times with distilled water and visualized
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with light microscopy. Osteogenic differentiation was identified by staining for alkaline
phosphatase activity. To visualize individual cells, the nuclei of the cells were stained
with 100 pL of DAPI solution (1 pg/mL in PBS) after treatment with 100 pL of 0.1%
TRITON X solution in PBS. ImageJ@ software was used to quantify the percentage of
MSCs stained positively for alkaline phosphatase. Some cultures stained for ALP were
further examined for the presence of mineralization via Von Kossa staining. Briefly,
plates were rinsed 3-4 X in ddH 20, and stained with 2.5% silver nitrate for 30 min. After
rinsing 3-4 X in ddH 20, plates were incubated in sodium carbonate formaldehyde for 1-
2 min, rinsed, air dried, and examined by light microscopy.
Differentiation of particle modified cells
Microparticles containing DEX were incubated with MSCs for 24 hr followed by
rinsing to remove free particles and the media was replaced with P-glycerolphosphate
(G) and Ascorbic Acid (A) containing media. Cells grown in a-MEM complete media
served as a negative control, while cells grown in media supplemented with DEX, G and
A served as a positive control for osteogenic differentiation. Additional controls included
media containing only G or A and cells containing empty PLGA particles (no DEX).
Cultures were maintained for 21 days and then assessed for osteogenic differentiation
by ALP staining as described above.
Differentiation of neighboring and distant cells
To assess the potential of MSCs modified with DEX-PLGA microparticles to
induce osteogenic differentiation of adjacent unmodified MSCs, a model assay was
developed. MSCs modified with DEX-PLGA particles were mixed with equal number of
unmodified MSCs and plated at a density of 300,000 cells per well in a 6 well plate. The
media was supplemented with P-glycerolphosphate (G) and Ascorbic Acid (A). Cells
grown in a-MEM complete media served as a negative control, while cells grown in
media supplemented with DEX, G and A served as a positive control. Other controls
included media containing only G or A and cells containing empty PLGA particles.
Cultures were maintained for 21 days and then assessed for osteogenic differentiation
as described above. To assess the potential of DEX-PLGA microparticle modified MSCs
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to induce osteogenic differentiation of unmodified MSCs at a distant site, two model
assays were developed. First, MSCs containing DEX-PLGA microparticles were plated
in 6-well culture plates and unmodified MSCs were plated in separate 6-well culture
plates. The media added to DEX-PLGA modified MSCs was supplemented with G and
A. Media from the particle modified MSCs was transferred to wells containing
unmodified MSCs every third day and fresh media with P-glycerolphosphate (G) and
Ascorbic Acid (A) was replenished. Cells grown in a-MEM complete media served as a
negative control, while cells grown in media supplemented with DEX, G and A served
as a positive control. Other controls included media containing only G or A and cells
containing empty PLGA particles. Cultures were maintained for 21 days and then
assessed for osteogenic differentiation as described above. To rule out the possibility
that the observed induction of osteogenesis was mediated by factors secreted by the
differentiating DEX-PLGA modified MSCs, the experiment was repeated using lung
microvascular fibroblasts (in place of MSCs) modified with DEX-PLGA particles.
Towards the same goal, the impact of transferring media from fully differentiated
osteogenic cultures of MSCs (without particles) to a separate culture dish containing
unmodified cells was assessed. Second, MSCs containing DEX-PLGA microparticles
were plated on the bottom well of a transwell plate. Unmodified MSCs were then plated
on the membrane of the transwell and the media was supplemented with P-
glycerolphosphate (G) and Ascorbic Acid (A). Cells grown in a-MEM complete media
(without osteogenic factors) served as a negative control, while cells grown in media
supplemented with DEX, G and A served as a positive control. Other controls included
media containing only G or A and cells containing PLGA particles without DEX. Cultures
were maintained for 21 days and then assessed for osteogenic differentiation as
described above.
Effect of Cryopreservation
To examine the effect of cryopreservation on DEX release and ability to influence
the cellular microenvironment, the DEX-PLGA particles were incubated with MSCs for
24 hr followed by trypsinization with 1X trypsin-EDTA solution. The particle modified
cells were frozen in complete cell culture media supplemented with 5% dimethyl
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sulfoxide at -140'C. After 10 days the cells were thawed, plated, and the release of DEX
was examined in addition to repeating the osteogenic differentiation experiments
described above.
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Chapter 3 Preface
The goal of this chapter is to provide a detailed protocol for the synthesis,
characterization, and application of drug loaded microparticles to MSCs and other cell
types. While Chapter 2 focused on demonstrating the utility of the particle-in-cell
platform in a differentiation assay and cell tracking assay, Chapter 3 is meant to enable
others to quickly adapt the platform to their own application. In developing this platform
a number of challenges arose that required troubleshooting. Examples of positive and
negative data and solutions to these challenges are included.
This article is an adaptation of an article that has been submitted to Nature Protocols.
Glossary of Terms
Emulsion: A mixture of two immiscible liquids by mechanical agitation
Drug Loading: The mass of drug in a particle over the total weight of the particle
Encapsulation Efficiency: The mass of drug encapsulated over the total mass of drug
added.
Particle Association: Particles appear to be on the surface or on the interior of cells as
measured by microscopy and flow cytometry.
Particle Internalization: Particles are found inside the outer plasma membrane of cells in
intracellular compartments or free in the cytosol as determined by confocal microscopy.
?TROUBLESHOOTING: Tip to overcome common problems can be found in Table 1.
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Chapter 3: Engineering cells with intracellular depots to
control cell phenotype
Abstract
Cell therapies enable the unprecedented treatment of diseased and damaged
tissues by harnessing natural biological processes to replace tissues, destroy tumors,
and facilitate tissue regeneration. The greatest challenge facing exogenous cell therapy
is the ability to control cell viability, fate, and function following transplantation. Failure to
control the phenotype of transplanted cells can be detrimental to patients, leading to
poor engraftment following hematopoietic stem cell (HSC) transplantation, reduced
insulin production or inadequate glucose sensitivity following pancreatic islet or beta cell
transplantation, and insufficient expression of immunomodulatory factors that are
essential for the success of mesenchymal stem cell (MSC) based therapies. We have
recently developed an approach to control cell phenotype in vitro and following
transplantation that involves engineering cells with intracellular depots that continuously
release phenotype-altering agents that can impact the cell's secretome, viability
(persistence), proliferation, and differentiation, regardless of the cell's
microenvironment. The same depots can encapsulate contrast agents to permit long-
term tracking of transplanted cells, and the depots can be used to deliver drugs or other
factors to control the cell's microenvironment (i.e. use the cell as a delivery vehicle). The
development, efficient internalization and stabilization of -1-pm polymeric drug-loaded
microparticles within cells is critical for attaining sustained control of cell phenotype.
Herein we provide a detailed protocol to generate and characterize agent doped
poly(lactic-co-glycolic) acid (PLGA) particles using a single-emulsion evaporation
technique (7 hrs), to uniformly engineer cultured cells (15 hrs), to confirm particle
internalization, and to troubleshoot the most commonly experienced obstacles.
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Introduction
The success of exogenous cell therapies depends on the fate, function and
viability of cells following transplantation. Controlling the phenotype and engraftment of
cells following transplantation is critical for the success of cell-based therapies. Unlike
the exquisite control that one can exert over cells in a culture dish, once cells are
transplanted they are entirely at the mercy of the biological milieu and behave differently
depending on their location. The lack of control of transplanted cells leads to variability
in cell function and ultimately poor therapeutic outcomes (1, 2). Both allogeneic and
autogenic cell-based therapies are prone to significant variability due to heterogeneity
within and between cell populations that can be impacted by differences in donors,
isolation techniques, and culture mediums. For example, the propensity of embryonic
stem cells and iPS cells to differentiate into specific lineages has been shown to vary
significantly within and between cell lines (3). Variation in the glucose sensitivity of
transplanted pancreatic islets can lead to a failure to restore insulin independence (4).
In addition, MSC differentiation efficiency down osteogenic, chondrogenic, or
adipogenic lineages is strongly influenced by the MSC's tissue of origin (5).
Furthermore, the ability of MSCs to secrete growth factors, chemokines, and cytokines
in response to inflammatory stimuli and suppress activated T-cells varies significantly
between donors (2, 6). Specifically, MSC secretion of vascular endothelial growth factor
(6), a primary mediator of MSCs' angiogenic potential, and production of indoleamine
2,3-dioxygenase (2), a primary mediator of MSCs' immunomodulatory potential, vary
significantly depending on the donor that the MSCs are isolated from. Thus, there is a
significant need to develop methods to polarize MSCs toward therapeutic phenotypes to
maximize their therapeutic potency regardless of their source. While small-molecule
drugs have the ability to influence MSC phenotype in vitro (7-10); adaptation of pre-
conditioning regimens has been substantially limited given that they typically activate
signal transduction pathways only for short durations and thus the induced effects do
not persist following transplantation.
To maximize potency, establish stable control of cell phenotype, and
longitudinally track cell distribution following transplantation, we developed a technique
to engineer cells with intracellular agent-loaded microparticles (11). Using an osteogenic
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differentiation assay we demonstrated the ability of internalized dexamethasone-loaded
microparticles to stimulate uniform differentiation of MSCs (11). Furthermore, drug
released from particle-engineered cells into the microenvironment induced the
differentiation of unmodified neighboring and distant cells in a paracrine-like and
endocrine-like manner (see Sarkar et al. for a detailed report). In addition to establishing
control over MSC differentiation, we observed that the efficiency of MSC particle
internalization was dependent on the size as well as surface properties of PLGA
microparticles. MSCs more efficiently internalized antibody-coated or positively charged
particles over negatively charged particles. While multiple cell types efficiently
internalize nanoparticles, significant particle leakage through exocytosis has been
documented (12-16). In addition, nanoparticles typically exhibit lower drug loading and
faster release compared to larger microparticles, limiting sustained control of cell
phenotype. In contrast to nanoparticles that can be quickly exocytosed or cellular
backpacks which are designed to remain on the cell surface (17, 18), we discovered
that particles -1 pm in diameter remained internalized within MSCs for several weeks.
To demonstrate the utility of this approach as a platform, we recently adapted it to
enable longitudinal tracking of MSCs following transplantation. Tracking the location,
engraftment, and distribution of cells following transplantation is critical for evaluating
the success of cell-based therapies. While iron oxide nanoparticles have been used to
track cells by magnetic resonance imaging (MRI), low iron content per cell and
nanoparticle exocytosis prevented detailed and longitudinal monitoring of a cell's
location. To overcome these limitations, iron oxide nanoparticles were encapsulated
within -1-pm PLGA microparticles resulting in significantly enhanced iron oxide loading
and increased r2 relaxivity of MSCs (19). In addition, the enhanced residence time of
microparticles within MSCs enabled cells to be detected by MRI for >12 days compared
to only 4-6 for nanoparticle-engineered MSCs (see Xu et al. for a detailed report)(19).
Nuances and Limitations of the particle engineering platform
Previously we have shown the flexibility of the platform through cell
internalization of particles encapsulated with hydrophobic small molecules, rhodamine
6G and dexamethasone, as well as iron oxide nanoparticles (11, 19). Drug loading and
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release kinetics can be tuned for specific applications by modifying the particle
synthesis protocol through changing the composition and molecular weight of the
polymer. While we anticipate adaptation of the platform to other hydrophobic drugs will
be straightforward, encapsulation and delivery of hydrophilic molecules incuding
peptides, proteins, DNA, and RNA have yet to be optimized for this platform. Hydrophilic
small molecules can be adapted to the platform by modifying particle synthesis. Co-
solvents or double-emulsion techniques can be used to enhance the encapsulation of
hydrophilic small molecules in microparticles (20-22). Thus, iteration of particle
formulation strategies should enable adaptation of the particle engineered-MSC
platform to hydrophilic drugs. In addition to small molecules, many biological agents
including proteins, RNA, and DNA, have been used to control a cell's phenotype
including its expression of cell surface receptors, secretome, and differentiation (23-27).
While techniques to deliver these agents have been established, care must be taken not
to damage the structure of the molecules. Secondary and tertiary structures may be
damaged during particle synthesis due to exposure to organic solvents and high-
intensity agitation or upon sorting to acidic lysosomes following endocytosis. While
PLGA nanoparticles have been reported to undergo endolysosomal escape to deliver
genes and siRNA (28-31), achieving efficient intracellular delivery without inducing
cytotoxicity remains a challenge (32). In addition, if the goal is to deliver the agent to an
extracellular target, as in the case of growth factors that bind to cell surface receptors,
the agent must be able to transverse the plasma membrane via diffusion or active
transport. Therefore, while this platform can be easily adapted to accommodate a wide
variety of agents, a molecule's structure, target, and susceptibility to degradation should
be contemplated. With these considerations in mind, the protocol herein will serve as a
guide for successfully establishing non-viral transient control over locally or systemically
administered cells to develop more effective cell-based therapies (Fig. 1).
Materials
REAGENTS
Particle Preparation
50:50 Poly(DL-lactic-co-glycolic)-COOH (PLGA), i.v. 0.15-0.25 g/dL (Lactel Absorbable Polymers,
www.absorbables.com, B6013-1)
50/50 Poly(DL-lactic-co-glycolic)-COOH (PLGA), i.v. 0.55-0.75 g/dL (Lactel Absorbable Polymers,
www.absorbables.com, B6013-2)
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Day 1 Particle Formation ---
Drug Activity, Drug
Day 2 Particle Preservation Loading &I Release Kinetics
Day 3 Basic Characterization
Day 3 Surface Modification 14----------- 9'
I I 1Day 4 Icuate Paticeit tels'----------
Day 5 Wash and Raplate a AI
Down'tream Appocatiotns
Figure 1. Flow Diagram for the Particle Engineering Protocol. Generation and
characterization of appropriately sized and charged particles are essential to achieve
consistent particle internalization by cells. Drug activity, loading, and release kinetics
should be studied to determine the optimal particle characteristics for each application.
If drug activity is lost, loading is too low, or release kinetics are inappropriate for the
intended application, adjustments to the particle formation protocol should be made and
new particles should be generated. Once particles with desired characteristics have
been formed, cells can be engineered with particles, characterized, and used in
downstream applications. The dotted lines represent iterative loops to follow if poor
particle internalization is observed: i. Particles are aggregated, ii. Particles have
negative charge, iii. Particles are too large to be internalized. White boxes represent
steps involving only particles, while grey boxes represent cells in culture and may
require additional lead time to expand cells to the appropriate confluence.
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Dichloromethane (DCM) (Sigma Aldrich, www.sigmaaldrich.com, 270997-100ML) CAUTION
Poly(vinyl alcohol) (PVA), Mw 9,000-10,000, 80% hydrolyzed (Sigma Aldrich, www.sigmaaldrich.com,
360627-25G)
Filtered water (MilliQ or Sigma, www.sigmaaldrich.com, W4502-1 L)
Glass scintillation vials with polyvinyl-lined caps (VWR, www.vwr.com,, 66010-267)
Rhodamine 6G (Sigma Aldrich, www.sigmaaldrich.com, 252433-250MG)
MW >30,000 Poly-L-lysine hydrochloride (Sigma, www.sigmaaldrich.com, P9404-25MG)
Pasteur pipette (Fisher Scientific, www.fishersci.com, 13-678-4A)
Pasteur pipette rubber bulbs (Sigma Aldrich, www.siqmaaldrich.com, Z1 11597-12EA)
40-pm cell strainer (Fisher Scientific, www.fishersci.com, 22-363-547)
50-ml Steriflip 0.22pm vacuum filter (Millipore, Millipore.com, SCGP00525)
Transfer pipette (VWR, www.vwr.com, 16001-180)
Aluminum foil (VWR, www.vwr.com, 89068-734)
Disposable capillary cell (zeta potential) (Malvern, www.malvernstore.com, DTS1061)
12 mm square cuvette (DLS) (Malvern, www.malvernstore.com DTS0012)
Methanol (Sigma Aldrich, www.sigmaaldrich.com, 34860-4X4L-R)
Dimethyl sulfoxide (DMSO) (Sigma Aldrich, www sigmaaldrich.com, 472301-100ML)
Cell Engineering
Human mesenchymal stem cells (http://medicine.tamhsc.edu/irm/msc-distribution.html) CAUTION
T25 culture flask (VWR, www.vwr.com, 29185-300)
MEM-alpha (Invitrogen, www.invitrogen.com, 12561-072)
Fetal bovine serum (FBS) (Atlanta Biologicals, www.atlantabio.com, S11550)
Penicillin-Streptomycin (P/S) (Invitrogen, www.invitrogen.com, 15140-163)
L-Glutamine (Invitrogen, www.invitrogen.com, 25030-081)
Phosphate-buffered saline without calcium chloride and magnesium chloride (Sigma,
www.sigmaalrdich.com, A00475)
Analysis
20 kDa-MWCO dialysis tubing (Fisher Scientific, www.fishersci.com, 08-607-068)
Paired standard and weighted dialysis closures (Spectrum Labs, www.spectrumlab.com, 132749)
Fluorodish glass bottom dish (World Precision Instruments, www.wpiinc.com, FD35-100)
Vybrant DiO cell-labeling solution (Invitrogen, www.invitrogen .com, V-22886) CAUTION
Hoechst stain (Invitrogen, www.invitrogen.com, H3570)
10% neutral buffered formalin (Sigma, www.sigmaaldrich.com, HT501128) CAUTION
EQUIPMENT
Particle Preparation
Scale, Metier Toledo X5105 DualRange
50-ml glass beaker
1%2-inch magnetic stir bar
Stir plate, Corning PC-420D
Probe sonicator, Misonix Sonicator 3000 with microtip
Tissue homogenizer, Omni International Tissue Master 125 with 7-mm Probe
Clamp stand
Centrifuge, Eppendorf 5430 Centrifuge
Lyophilizer
Particle Characterization
Zetasizer, Malvern Instruments, ZEN 3690
Fluorescent microscope, Nikon Eclipse TE2000U
Bench-top flow cytometer, Accuri C6
Confocal microscope, Zeiss 700
REAGENT SETUP
Poly-L-lysine (PLL) solution: Dissolve 4 mg of PLL into 40 ml of filtered distilled water to make a 0.01%
(w/v) PLL solution. Store at 40C.
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Procedure
Preparation of Microparticles (7 hours)
1 Dissolve 200 mg of poly(vinyl alcohol) (PVA) in 20 ml of water to make a 1 % (w/v)
PVA solution. Add stir bar and place on magnetic stir plate for 1 hour to allow for
complete dissolution. Note: Concentration of 0.2%-0.5% PVA can also be used.
CRITICAL STEP PVA can aggregate and adhere to the bottom of the beaker. The
position of the stir bar should be periodically adjusted to free aggregates from the
beaker surface and ensure consistent generation of PVA solution.
?TROUBLESHOOTING
2 Add 50 mg of PLGA into a 10-ml glass scintillation vial.
3 Add 1 mg of Rhodamine 6G dye (or small molecule of choice) into the vial.
4 In a chemical fume hood, add 2 ml of dichloromethane (DCM) to the glass vial
containing PLGA/Rhodamine.
CAUTION DCM is an eye and skin irritant and harmful if swallowed. Use proper
personal protective equipment (PPE) and always work in a chemical fume hood.
CRITICAL STEP DCM will dissolve most plastics, use a glass syringe or glass
Pasteur pipette to avoid contamination of the polymer solution.
CRITICAL STEP DCM is an organic solvent with a low boiling point. Cap vial to
avoid evaporation and loss of volume.
CRITICAL STEP The concentration of polymer in the organic solvent is critical to
determining the final particle size.
PAUSE POINT A 1-2 hour break is acceptable at this point.
5 When the 1% PVA solution is completely dissolved, filter through a 0.2-pm vacuum
filter into a clean 50-ml glass beaker.
6 Place the beaker of PVA solution on ice and allow to chill to 4-8'C.
7 When PLGA:Rhodamine solution is completely dissolved, probe sonicate for 10
seconds at 10-12 W to ensure even distribution of the small molecule amongst
polymer chains.
CRITICAL STEP Wash probe sonicator with acetone and ethanol and dry it
completely prior to use to avoid contamination of particles.
?TROUBLESHOOTING
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Figure 2. Generation of Drug-Loaded Microparticles. (a) Schematic of single emulsion-
evaporation technique. Particles are generated by dissolving PLGA and drug into DCM.
Drug solution is then added drop-wise to a stabilizing solution of PVA while
homogenizing to create an emulsion. Particles are then allowed to solidify in suspension
while the solvent evaporates. (b) Representative distribution of particle diameters
generated using this method with 0.15-0.25 g/dL i.v. (Green line) or 0.55-0.75 g/dL i.v.(Red line) PLGA. Inset is a representative SEM image of particles. (Scale bar 1 pm)
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8 Secure the tissue homogenizer with a clamp stand over an ice bucket.
9 Place beaker of PVA in an ice bucket and position homogenizer probe so that probe
is submerged but not in contact with the glass surface (e.g. 0.5 cm).
10 Turn tissue homogenizer on to 35,000 rpm (highest speed on Tissue Master 125).
CAUTION Follow manufacturer's safety instructions in product manual.
11 Use a glass Pasteur pipette to add PLGA solution to PVA solution drop-wise while
homogenizing.
CAUTION Use safety glasses as part of PPE to avoid splash hazard.
CRITICAL STEP Solution will foam and undergo a two-fold increase in volume
during mixing. Use a 50-ml glass beaker to avoid overflow.
CRITICAL STEP When adding PLGA solution to the PVA solution, avoid dripping
PLGA onto the homogenizer probe or wall of the beaker.
12 Homogenize for 2 minutes to create single emulsion
? TROUBLESHOOTING
13 Turn off homogenizer and remove from beaker.
CAUTION Disconnect homogenizer from the energy source before removing.
14 Move particle suspension to a stir plate in a chemical fume hood and add a 1 -inch
magnetic stir bar.
15 Set stir plate to 300 rpm.
16 Cover with aluminum foil perforated with 10-20 holes to allow for evaporation of
organic solvent in a chemical fume hood.
17 Allow 4-5 hours for complete evaporation of the organic solvent.
CRITICAL STEP Incomplete evaporation of solvent will result in particle aggregation
and loss of microparticles in subsequent steps. To test, take 200 p of the sample
and centrifuge at 10OOg for 5 min at room temperature. Particles should easily re-
suspend into a single-particle suspension.
CRITICAL STEP Excessive evaporation time will lead to breakdown of particles due
to hydrolysis and gradual loss of dye or drug loading.
18 Transfer particle suspension to 15-ml centrifuge tubes and centrifuge at 10OOg for 5
min at room temperature.
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CRITICAL STEP Excessive centrifugal forces can cause aggregation of particles
that can be difficult to disperse.
19 Remove supernatant and gently re-suspend in 10 ml of distilled water using a
transfer pipette.
20 Repeat wash process 2 times.
21 After third wash, re-suspend particles in 1 ml of distilled water.
22 Filter through 40-pm cell strainer to remove large particulates and aggregates.
? TROUBLESHOOTING
23 Use 1 ml of fresh distilled water to wash cell strainer and collect additional particles.
24 Transfer particle suspension to 2-ml centrifuge tubes.
25 Remove 20 pl of particle suspension for characterization.
26 Freeze particle suspension at -80 0C and lyophilize for 24 hours.
PAUSE POINT Particles can be frozen overnight.
Preservation of Microparticles (24 hours)
27 Store lyophilized particles in 2-ml centrifuge tubes at -80'C. Seal lids with Parafilm to
prevent moisture contamination that can degrade particles.
PAUSE POINT Particles can be frozen for at least 6 months.
Characterization of Microparticles (1.5 hours)
28 Add 10 pl of particle suspension to 1 ml of distilled water in a cuvette.
29 Mix well and insert into Zetasizer to measure hydrodynamic diameter and
polydispersity index of the PLGA microparticles through dynamic light scattering
(DLS).
? TROUBLESHOOTING
30 Transfer 20 pl of diluted particle suspension to a clean glass slide.
31 Using a fluorescent microscope at 40X magnification, visualize particles to confirm
particle size and polydispersity. SEM can also be performed to confirm the size
distribution and assess the surface morphology.
CRITICAL STEP Presence of large particles or debris can cause errors in DLS
measurements.
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?TROUBLESHOOTING
32 Dilute 2 pl of concentrated particle suspension in 1 ml of distilled water.
33 Add diluted particle suspension into a disposable capillary cell and measure zeta-
potential with a Zetasizer. PLGA-COOH should generate particles with a zeta-
potential of - -40 mV.
CRITICAL STEP Excessive particle concentration and high ion concentrations (e.g.
cell media) can cause the electrodes on the capillary cell to burn resulting in
inaccurate measurements.
? TROUBLESHOOTING
Microparticle Surface Charge Modification (3 hours)
34 Measure 5 mg of lyophilized particles into a 1.5 ml centrifuge tube.
35 Quick spin to minimize loss of particles.
36 Add 1 ml of 0.01 % PLL solution and gently re-suspend particles.
37 Shake at 370C for 2 hours to allow for adsorption of PLL onto the surface of
particles.
38 Add 10 pl of PLL-modified particle suspension and dilute in 1 ml distilled water.
39 Measure zeta-potential as in step 33.
? TROUBLESHOOTING
PAUSE POINT: PLL-modified particles can be frozen at -20 0C for 6 months.
Engineering Cells with Microparticles (14-18 hours)
40 Grow MSCs to 70-80% confluence in T25 flask.
CRITICAL STEP Incubating cells with particles at lower confluence will result in
excessive amount of free particles in solution and particles adhered to the flask
surface.
41 Prepare particle-laden media by diluting 0.3 mg of PLL-modified particles in 1 ml of
MEM-alpha with 1% FBS, 1% P/S, and 1% L-glutamine.
42 Probe-sonicate at 1-3 W, pulsed for 10 seconds to ensure particles are uniformly
dispersed in solution.
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Figure 3. Surface modification of particles with polylysine to enhance particle uptake.Rhodamine-PLGA particles were imaged (a) before and (b) after surface modification
with positively charged FITC-poly-L-lysine (FITC-PLL). (Scale bar 5 pm). The FITC-PLL
coating results in a shift in zeta-potential from (c) -48 mV before coating to (d) +10 mV
after coating.
Sonication
Figure 4. Troubleshooting particle aggregation to improve MSC uptake of particles.Particle aggregation can be caused by numerous factors including high particle
concentration during preservation, presence of excessive residual PVA, or weak zeta-potential. Aggregation effectively reduces the concentration of particles in the mediathat MSCs are capable of internalizing (leading to reduced internalization). Shown are
representative images of a 0.1 mg/ml particle suspension in media (a) before and (b)
after sonication. If particle aggregation is suspected, use a fluorescence microscope to
confirm (if fluorescent dye was loaded in particles), and disassociate particle aggregatesthrough use of a sonication probe or water-bath sonication. (Scale bars 10 pm)
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43 Add suspended particles to 2 ml of 1 % FBS-supplemented MEM-alpha media to
create 3 ml of 0.1 mg/ml particle suspension.
44 Wash MSCs with PBS-/- three times.
45 Add particle-laden media to MSCs and incubate overnight (e.g. >12 hrs).
CRITICAL STEP Shorter incubation times will result in particle association with the
cell membrane; however internalization of particles may not be complete.
46 Aspirate spent media and wash flask three times with PBS-/- at room temperature to
remove free particles.
? TROUBLESHOOTING
47 Add 10% FBS media or split and proceed with downstream analysis or experiments.
48 See 'Quantification of Drug Loading and Release' and 'Analysis of MSC
Microparticle Uptake.' for instructions on further characterization of particles and
particle loaded cells.
Quantification of Drug Loading and Release
The concentration of drug and duration of MSC exposure to small molecules is
critical to control the phenotype. For example, protocols to induce differentiation of
MSCs in vitro typically rely on multiple days of continuous activation of signal
transduction pathways by select agents included within the media. With the particle
engineering approach, the drug loading and release kinetics can be altered by
modifying the particle synthesis protocol through changing the specific composition and
molecular weight of the polymer, the concentration of drug, or through using co-solvents
to aid in dissolution of the small molecule in the polymer solution. Quantification of drug
loading, encapsulation efficiency, and release kinetics should be iterated until a
formulation with desirable characteristics is generated. Drug loading is the mass fraction
of a particle that is composed of drug and calculated by Equation 1. Meanwhile,
encapsulation efficiency describes the fraction of drug incorporated into particles
compared to the total amount of drug that was added during particle synthesis and is
calculated by Equation 2.
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Quantification of drug loading and encapsulation efficiency: Weigh 2 mg of
particles into each of three 1.5-ml centrifuge tubes. Collect dry particles into the bottom
of the tube by quickly spinning in a benchtop centrifuge. Two methods can be used to
solubilize drug contained in the particles i) dissolving the particle (polymer and drug) in
a solvent such as DMSO or ii) swelling the particle to allow release of the drug into
solution. To dissolve particles, add 0.5 ml of DMSO to particles and allow particles to
completely dissolve. The DMSO solution can then be analyzed directly by
spectrophotometry. Releasing drug by the swelling method maintains the PLGA as a
solid and can easily be separated from the drug in solution, however this method should
only be used if the encapsulated drug has high solubility in methanol. Add 0.5 ml
methanol to swell particles and release small molecules into solution. Particles will
clump together and release will be rapid. To ensure complete release, incubate on a
shaker at 37'C for 1 hour. Centrifuge solutions at 2000g for 5 min at room temperature
to pellet debris and collect supernatant into labeled tubes. Samples can be analyzed by
high-performance liquid chromatography according to the absorbance spectrum of the
small molecule. Prepare standard solutions of the small molecule in methanol
(alternative solvents may be required dependent on the solubility of the small molecule)
for calibration. Include a control generated from blank particles (i.e. without the small
molecule). Drug loading and encapsulation efficiency can be determined by Equations 1
and 2 respectively, where CR is the drug concentration of the release media, VR is the
volume of release media, mmp is the mass of microparticles, and mD and mPLGA are
respectively the mass of drug and mass of PLGA initially added during particle
synthesis.
Drug Loading: %DL - CRVR X100 (1)
mhnp
CRVR
Encapsulation Efficiency: %EE = nmm7p x100 (2)
MD+mPLGA
Release kinetics: Release of small molecules from microparticles in vitro can be
determined using dialysis as previously described(33, 34). While release kinetics of
drug from particles internalized within cells is influenced by the intracellular environment
(e.g. presence of enzymes or altered pH), the simplified dialysis system is an important
79
tool that can provide insight into the release kinetics and should highlight relevant trends
as well as pitfalls including excessive burst release and incomplete release. Verify that
the maximum drug concentration in the release media remains an order of magnitude
below the solubility limit in the release media; elevated bulk concentrations reduce the
rate of dissolution of drug from the particle(35). Prepare a 10 mg/ml particle suspension
in PBS. Pipette 200 pi of solution into a 2-inch section of 20 kDa-MWCO dialysis tubing
clamped with a weighted closure. Carefully close the second end of the dialysis tubing
with an un-weighted closure. Load two additional tubings for replicates (for n=3). Place
loaded tubings within 50-ml centrifuge tubes. Add 40 ml of PBS-/- to each tube and cap
securely. Place tubes in a rack on an orbital shaker at 370C. At each time point, collect
1 ml from the outer fluid and store in a labeled centrifuge tube. Replace with an equal
volume of fresh PBS-/-. Samples can be frozen at -80'C until analysis. Samples may
need to be diluted with methanol or another solvent prior to analysis to reach a
detectable drug concentration within the linear range of the calibration curve.
Cumulative release can be determined from Equation 3 where CRt is cumulative drug
release at sample time 't', C is drug concentration of sample at time 't', VR is volume of
release media, C is drug concentration at sample time 'i' and Vr is volume removed at
each sample time.
Cumulative release at time 't': CRt = CtVR ± -' Cjri (3)
Release media can also be used to assess the bioactivity of the released agent to
ensure the agent was not damaged during encapsulation. The intracellular
concentration of drug at specific time points can be determined by washing MSCs that
contain internalized particles with PBS, followed by a PBS solution containing 0.1% (v/v)
Triton X 100 to lyse the cell membranes. Drug within the solution can then be analyzed
to determine the intracellular drug concentration.
Analysis of MSC Microparticle Uptake
After engineering of MSCs with microparticles, it is critical to analyze the cells to
ensure efficient internalization. Poor uptake of particles will result in non-uniform
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exposure of cells to the encapsulated agent and reduce the concentration and duration
in which the particles are able to control cell phenotype. Described here are techniques
to assess the uniformity of microparticle uptake within the cell population, presence of
free microparticles, and subcellular location of microparticles.
Quantifying the uniformity and degree of microparticle association with cells:
Following step 46, MSCs can be analyzed by flow cytometry to determine the degree
and uniformity of cell uptake of dye-loaded microparticles. Harvest cells by washing
three times with 2 ml PBS-/- and incubating for 3-4 min with trypsin or Accutase cell
detachment solution. Centrifuge detached cells in a 15-ml conical tube at 300g for 5 min
at room temperature to pellet cells. Re-suspend pellet in 1 ml of fresh culture media and
analyze with a flow cytometer. Unmodified (native) MSCs and free microparticles serve
as useful controls to determine cell gating and to set the threshold for background
fluorescence. Fluorescence intensity of microparticle-engineered MSC will rise with
increased microparticle loading. Side scatter has also been observed to increase due to
the increased granularity of the microparticle-loaded cells. Following analysis via flow
cytometry, samples can be plated on glass slides and visualized with a fluorescent
microscope to assess the relative number of free microparticles vs. cell-associated
microparticles. While flow cytometry and fluorescence microscopy are useful aids in
determining ideal microparticle formulations and incubation conditions that maximize
association of microparticles with cells, they cannot easily distinguish between
membrane-bound and intracellular microparticles.
? TROUBLESHOOTING
Confirming microparticle internalization: To assess internalization of microparticles
within cells, MSCs can easily be analyzed by confocal microscopy. Engineer MSCs with
dye-loaded microparticles as described above in steps 40-47. Coat a glass-bottom dish
or chamber slide with 100 pl of 20 pg/ml fibronectin for 1 hour to aid in rapid cell
attachment. Meanwhile, harvest MSCs and re-suspend in media supplemented with 5
pl/ml Vybrant DiO membrane dye and 1 pg/ml Hoechst nuclear dye. Incubate on ice for
15 min. Aspirate fibronectin from dish or slide, and add 100 pl of cell suspension as a
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droplet on the fibronectin-coated spot. Carefully transport to 37*C incubator and
incubate for 5 min. Use microscope to examine cell attachment: the majority of cells
should be attached but not spread on the culture surface. Aspirate liquid and replace
with 1 ml of 10% neutral buffered formalin. Fix cells for 5 min, wash 4 times with PBS-/-
and analyze by confocal microscopy.
CRITICAL Extended incubation after plating will lead to cell spreading making it difficult
to determine if microparticles are intracellular or membrane associated.
? TROUBLESHOOTING
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Figure 6. Confirming cellular internalization of microparticles. (a) An inverted
fluorescence microscope can be used to examine the association of cells and particles,
and the presence of free particles (arrows) but cannot be used to conclusively
determine if particles have been internalized. The cell perimeter is outlined in the red
fluorescence channel to distinguish particles that could possibly be internalized from
those that are on the periphery. Representative confocal microscopy images of MSCs
with particle internalization at (b) low and (c) high efficiencies. Images represent a slice
through the cell at the plane of the nuclei showing the presence of (b) mostly outer
membrane associated particles and (c) numerous intracellular particles. (Scale bars 10
pm)
83
Troubleshooting
TABLE 1: Troubleshooting table.
Step Problem Possible Reason Solution
1 PVA not dissolving PVA stuck to beaker Use ultrasonic water bath to detach
PVA clumps from beaker
7 PLGA not dissolving
12 Solutions not mixing,
two layers visible
Emulsion overflows
21 Particle clumping
29 Repeat readings
yield different results
31 Presence of large
particles
33 Zeta-potential is near
zero
39 No change in zeta-
potential after PLL
modification
Large polymer pellets or
high molecular weight PLGA
take more time to dissolve
Surface area of beaker is
too large
Homogenizer is not
adequately submerged
PVA solutions have a
tendency to foam.
Beaker is too short
Solvent evaporation was not
complete
Centrifugal forces too high
Particles have neutral
charge due to excessive
PVA coating
Presence of large particles
or debris that are settling
PLGA concentration or
agitation speed were not
adequate
Ion concentration is too high
causing electrodes to burn
Excessive PVA residue on
particle surface
Inadequate adsorption of
PLL onto the particle surface
Use ultrasonic water bath to facilitate
dissolution of polymer pellets
Use a beaker with a smaller diameter to
reduce surface area
Lower homogenizer so tip is submerged
in PVA solution
Reduce PVA concentration to 0.25-
0.5%
Use taller beaker
Leave suspension on stir plate for an
additional 2 hours with adequate
ventilation
Reduce centrifuge speed and increase
time to pellet particles
Wash with larger volume of distilled
water before initial spin or reduce PVA
concentration to 0.25-0.5%
Filter suspension with cell strainer prior
to measurement or allow large particles
to settle out for 2 min and then carefully
collect particles in suspension into a
new tube
Filter the particle suspension with 5-pm
Supor Membrane using a 20-mL
syringe
Dilute particle suspension and use a
new capillary cell
Reduce PVA concentration to 0.25-
0.5% or add additional wash step prior
to measurement
Prepare fresh batch of PLL and make
sure particles remain in suspension
during modification
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Step Problem
46 Excessive number of
free particles remain
after washing
Particle Poor or inconsistent
Uptake particle loading in
cells
Possible Reason
Concentration of particle-
laden media was too high
Particles added when cells
were at low confluence
Particles are too large
Particles are clumping
Particle suspension not
evenly distributed over cells,
flask tilted
Low particle fluorescence
due to low dye loading
Poor cell health
Reduce the size of the beaker used
during emulsification so solution is more
evenly and vigorously mixed
Probe-sonicate to break up clumps and
confirm with microscopy before adding
to cells
Excipients such as polyethylene glycol,
sorbitol, or mannose can be added prior
to lyophilization at non-toxic
concentrations
Reduce particle concentration
Gently tilt flask front-to-back and side-
to-side in incubator to evenly coat cells;
DO NOT SWIRL
Check and increase dye loading
Check viability and morphology of
MSCs before particle incubation and
use fresh media
Check toxicity of drug and reduce drug
loading accordingly
Reduce particle concentration
Reduce duration of particle incubation
in 1% FBS
Check for microbial contamination
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Solution
Reduce concentration of particle-laden
media
Re-plate cells, allow cells to attach for
20 min, then wash with PBS to remove
free particles
Separate cells from free particles using
Ficoll Density Gradient Separation
Wash cells with trypsin for 1 min to
remove particles, then replace with
normal full serum media
Reduce polymer concentration or
increase agitation speed to generate
smaller particles, and carefully verify
size distribution
Anticipated Results
This protocol establishes a robust technique for controlled delivery of small
molecules or other cargo intracellularly to an exogenous population of cells through the
generation of drug-loaded microparticles (Fig. 1, 2), followed by surface modification of
microparticles (Fig. 1, 3), and functionalization of cells with microparticles (Fig. 1, 6).
Particles can be loaded with a wide variety of agents known to influence cell phenotype
and to control cells following transplantation (Fig. 7). This technique has previously
been employed to induce MSC osteogenic differentiation(11) and enable longitudinal
MRI tracking(19).
We anticipate this protocol can be adapted to deliver a wide range of molecules
to a many cell types to influence cell phenotype, control cell microenvironment, and/or
track cells following local or systemic administration. For example, here we show that in
addition to MSCs, MIN6 beta cells, and macrophages are easily functionalized with
internalized -1-pm microparticles using this protocol (Fig. 8). The particle-engineered
cell platform is highly tunable and can be adapted to a variety of applications such as
promoting and accelerating engraftment of HSCs, enhancing glucose sensitivity of
transplanted beta cells, and maximizing the immunomodulatory function of MSCs (Fig.
7). This protocol has been optimized to reproducibly produce particle-modified MSCs
and to provide tips to troubleshoot commonly experienced problems throughout the
process (Table 1) such as particle aggregation (Fig. 4) and cell gating for flow cytometry
(Fig. 5). We envision this platform being useful to continually deliver agents to cells in
vitro and in vivo to influence cell phenotype including differentiation, direct
reprogramming, survival, secretome, immunogenicity, and proliferation. By controlling
drug loading, molecular weight and composition of the microparticles, release kinetics
can be tuned to continuously release drugs over days to weeks and potentially even
months. We anticipate the platform could also be adapted to accommodate the use of a
particles made from other materials such as alginate, which may be desirable for
encapsulating hydrophilic or sensitive molecules such as peptides or proteins. In
addition, molecules can be transported to the extracellular environment passively via
diffusion or actively through exosomes or drug efflux pumps (Fig. 7). This can be used
to influence the cell's microenvironment as we have previously demonstrated with
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Figure 7. Tailoring cells with intracellular depots for multiple applications. (a) A diverse
toolbox of particles can be generated and used to engineer cells to track their location,
to locally deliver drugs, or to control cell phenotype including proliferation, viability,differentiation, and secretome by targeting i) intracellular targets, ii) membrane bound
targets (in an autocrine-like manner), and iii) extracellular receptors (in a paracrine-like
manner). (b) Engineered cells can be transplanted locally or systemically. For example.
drugs released from intracellular particles can be used to control the phenotype of the
particle-modified cell by enhancing (b-top) the MSC' secretome. Alternatively the
plafform can be used to (b-bottom) locally deliver drugs to tissues where cells reside(where the cell is used as a delivery vehicle).
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dexamethasone(11). Furthermore, particle-engineered MSCs maintain their phenotype
after cryopreservation, enabling off-the-shelf control of MSC phenotype(11). Finally, we
have shown particle formulations containing dexamethasone, rhodamine, or iron oxide
remain stable within MSCs for >18 days making this a useful platform for prolonged
exposure to small molecules(11) and simultaneous longitudinal tracking of a cell's
location(19).
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Figure 8. Potential for universal applicability of the particle engineered cell platform.
The particle engineering protocol was applied to (a,b human bone marrow MSCs, (c,d)
MIN6 beta-cells, and (e,f) RAW 264.7 macrophages. One day following particle
engineering, cells were harvested and analyzed by flow cytometry. All cells showed
increased fluorescence (black lines) compared to unmodified controls (red lines). The
percentage of cells with particles are stated in the upper right corner of each graph. To
confirm particle internalization, confocal imaging was performed as described above.
Images represent a slice through (b) an MSC, (d) a MIN6 cell, and (f) a RAW 264.7
macrophage at the plane of the nuclei showing internalization of particles. (Scale bars
10 pm, Green: membrane, Red: particles, Blue: nuclei)
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Chapter 4 Preface
This chapter is intended to introduce readers to an emerging challenge in MSC therapy
and motivate the need for the application discussed in Chapter 5. As described in
Chapter 1, MSCs have classically been proclaimed to be 'immune privileged' allowing
for cells to be taken from a donor and injected into an unrelated patient without the need
for immunological matching. However, recent evidence has shown that MSC
interactions with immune cells are more nuanced and MSCs are not 'immune privileged'
as classically thought. In this chapter, I provide an up-to-date survey of MSCs clinical
use and provide a historical perspective looking back at the origin of the 'Universal
Donor' hypothesis and recent reports that challenge its validity. We provide a vision for
the future of MSC based therapies and the need for strategies to minimize MSC
immunogenicity and maximize MSC immunomodulatory potency, a challenge I address
with a particle-in-cell approach in Chapter 5.
This article is an adaptation of a manuscript under review at Nature Biotechnology
Glossary of Terms
Antigen: Small fragment of protein that can elicit a response from the immune system
MHC: Major histocompatibility complex proteins are expressed on the surface of cells,
MHC-1 displays self-antigens to immune cells and MHC-Il displays antigens from the
environment.
Immune privileged: A property of a cell or location that prevents a cell that would
normally be rejected from being eliminated by the immune system.
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Chapter 4: Mesenchymal stem cells are immune evasive, but
not immune privileged: A historical perspective
Abstract
The diverse immunomodulatory properties of mesenchymal stem cells (MSCs)
present a significant opportunity for the treatment of a multitude of inflammatory
conditions. MSCs have long been reported to be hypoimmunogenic or 'immune
privileged', enabling transplantation across MHC barriers and the creation of off-the-
shelf culture-expanded MSC therapies. However, recent studies suggest that MSCs do
not persist long-term in vivo and may not be immune privileged as initially considered
leading to immune rejection and the generation of anti-donor antibodies. MSC's appear
to mask their immunogenicity, at least initially, via their immunosuppressive properties.
The impact of rejection on the efficacy of allogeneic MSC therapies has yet to be
determined. Also, no definitive clinical advantage of autogeneic MSCs over unmatched
allogeneic MSCs has been demonstrated to date, although comparisons are currently
under investigation. While MSCs may function through a brief 'hit and run' mechanism,
it is hypothesized that evasion from host immune detection and prolonged MSC
persistence may improve clinical outcomes and prevent patient sensitization towards
donor antigens. Herein we review the current state of MSC clinical trials and then
provide a historical perspective by revisiting the original discoveries of MSCs
immunosuppressive potential and the development of the 'Universal Donor' promise.
We also provide an overview of the allogeneic MSC rejection literature, and discuss
emerging strategies for overcoming barriers to MSC persistence to guide the future of
MSC based therapeutics.
Landscape of MSC Therapy
Mesenchymal stem cells (MSCs), also referred to as multi-potent mesenchymal
stromal cells, were originally identified by Friedenstein over four decades ago by their
multi-lineage differentiation potential(1-3). However, the current primary therapeutic
interest is based on their ability to modulate inflammatory processes. MSCs produce
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exosomes and a multitude of cytokines and growth factors that reduce immune
responses through inhibiting B- and T-cell proliferation, monocyte maturation, and
promoting induction of Tregs and M2 macrophages(4-6). Positive data from pre-clinical
models and elucidation of the immunomodulatory properties of MSCs has prompted a
significant rise in the number of clinical trials that harness MSCs for the treatment of
multiple diseases including myocardial infarction, stroke, graft versus host disease
(GvHD), lupus, arthritis, Crohn's disease, acute lung injury, chronic obstructive
pulmonary disease (COPD), cirrhosis, multiple sclerosis, amyotrophic lateral sclerosis
(ALS), and diabetes(7).
Today, numerous cell preparations from academic and corporate institutions are
being investigated in nearly 300 clinical trials ( >80% of which are Phase I or II, Figure
la, 125 have reached their scheduled completion, and 28 have been reported to be
placebo controlled). Clinical trials examining the safety and efficacy of MSCs have used
both allogeneic (165) and autogeneic (125) cells (Figure 1b). MSCs are typically
manipulated via culture expansion as in situ they exist in limited quantities, thus they
require clinical trials to gain FDA approval and have only recently begun to reach
market approval. In contrast, minimally manipulated (e.g. non-culture expanded) MSCs
have been used clinically for bone regeneration during the past decade. Cellect by
DePuy, an intraoperative technique to concentrate auto-MSCs for bone regeneration
entered the market in 2003(8) (the product has since been discontinued following a
change in FDA regulatory requirements), and Osteocel by Osiris Therapeutics Inc. (now
Osteocel Plus by NuVasive), a cryopreserved immuno-depleted bone allograft retaining
native adherent allo-MSCs has been available since 2005(9). Clinical trials to explore
MSC therapy have been driven predominately by companies with proprietary allogeneic
MSC (allo-MSC) preparations such as Osiris' Prochyma T M , Mesoblast's Revascor@,
Athersys' MultiStem@, Stemedica's Stemdyne-MSC T M , Allocure's AC607, Cellerix's
Cx601, Stempeutic's Stempeucel TM, and Orthofix's Trinity Evolution T M . Many of these
preparations derive their product from a small number of donors through extensive
culture expansion to generate therapeutic doses to treat entire cohorts of patients. In
addition, smaller clinician sponsored trials have also been conducted in medical centers
and academic institutions, often under hospital exemption in Europe, although these
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studies typically utilize much lower passage MSCs(10). Importantly, allo-MSC therapy
has consistently been shown to be safe, enabling future trials to be conducted with
improved trial design and refined MSC-based therapies(7, 11).
Several recent industry sponsored Phase 11 clinical trials and clinician sponsored
trials have generated positive results. Tigenix's Cx611 culture expanded adipose-
derived allo-MSCs reduced joint swelling by 20% or more in 1/5 of patients at a 6-month
follow-up, while placebo treated patients showed no improvement(12). Additionally,
Mesoblast reported improved heart muscle function and reduced major adverse cardiac
events by 78% compared to placebo in congestive heart failure patients at an 18-month
follow-up in a placebo controlled Phase 11 trial(13). In late 2011 Athersys reported 13.5%
and 10.9% increase in ejection fraction in acute myocardial infarction patients receiving
50 and 100 million cells, respectively, via intracoronary adventitial injections compared
to historical controls (phase I trial)(14). Osiris reported reduced stress-induced
arrhythmias and hypertrophy compared to placebo in an ongoing Phase I trial of
ProchymaTM for acute myocardial infarction, although data on the primary endpoints
has yet to be reported(15). In 2011, FBC-Pharmicell's auto-MSC preparation,
Hearticellgram-AMI@, gained approval in South Korea, becoming the first culture-
expanded MSC therapy to receive regulatory approval(16). To date one allogeneic
culture-expanded MSC product has received regulatory approval, Osiris' ProchymaTM,
approved in Canada in May of 2012 and shortly after in New Zealand for the treatment
of steroid-refractory GvHD in children(17). Prochyma T M is now available for adults and
children in 8 other countries including the United States for steroid refractory grade IlIl
and IV GvHD under an Expanded Access Program. Clinician driven studies without
placebo controls have also generated positive data with unmatched-allogeneic and
haplo-identical MSCs for the prevention and treatment of acute GvHD(18, 19).
Prophylactic treatment with MSCs at the time of bone marrow transplantation reduced
the incidence of grade Ill or IV GvHD, 0% vs 26% compared to historical data(19). In
another study, 30/55 patients with severe GvHD showed a complete response to MSC
therapy (resolution of all symptoms) and had significantly improved survival, 52% vs
16%, compared to patients that showed little or no improvement following MSC
therapy(18).
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Figure 1 The rise of MSC therapy. (a) The number of clinical trials in each phase using(Red) allogeneic or (Blue) autogeneic MSCs as reported by clinicaltrials.gov. (b) The
cumulative total number of clinical trials that utilize allogeneic or autogeneic MSCs are
plotted according to the year they were initiated. (c) Cumulative citations from (Purple)
early publications that support the 'Universal Donor' hypothesis and from (Green) work
that highlights MSC immunogenicity are plotted from 2000-2012. Shades represent
contributions of individual papers (references denoted on right). This graph represents
the overall influence each paper continues to exert on the field staring from (bottom) the
most influential to the (top) least influential. (d) Timeline of significant milestones that
have marked the progress of MSC therapy. Data was collected for (a) and (b) from
ClinicalTrials.gov registry on 25 Feb, 2013. Searches for 'Mesenchymal Stem Cells',
'Mesenchymal Stromal Cells', 'Multipotent stromal cells', 'bone marrow stromal cells',
'Stem cells for Spinal Fusion', 'Prochymal', and 'connective tissue progenitor' returned
293 unique MSC trials. 5 trials did not indicate the source (auto vs allo) of the MSCs,
and two reported using both allogeneic and autogeneic MSCs. Citation data for (c) was
collected from Web of Knowledge (Searched April 24, 2013).
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I I
While case studies(20, 21) and clinical studies of small groups of patients(10, 18)
have suggested MSCs have significant clinical utility, demonstration of MSC therapeutic
effect in large placebo-controlled trials has remained elusive, thus limiting the clinical
application of MSCs. Several placebo controlled studies have yielded disappointing
results, showing only marginal improvement or failing to show efficacy over placebo,
including Osiris Prochyma T M trials targeting steroid-resistant GvHD, first-line GvHD,
COPD, and type 1 diabetes. Of note, MSC products in general have not been optimized
to maximize therapeutic potential and it is believed that certain allo-MSC products may
be over-passaged leading to reduced potency. Furthermore, cell therapy trials often
suffer from a large placebo effect making it difficult to show efficacy. Importantly,
retrospective sub-population analysis of the steroid-resistant GvHD trial earned
Prochyma T M its first approval in Canada.
While allo-MSC therapy faces several challenges, auto-MSC therapy is not
without drawbacks. Auto-MSC therapy generally requires several weeks after cell
harvest to expand MSCs ex vivo to generate a therapeutic dose. Furthermore,
significant variation in MSCs' secretome and immunomodulatory potency has been
observed between donors. Thus, auto-MSC therapy may not be suitable for the
treatment of acute conditions and variability between patient-derived MSCs is likely to
lead to highly variable outcomes. While both auto-MSCs and unmatched allo-MSCs are
being explored in clinical trials, direct comparisons are scarce. In the recent POSEIDON
trial, the safety and efficacy of auto- and allo-MSCs were compared after administration
into the remodeled cardiac scar of patients with chronic cardiac ischemia. Unfortunately,
clinical improvement was limited at 30 days in both allogeneic and autogeneic groups.
Auto-MSCs were associated with marginal improvements in a 6 min walk test and
Minnesota Living with Heart Failure Questionnaire while allo-MSCs were associated
with fewer, but not statistically significant, arrhythmias. Administration of either auto- or
allo-MSCs resulted in a small improvement in ejection fraction (-2%). Without a strong
positive effect, a placebo group, or analysis of donor cell persistence, it is difficult to use
this trial to effectively compare the efficacy of allo- vs auto- MSCs. Although both were
shown to be safe, comparisons of auto- and allo- MSCs are warranted in future
studies(22). Furthermore, in contrast to auto-MSC therapy, allo-MSC therapy has the
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luxury of harvesting MSCs from healthy donors and selecting lots based on potency
assays(23).
It is critical to consider that most patients receiving allo-MSC transplantations
undergo minimal to no MHC matching prior to treatment, as MSCs are classically
thought of as immune privileged. As such, allogeneic preparations are treated as a
"one-size-fits-all" off-the-shelf cell-based therapy. However, MSCs have been shown to
have variable expression of immunogenic and immunosuppressive factors that make
their interaction with immune cells nuanced and context dependent. To understand the
origin of the "immune privileged" promise, we must revisit the early discoveries of the
immunomodulatory potential of MSCs, and the clinical trials that swiftly followed. Herein
we aim to provide a historical review of the origin of MSC's immune privileged status
and review old and new evidence that challenges the 'Universal Donor' hypothesis (Box
1). For a recent in-depth immunological analysis of allogeneic MSC rejection see Griffin
et. al(24).
The Rise of Mismatched MSC Therapy
From 1998 to 2000, researchers at Osiris Therapeutics presented a series of
abstracts at American Hematological Society meetings that suggested MSCs interaction
with hematopoietic cells extended beyond supporting hematopoiesis(25, 26) to serving
a key role as immune regulators(27-29). Specifically, they reported hMSCs suppressed
activated T-cell proliferation(29, 30) and mixed lymphocyte reactions (MLR) in a
genetically-unrestricted manner(28, 31). As even third party MHC-mismatched hMSCs
were capable of suppressing an ongoing MLR, Klyushnenkova et. al. proposed the
concept of generating a large supply of culture expanded allo-MSCs from a 'Universal
Donor', that could then be used to treat all patients(28, 31). While these early reports
illuminated the therapeutic potential of allo-MSCs, the mechanisms mediating their
immunosuppressive properties were not understood. Additional work by Osiris and
others supported and extended these findings within in vivo models.
In 2002, Bartholomew et. al. showed that the addition of baboon MSCs to
cultures of stimulated allogeneic peripheral blood leukocytes (PBL) resulted in
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Box 1. Take Home Messages
1. MSCs were declared immune privileged without a complete understanding of
their context-dependent immunosuppressive and immunogenic potential. As
such, MSCs are often cited as immune privileged to justify their allogeneic use.
2. Confusion over whether MSCs are immunogenic draw largely from early in
vitro studies that declared MSCs as non-immunogenic, and from the lack of
infusion related reactions in clinical trials. In hindsight it appears MSCs'
immunosuppressive nature, which distinguishes them from fibroblasts, masks
their immunogenicity.
3. Animal studies suggest that MSC persistence depends on MHC expression,
route of administration, and destination of the cells (e.g. within tumors
mismatched allo-MSC persist). Importantly, allo-rejection does not impact the
efficacy of MSC therapy in all cases as a brief 'hit and run' mechanism may be
sufficient to achieve a therapeutic effect.
4. Clinical trials and animal studies have revealed allogeneic MSCs elicit an anti-
donor antibody response. Preclinical studies show that this leads to rapid
rejection of repeat MSC doses and prevents MSC recipients from accepting
subsequent tissue/blood transplants, although this has yet to be demonstrated
clinically.
5. While preclinical evidence shows both extended MSC persistence (through
obviating transplantation shock) and immune evasion enhances treatment
efficacy, advantages of using autologous over allogeneic MSCs have yet to be
demonstrated in clinical trials.
6. Approaches to enhance immune evasion through modification of MSCs or the
host exhibit significant potential to improve MSC persistence enabling MSCs to
function beyond a 'hit and run' mechanism, and should be considered for next
generation MSC based therapy.
7. Standard MSC phenotype analysis should include examination of
immunomodulation and immunogenicity (MHC receptor expression) at
baseline and after activation (e.g. TNF-a and/or IFN-y stimulation) to simulate
MSC exposure to inflammatory signals post-transplantation.
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suppression of PBL proliferation in an MSC-dose dependent manner(32). Furthermore,
the addition of MSCs to an ongoing MLR resulted in suppression of the proliferative
response regardless of the MSC donor (auto-, allo-, and third-party MSCs). Although,
suppression was partially reversed by the addition of IL-2, suggesting MSCs did not
induce allogeneic anergy(32). To test the immunosuppressive potential of MSCs in vivo,
skin grafts from MHC-mismatched baboons were performed immediately prior to
intravenous injection of donor-matched or third-party MSCs. Administration of donor or
third party MSCs extended the survival of the skin graft from 7 days (control without
MSCs) to 11.3 and 11.8 days, respectively(32). In parallel, Liechty et. al. reported the
finding that human MSCs could persist as long as 13 months after intraperitoneal
injection into pre-immune and immune competent fetal-sheep (a model in which
xenogenic or allogeneic HSC are rejected)(33). Others have subsequently reported that
donor-derived MSCs promote tolerance of other transplanted tissues, including
pancreatic islets(34) and heart allografts(35), however specific tolerance towards
unmatched MSCs or repeat doses of MSCs has not been convincingly demonstrated.
MSC mediated immune suppression has been shown to be dependent on a
myriad of factors including cell dose, proximity to immune cells, and requisite stimulation
by inflammatory cytokines(36, 37). Extensive in vitro work during the past decade has
shown that MSC immunomodulatory potential is MHC unrestricted, and significant
efforts have begun to elucidate the mechanism of MSC-immunomodulation. Specifically,
not only do allo-MSCs fail to elicit a response in MLRs, but third party MSCs suppress
ongoing MLRs as effectively as auto-MSCs in a dose-dependent manner(30, 38-40). In
addition, allo-MSCs inhibit T-cell proliferation induced by the potent mitogens, PHA, Con
A, and SpA(38, 39). Interestingly, MSC T-cell suppression is also transient, as T-cells
respond to allo-antigen upon removal from MSC co-cultures(40).
Over a decade ago MSCs were postulated to act as immune regulators either
through cell contact dependent signaling or secretion of cytokines and growth factors,
leading to a series of studies to elucidate the mechanism of MSC:immune cell
interactions(38, 39). Culture expanded hMSCs typically express low levels of MHC 1,
are MHC 11 negative, and do not express the co-stimulatory molecules B7-1, B7-2, or
CD40, suggesting cell contact may not be the primary mechanism of
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immunomodulatory action(30, 39, 41). This was verified by the initial studies examining
the mechanism of MSC T-cell suppression, that showed immune-suppression was not
dependent on cell contact, but was augmented by close proximity. Specifically while
hMSC mediated suppression of T-cells was apparent in both mixed co-cultures (direct
cell-cell contact) and transwell assays, immune-suppression was maximized in mixed
co-culture conditions(38). Tse et. al. examined the effect of soluble factors through a
series of inhibitor studies. Inhibition of either PGE2 or indoleamine-2,3-dioxygenase
(IDO) each resulted in only a partial reduction of hMSCs suppressive effects(30). These
and other studies suggest that MSC suppressive potential cannot be pinned to a single
factor, but rather a cocktail of soluble factors, many of which are inducible by
inflammatory environments(6, 36). Inflammation responsive immune-suppression is
supported by data showing enhanced T-cell suppression when MSCs are
preconditioned with IFN-y for 48 hours(41), and by data showing a limited effect
observed in transwell(38, 40) and conditioned media(40) experiments in which MSC
exposure to IFN-y is minimized or eliminated. Furthermore, recent studies have shown
MSCs can be polarized to pro- and anti-inflammatory phenotypes by preconditioning
with cytokines, including IFN-y and TNF-a(5, 42), and signaling through toll-like
receptors(37, 43, 44). See reviews by Ren et al(45), Ranganath et al.(36), and
Prockop(6) for a thorough discussion of MSC's therapeutic secretome and its'
immunosuppressive potential.
First Clinical Trials
With MSCs immunomodulatory potential established in MLRs and early pre-
clinical models, MSCs were rapidly transitioned to the clinic. In 2004, Le Blanc et. al.
were among the first to clinically administer allo-MSCs(21). Third party haploidentical
MSCs were harvested from the mother of a 9-year-old boy suffering from treatment
resistant grade IV GvHD. The boy received MSCs 73 and 170 days after bone marrow
transplantation, with rapid recovery after each MSC infusion, and survival beyond 1
year. In contrast, the 24 patients at the same treatment facility with acute grade IV
GvHD not receiving MSC therapy died an average of 2 months following bone marrow
transplantation. This landmark case study provided an early glimpse of MSCs'
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therapeutic potential. Just 8 months after the publication of Le Blanc's Lancet article,
Osiris Therapeutics began recruiting patients for the first large scale clinical trials of allo-
MSCs for the treatment of acute GvHD and acute myocardial infarction
(ClinicalTrials.gov).
While the mechanisms mediating MSC immune-modulation and apparent
immune privileged status were beginning to be examined, MSC use in clinical trials
soared (Figure 1b). By 2010, over 100 clinical trials were underway worldwide, with over
half utilizing allo-MSCs(7). Unfortunately, while safety endpoints were consistently met,
MSCs failed to show efficacy over placebo in the first randomized double blind placebo
controlled phase Ill clinical trials(46, 47). These setbacks have raised several questions
regarding limitations of current approaches and how MSC therapy can be improved to
realize its potential(48).
MSC Persistence is Limited
A limitation of MSC therapy is that MSCs do not persist following infusion. Using
bioluminescence imaging, intravital microscopy, donor DNA analysis, and donor RNA
analysis, the persistence of human (in SCID mouse), mouse (in syngeneic mouse), and
rat (in allogeneic rat) MSCs was shown to be limited with the majority of cells dying
within 48 hours following systemic infusion(49-51). This trend has recently been
confirmed through analysis of tissues at autopsy of patients who received allo-MSC
infusions within a year prior to their death(52). Tissues from 18 patients who received
MHC-mismatched or haplo-identical MSCs were analyzed; no ectopic tissue was
observed, and only one patient showed significant levels of donor DNA in multiple
tissues. However, the donor positive patient was not representative of the average
patient, as he was severely immune compromised, septic, and received the MSC
infusion just 7 days prior to his death(52). While allo- and auto-MSCs alike may fail to
persist following systemic infusion simply due to stresses encountered during
transplantation (nutrient/growth factor deprivation due to transport limitations of nutrients
and oxygen(53), shear stress, lack of attachment), it is likely that a more active
immunological process is also responsible for the limited persistence of allo-MSCs.
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Allo-MSCs are Not Immune Privileged
Preclinical and clinical observations have led multiple groups to question the
'immune privileged' status of MSCs, and subsequently, the use of a 'Universal Donor'
for MSC therapy. While the majority of in vitro studies have highlighted the
immunosuppressive properties of MSCs, several studies have provided evidence that
mismatched MSCs are immunogenic. While culture expanded MSCs express low levels
of MHC I and are negative for MHC II, exposure to IFN-y or differentiation into mature
cell types has been shown to significantly increase expression of both MHC
classes(41).
In 2005 one of the earliest reports of MSC allo-rejection was published.
Eliopolous et. al. examined the persistence of mMSC transfected with erythropoietin
(EPO-MSC) in syngeneic and allogeneic unmatched hosts(54). EPO-MSCs were
seeded on a collagen scaffold and injected subcutaneously in syngeneic (C57/B16) or
allogeneic (Balb/c) hosts. As a surrogate for MSC survival, the rise in hematocrit (HCT)
in response to EPO production was measured for over 140 days. Mice receiving
syngeneic EPO-MSC exhibited a sustained increase in HCT while those receiving
allogeneic EPO-MSC exhibited a spike in HCT followed by a return to baseline. Analysis
of collagen scaffolds removed 15 days post-implantation revealed significant infiltration
by CD8+ T-cells and NK cells only in the allogeneic EPO-MSC treated animals. In
addition, administration of a second dose of allogeneic EPO-MSC resulted in a second
but diminished spike in HCT suggesting the initial challenge may have sensitized the
animals to allo-antigen(54).
While allo-MSCs are not as immunogenic as unmatched fibroblasts or
hematopoietic stem cells which elicit rapid rejection in immunocompetent hosts, MSCs
are not 'immune privileged' and elicit a humoral and cellular immune response in vivo,
as Eliopoulos et. al. first reported nearly a decade ago. Zangi et. al. injected luciferase
expressing mMSCs or fibroblasts in syngeneic and allogeneic hosts and compared their
persistence(55). The majority of syngeneic mMSCs and fibroblasts were detectable for
the duration of the experiment (40 days), while in the allogeneic setting fibroblasts died
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by a day 10 and mMSCs by day 20. In addition, mice showed enhanced sensitivity to
allogeneic fibroblasts if the mice had previously been treated with allo-MSCs from the
same donor, rejecting fibroblasts at day 2 compared to day 14 in naive mice. In
addition, allo-MSC treated mice had elevated levels of CD4+, CD122+ CD44+, and
CD62L'OW T-cells indicating the formation of T-cell memory(55). Others have since
reported that infusion of allo-MSCs can induce immune memory. Mice inoculated with
unmatched allo-MSCs exhibit rapid rejection of donor derived splenocytes within 24
hours of the second transplant, suggesting the initial mMSC injection sensitized the host
to donor antigens and induced a memory T-cell response(56). In another model, mice
receiving intraperitoneal injections of allo-MSCs produced elevated titers of allo-reactive
antibodies and rejected subsequent allogeneic skin grafts(57). Similarly, evidence of
immune detection and lack of long-term engraftment of allo-MSCs has been observed in
a variety of other species, including rat(58, 59), baboon(60), rhesus macaquea(61), and
pig(62). In addition to generation of allo-reactive antibodies, intracranial injection of allo-
MSCs resulted in an increase in CD4+ and CD8+ T-cells in mice(58) and CD8+,
CD16+, and CD8+/CD16+ T-cells in rhesus macaques(61). Allo-MSCs have been
shown to be susceptible to antibody-dependent complement mediated cytotoxicity in
pigs(62) and rats(59). Allo-MSC also appear to elicit a response from innate immunity.
Human MSCs were shown to promote macrophage and neutrophil infiltration at the
injection site in rats and mice(63, 64). Furthermore, hMSC engage complement on their
surface(65), although the effect of complement on MSC function is currently debated
and complement mediated lysis of MSCs is likely allo-antibody dependent(66, 67).
MSC Immunosuppression Masks Immunogenicity
While MSCs cannot be generally considered as immune privileged, they appear
to delay their own allo-rejection. The timing and severity of MSC rejection appears to be
strongly context dependent and is dictated by a balance between MSC's expression of
immunogenic factors and the potency of immunosuppressive factors (Figure 2). Indeed
it appears the immunosuppressive properties of MSCs may mask their immunogenicity
within in vitro assays (such as MLR or T-cell suppression assays), where the
concentration of MSCs is high enough to strongly influence the microenvironment within
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the cell culture well. Similarly, unmatched allo- and xeno-MSCs have been reported to
preferentially persist within in vivo environments that are immune suppressed such as
tumors while failing to persist in other tissues within the same animal(51, 68). This
suggests that local immune suppression is required to mask MSC immunogenicity(68).
Detailed in vivo studies on MSC immunogenicity are needed using human MSCs or
non-human primate MSCs that more closely mirror human biology as murine and
human MSCs exhibit differences in expression of immunomodulatory factors(69).
Specifically, hMSC immune modulation is often mediated through IDO, while mMSCs
secrete virtually no IDO but high levels of iNOS(69).
Importantly, it has yet to be shown clinically that MSC persistence or immune
tolerance is required or would lead to enhanced treatment efficacy. Many believe the
observed therapeutic effect of MSCs is due to a 'hit and run' mechanism through the
production of exosomes or secretion of trophic factors during the initial days following
injection(6, 52) while others believe that the main therapeutic response may be
achieved through a yet-to-be-defined reprogramming of the immune system mediated
through apoptotic bodies(70). Conventional wisdom suggests that MSC therapy could
be significantly advanced, at minimum by increasing duration of secretome expression
through extending their persistence following transplantation(36).
Interestingly, while no adverse events have been linked to administration of allo-
MSCs, an anti-donor response has been observed. Both the POSEIDEN trial and a
recent phase 11 Mesoblast trial reported generation of anti-donor antibodies in 13% of
allo-MSC treated patients. The impact of antibody production on the efficacy of MSC
therapy is still under investigation. However, the therapy still appears safe as Osiris and
others frequently administer repeat doses without complications(11). Depending on the
therapeutic mechanism of MSCs, such a response may not negatively impact the
therapy, however, sensitization to donor antigens could have long-term consequences.
Patient sensitization to donor antigens could facilitate rapid rejection of subsequent
MSC infusions as seen in animal models discussed above and could disqualify patients
from future cell, tissue, and organ transplants. To become a sustainable model of
therapy, strategies to overcome allogeneic rejection and allo-antibody production should
be established.
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Prior to transplantation, MSCs typically exhibit low
immunogenicity and do not secrete significant
levels of immunomodulatory factors
MSCs in vitro
Exposure to cytokines in situ
activates signaling cascades that
alter MSCs'immunogenicity and
immunosuppressive
potential
Following cytokine exposure,
MSCs express high levels of
MHC-I and MHC-1l as well as
immunosuppressive factors
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Figure 2 Proposed model for the interplay between MSC immunosuppression and
immunogenicity. MSCs immunosuppressive potential and immunogenicity are both
induced by elevated levels of systemic or local inflammatory cytokines (secreted by T-
cells and other cell types). High immunosuppressive potential permits MSCs to
suppress inflammation and delay or evade allo-rejection through suppression of T-cell
activation and inhibition of APC maturation. However, MSCs that fail to tip the balance
towards immunosuppression, are prone to immune detection and destruction through
multiple modes of rejection(24). (*shown in xenogenic models(63, 64), tdescribed within
in vitro assays(65))
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Immune Evasion Strategies Appear Promising to Improve
MSC Persistence
Overcoming MHC-barriers is a significant challenge in transplant biology. Recent
progress has been made in solid organ transplantation through induction of mixed
hematopoietic chimerism facilitated by donor HSC transplantation(71). In addition,
allogeneic cell products like Viacyte's PEC-01 TM harnesses immune-isolation membrane
based devices (Encaptra®) and tissue engineered products like Organogenesis'
Apligraf® and Shire's SRM003(Formerly VASCUGEL®) temporarily avoid rejection by
encasing differentiated allogenic cells in collagen or gelatin gels. Unfortunately without
induced tolerance or physical barriers the majority of allogeneic tissues and cells, MSCs
included, remain susceptible to rejection. Work is currently underway to enhance MSC
persistence by overcoming allo-rejection, which in turn may enhance the therapeutic
effect of MSCs. These strategies can be divided into two primary categories:
modification of the host, and modification of MSCs.
To prevent host rejection of donor cells and extend MSC persistence, several
groups have experimented with combining MSCs and anti-rejection drugs classically
used in organ transplantation. Interestingly, the strongest clinical evidence of MSC
therapeutic effect, as described above, has been observed in patients with steroid-
resistant acute GvHD, who receive MSC therapy in the context of a standard regimen of
immunosuppressant drugs. While this observation is currently correlative, work is
underway to investigate synergistic effects of immunosuppressant drugs and MSCs.
Adding cyclosporine A to co-cultures of MSCs in an in vitro MLR assay resulted in
significantly enhanced suppression of cell lysis over cyclosporine A or MSCs alone(72).
However, Buron et. al. found that mycophenolate acid consistently synergized with
MSCs to suppress MLRs, although the effect was mild. In contrast, dexamethasone,
rapamycin, cyclosporine A, and tacrolimus synergized or antagonized MSC MLR
suppression depending on the dose of the drug and the responder:MSC ratio(73).
Unfortunately, the mechanism by which immunosuppressive drugs augmented or
interfered with the immunosuppressive properties of MSCs were not evaluated, and
detailed mechanistic studies are needed. In one of the few studies of
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immunosuppressive drug interactions with MSCs in vivo, Ge et. al. investigated the
effect of low dose rapamycin and MSCs in a cardiac allograft model(74). Combining a
14-day course of low dose rapamycin with unmatched allo-MSC therapy resulted in
long-term persistence of GFP-labeled allo-MSCs and tolerance (100 day) of a heart
graft of MSC donor origin(74). The mice did not accept 3rd party allografts, indicating
generation of specific tolerance toward the MSC donor antigens. Mice receiving
rapamycin and MSC therapy showed elevated levels of tolerogenic dendritic and T-cells
and no signs of allo-antibodies(74). More research is needed to characterize the impact
of immunosuppressive drugs on MSC phenotype and in vivo persistence. Nevertheless,
specific combinations of immunosuppressive drugs, including rapamycin, may have
synergistic effects with MSCs through protecting MSC's from host rejection. We have
also recently shown that steroid conditioning of MSCs can augment their anti-
inflammatory properties (unpublished). Furthermore, short-course immunosuppression,
which has shown promise in preventing GvHD(75) and prolonging liver allograft
survival(76, 77), may be sufficient to extend MSC persistence and augment their
therapeutic effect. In addition to the administration of small molecules to prevent allo-
rejection, the host immune response could also be modulated by antibody-mediated
depletion of specific cells, such as NK or cytotoxic lymphocytes. However, such
strategies could increase the risk of infection in vulnerable patient populations.
Rather than modify the host to prevent allo-MSC rejection, or use physical matrix
or membrane-based barriers that are not amendable to systemic infusion, MSCs can be
directly modified to reduce their immunogenicity (Figure 3). For example, de la Garza-
Rodea et al. looked to viruses for inspiration in evading immune detection. To
permanently suppress MHC-1 surface expression, hMSCs were transfected with viral
immunoevasins from Bovine Herpes Virus Type 1, Epstein-Barr Virus and Human
Cytomegalovirus (HCMV)(78). Of these, only the US1 1 protein from HCMV was found
to strongly suppress hMSC expression of MHC-l. US11-MSCs locally injected into the
ear of immunocompetent mice persisted similarly to hMSC in immunodeficient mice
(-50% detectable at 14 days), However immune evasion was achieved only after NK
cell depletion, as the lack of MHC-1 expression made hMSCs susceptible to NK cell
lysis(78). Similarly, Soland et. al. infected hMSCs with immunoevasins from HCMV(79).
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Figure 3 Strategies to facilitate MSC immune evasion. While co-administration of
immunosuppressive drugs with MSCs and transfection with immunoevassins have been
harnessed, multiple engineering strategies can likely be applied to achieve
immunoevasion including (a) viral and non-viral modification, (b) cell surface
engineering, and (c) small molecule, biological agent, and biomaterials approaches. The
response time can potentially be extended by use of (c) agent-doped cell internalized
degradable microparticles(80) or nanoparticles or seeding cells on agent-doped
scaffolds prior to implantation. (d) Surface expression of decoy or inhibitory receptors
can also be directly engineered onto the cell surface through several techniques
including (b) chemical modification including covalent conjugation chemistry(81, 82),
engineered vesicles(83), or through insertion of antibody fusion proteins into the cell
membrane via palmitated protein G (PPG)(84). Increased persistence can also be
achieved through reducing immunogenicity through the use of (e) immunoevasins or (f)
sustained release of immunosuppressive factors.
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hMSCs were genetically engineered to express HCMV proteins, US2, US3, US6, or
US11. Expression of two of the viral proteins, US6 and US11, resulted in significant
suppression of MHC-l surface expression, thereby avoiding recognition of the hMSCs
by cytotoxic lymphocytes. Interestingly, in contrast to de la Garza-Rodea's report,
expression of US1 1 also resulted in protection from NK cell lysis in co-cultures with NK-
92MI cells. However, the mechanism of NK cell evasion was not fully elucidated. Virally
modified hMSCs injected into the liver of pre-immune fetal sheep were less susceptible
to NK toxicity and had a 1.8 fold increase in engraftment (% of cells found in the liver of
donor origin) compared to unmodified hMSCs(79). While these viral strategies appear to
address an aspect of MSC rejection, they have yet to be demonstrated as a viable
strategy to prevent immune memory induction in a fully immune competent host, or to
enhance the therapeutic effect of MSCs in disease models. In addition to forced
expression of viral immunoevasins (Fig. 3a,e), MSCs could be engineered to
overexpress inhibitory molecules that suppress complement activation (CD46, CD55,
CD59) and inhibit NK activation (HLA-E, HLA-G) (Fig. 3a,d). MSCs could also be
decorated with immune evasive moieties through chemical cell surface modification
approaches(82-84) (Fig. 3b,d). Alternatively, MSCs could be preconditioned or
loaded(80) with small molecule drugs or biologicals that increase the expression of
surface receptors or the production of immunosuppressive factors (e.g. PGE2, IDO,
HLA-G, IL-10), increasing their immunomodulatory potency and possibly inducing
tolerance (Fig. 3c,f).
A Revised Vision for Allogeneic MSC Therapy
While a comprehensive understanding of MSC allo-rejection is still under
development and questions remain, it is clear that MSCs are not immune privileged, at
least not to the extent that has been classically proclaimed, but could be considered
'immune evasive'. Despite substantial data on MSC allo-rejection, unmatched allo-
MSCs have continued to be referred to as immune privileged and their use in clinical
trials has continued to escalate (Figure 1). In addition, the community appears reluctant
to abandon the immune-privileged paradigm, evidenced by the number of citations for
articles that support the 'Universal Donor' hypothesis compared to the number of
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citations for articles that highlight MSC immunogenicity (Figure 1C). It is clear that
immunogenicity needs to be recognized as a characteristic of MSCs and its impact on
MSC therapy needs to be examined.
MSC production of potent immunomodulatory exosomes and secreted factors
has shown significant promise in pre-clinical models and in select clinical trials as
discussed. Furthermore, efficient expansion of MSCs enables them to overcome the
fundamental limitation of solid organ and hematopoietic stem cell transplantation;
supply. Unmatched MSCs may be an appropriate option where a 'hit and run'
mechanism of action mediated through transient secreted factors(50), exosomes(85), or
mitochondrial transfer(86, 87) is sufficient to provide therapeutic benefit. In addition,
apoptotic bodies generated from dying cells have been shown to be able to modulate
inflammatory reactions(70), however this mechanism of action has yet to be credited for
MSCs therapeutic effects. Moreover, the hypothesis that extended persistence will
translate to sustained therapeutic effect and improved clinical outcomes has yet to be
tested clinically. Nevertheless, for the millions of patients suffering from chronic
conditions, who have placed their hope in stem cell-based therapies, the approach for
allo-MSC therapy needs revision. Patients must be prevented from becoming
immunized, which could blunt or inhibit the activity of future MSC therapies. In addition
to the immune evasion strategies discussed above, banking MSCs from a diverse donor
population or harnessing patient specific MSCs through iPS cells(88) are alternative
solutions to avoid patient sensitization. Due to the ease of MSC expansion, a banking
system, much like that for blood, is not difficult to imagine. MSCs from a representative
subset of the population could be harvested, typed, and expanded for clinical use. With
time, healthy donors would populate the cell bank with sufficient variety of MHC
antigens. Evidence suggests this should improve outcomes(74) as well as enable serial
injection of MSCs without rejection or co-administration of immunosuppressive drugs.
Work is already underway via a recently awarded $10 million NIH grant to compare
efficacy of MHC matched and mismatched MSCs in a non-human primate model of
pancreatic islet transplantation(89).
As MSC persistence correlates with the relative expression of immunogenic and
immunosuppressive factors (Figure 2), development of next generation MSC therapies
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should focus on shifting this balance. Specifically, MSC potency assays must be
established based on MSCs expression of immunogenic/immunosuppressive factors at
baseline and after TNF-a and IFN-y stimulation (simulates MSC exposure to
inflammatory signals post-transplantation), and standardized to ensure patients receive
functional and comparable doses(23). The ISCT minimal criteria that is often used in
research cannot predict immunomodulatory function or immunogenicity of a batch of
MSCs and significant variability in immunomodulatory potency between donors, tissue
sources and culture conditions has been documented(5, 90-92). For MSCs to reach
their potential in the next decade, new strategies to maximize MSC potency are needed.
In addition to finding optimal sources of MSC, the therapeutic potential of MSC can
likely be enhanced through increasing their persistence and controlling the MSC
secretome by polarizing them to an anti-inflammatory phenotype prior to delivery(36,
37). It will also be critical to prevent patients from becoming sensitized to allo-antigens
which would lead to rapid rejection of subsequent MSC doses and reduce the efficacy
of MSC therapy.
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Chapter 5 Preface
In this chapter the particle-in-cell platform is put to use to minimize MSC
immunogenicity and maximize MSC's immunomodulatory potency. As described in
Chapters 1 and 4, MSC therapy depends on the ability of MSCs to modulate
inflammatory processes through the expression of immunomodulatory factors. In this
chapter, a small molecule is identified that significantly enhanced MSC's therapeutic
potential, without negatively impacting other aspects of cell phenotype including
viability, proliferation, and morphology, and metabolic activity. As the enhancement is
most prominent when the drug is continuously present, the particle-in cell approach is
then used to enable sustained control of MSCs' therapeutic phenotype.
This article is an adaptation of a manuscript submitted to Nature Biotechnology.
Glossary of Terms
Indoleamine-2,3-dioxygenase: Intracellular enzyme responsible for degrading
tryptophan
Budesonide: Synthetic glucocorticoid steroid.
Peripheral Blood Mononuclear Cells: Immune cell population (Predominately CD4+ and
CD8+ T cells) isolated from blood after depleting neutrophils and red blood cells.
1-methyl-tryptophan: Competitive inhibitor of IDO, prevents degredation of tryptophan
RU486: Competitive inhibitor of the glucocorticoid receptor, prevents docking of
glucocorticoid steroids
siRNA: short double stranded RNA sequence used to destroy mRNA in a cell, thereby
knocking down expression of the gene.
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Chapter 5: Enhanced mesenchymal stem cell
immunomodulatory potency through sustained intracellular
delivery of small molecules
Abstract
Mesenchymal stem cells are being explored to treat numerous inflammatory
conditions, however, clinical studies have yielded mixed results. Recent data suggests
that this is due to highly variable and inadequate MSC potency. We report a discovery
that glucocorticoid steroids significantly augment MSC expression and activity of
indoleamine-2,3-dioxygenase, a primary mediator of MSC immunomodulatory function.
This effect is dependent on signaling through the glucocorticoid receptor and mediated
through up-regulation of FOXO3, which acts as an enhancer. Treatment of MSCs with
the glucocorticoid steroid budesonide, results in a significant up-regulation of IDO 24
hours following IFN-y stimulation and the enhancement is most notable when cells are
continuously exposed to budesonide compared to a simple pre-treatment regimen. To
translate this finding to a platform that could be used in vivo without requiring systemic
glucocorticoid immunosuppression, we engineered MSCs with intracellular PLGA
microparticles loaded with budesonide. MSCs efficiently internalized budesonide
microparticles and exhibited enhanced expression and activity of IDO over budesonide
preconditioned and naive MSCs, resulting in a 2-fold enhancement in MSC suppression
of stimulated PBMC co-cultures. In addition to suppressing PBMC proliferation,
budesonide modified MSCs (BUD-MSCs) also suppressed PBMC secretion of IFN-y.
Addition of the IDO inhibitor 1-methyl-tryptophan abolished the suppressive properties
of the BUD-MSCs, implicating IDO as the primary mediator of BUD-MSC's enhanced
immunosuppressive effects.
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Introduction
The potential of mesenchymal stem cells (MSCs) to ameliorate inflammation
arising from numerous diseases has been established in preclinical animal models
leading to hundreds of MSC clinical trials (1). While MSCs appear to be beneficial in
several disease models, treatment of patients has led to highly variable outcomes. For
example, subsets of patients with graft versus host disease (GvHD) have responded
remarkably well to MSC therapy with at least temporary resolution of symptoms (2, 3),
while for others their prognosis is unaltered (4, 5). Factors limiting MSC therapy include
variable immunomodulatory potency (6-8), dependence on in vivo activation by host
inflammatory mediators to achieve MSC immunomodulation (7-9), and limited MSC
persistence (10, 11). Recent work has shown significant variability in MSCs' cytokine-
induced secretome (8), in vitro immunomodulatory potential (6, 7), and treatment
efficacy dependent on donor (6, 7), the MSCs tissue of origin (6, 12), and cell
preparations from different passages (2). Furthermore, limited persistence shortens the
therapeutic window in which MSCs modulate inflammatory responses via secretion of
growth factors and cytokines, release of exosomes, or activity of immunomodulatory
enzymes such as iNOS and IDO. Thus, techniques to augment the potency of MSCs
are needed for a therapeutic effect to be exerted within a short therapeutic window. We
hypothesize that engineering MSCs to maximize and sustain immunosuppressive
potential will enable the generation of enhanced cell-based therapies and eliminate the
need to contemplate which tissue or donor MSCs are derived from.
One of the primary factors mediating MSC immune suppression is the tryptophan
depleting enzyme indoleamine-2,3-dioxygenase (IDO). Inhibiting IDO with 1-methyl-DL-
tryptophan (1-MT) in human MSCs abrogates MSCs' immunosuppressive potential in
peripheral blood mononuclear cell (PBMC) co-cultures (7, 13). In contrast to secreted
factors implicated in MSC immune suppression such as PGE2 (14) or TSG-6 (10), IDO
is an intracellular enzyme. Specifically, IDO is the first and rate-limiting enzyme involved
in degradation of tryptophan down the kynurenine pathway and is predominately
expressed in antigen presenting cells (APCs) in response to type I interfons (15).
Additionally, human MSCs have been shown to have IDO dependent antimicrobial
affects against staphylococcus aureus, staphylococcus epidermis, and toxoplasma
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gondii (16). As in APCs, expression of IDO in MSCs occurs in response to inflammation,
induced by exposure to interferon-y (IFN-y). Both the depletion of tryptophan and the
generation of kynurenine byproducts have potent suppressive effects on immune cells
(15, 17). IDO has been implicated in promoting both physiological and pathological
tolerance. IDO expressed by cells in the placenta is responsible for fetal tolerance, and
inhibition of IDO by the inhibitor 1-methyl-tryptophan (1-MT) results in allograft rejection
of the fetus (18). More recently, IDO has been found to be overexpressed in solid
tumors, promoting tolerance towards tumor antigens (19) and tryptophan depletion has
been shown to suppress T-cell proliferation through activation of general control non-
depressing 2 (GCN2) kinase (20). In addition to tryptophan depletion, IDO generates
tryptophan catabolites that inhibit the proliferation of activated T-cells (21) and induce
naive T-cells to become FoxP3+ T-regulatory cells (22). Due to the role of IDO as a
negative regulator of inflammation and inducer of tolerance, the level and regulation of
its expression is of great interest for maternal-fetal tolerance, tumor immunity, allergy,
autoimmune disease, transplant tolerance, and MSC therapy. Unfortunately, the level
of MSC IDO expression varies significantly between donors and between MSC tissue
sources leading to variability in MSC's ability to suppress activated T-cells (6, 7).
As elevated IDO activity correlates with enhanced suppression of T-cell
activation and proliferation, augmenting MSC IDO levels should increase their
immunomodulatory potency. Interestingly, IDO expression in macrophages and
dendritic cells has been shown to be augmented by exposure to glucocorticoid steroids
mediated in part through cell-cell contact signaling through GITR and GITRL
interactions (23, 24). Similarly, augmented IDO expression following glucocorticoid
steroid treatment has also been observed in astrocytes, although the mechanism of
steroid enhanced IDO activity is not known (25). While MSCs are frequently
administered to patients with GvHD who are already receiving glucocorticoid steroids (3,
26), the impact of glucocorticoid steroids on MSCs broadly, and IDO activity specifically
has not been investigated.
Herein we report that glucocorticoid steroids significantly boost MSC's IDO
activity and immunosuppressive phenotype and we introduce a cell engineering strategy
to sustain therapeutic potency. Specifically, we observe that budesonide treated MSCs
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show similar metabolic activity, viability, and morphology to untreated MSCs, yet exhibit
a favorable shift between their expression of immunogenic and immunosuppressive
factors. In addition to enhancing IFN-y-induced IDO expression and activity, budesonide
treatment also significantly reduced MSC expression of MHC molecules. We found that
combined exposure to both budesonide and inflammatory cues resulted in the highest
levels of IDO expression, as IDO is only expressed in response to inflammatory
signaling. Additionally, the response was broadly applicable to glucocorticoids as
dexamethasone produced a similar IDO response, and blocking the glucocorticoid
receptor inhibited the enhanced IDO expression. To engineer cells with enhanced and
sustained immunosuppressive potency that can be activated upon entering an
inflammatory environment without requiring systemic administration of
immunosuppressant drugs, we utilized a particle engineering approach. Budesonide
loaded microparticles were efficiently internalized by MSCs and resulted in significant
enhancement of MSC IDO expression and activity, similar to soluble budesonide. In
vitro co-culture assays with PBMCs revealed the engineered MSCs could be activated
in situ in response to IFN-y produced by PBMCs. Engineered MSC suppression of
PBMCs was enhanced further by pre-activating MSCs with IFN-y to increase expression
of IDO prior to the initiation of the PBMC co-cultures. Addition of the IDO inhibitor 1-
methyl-tryptophan completely abolished the suppressive properties of the engineered
MSCs, implicating IDO as a key immunosuppressive factor. We believe this engineering
strategy could be used to augment MSC potency, resulting in enhanced cell-based
therapies.
Results
Impact of budesonide on MSC phenotype
Glucocorticoid steroids are commonly prescribed anti-inflammatory drugs that
have diverse effects on immune cells, however their effect on MSC immunogenicity and
immunomodulatory potential has not been thoroughly examined. Glucocorticoid steroids
exert their effects through binding cytoplasmic glucocorticoid receptors and
translocating to the nucleus where they bind glucocorticoid responsive elements
(GREs), resulting in promotion or suppression of gene expression (27). As such,
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glucocorticoid steroids, such as budesonide, have variable effects on cells of different
origins, including growth inhibition (28), suppression of MHC expression (27, 29), and
induction of IDO (25).
To examine if budesonide alters MSC potency without negatively impacting MSC
phenotype, MSCs were exposed to 0.001-100 pM budesonide for 24-72 hours.
Metabolic activity, as assessed by XTT, was not significantly affected by budesonide
treatment for 24, 48, or 72 hours over the dosage range tested (Fig. 1a). Flow cytometry
analysis revealed no significant changes in MSC viability as evidenced by dual negative
staining for Annexin-V and propidium iodide after 72 hours of budesonide exposure
(Fig. 1b). Phase contrast imaging of treated cells did not show any appreciable impact
of budesonide on the morphology of MSCs after 48 hours of budesonide exposure (Fig.
1c). In addition, MSCs treated with budesonide for 48 hours showed no evidence of
increased cell death when evaluated for double stranded DNA breaks by TUNEL
staining (Fig 1d). Collectively these data show MSC metabolic activity, morphology,
proliferation, and viability were preserved over a wide range of budesonide
concentrations.
Next we analyzed the effect of budesonide on MSC expression of MHC I and
MHC II molecules. MSCs' naturally low expression of MHC 1, lack of MHC II, and failure
to elicit hyperacute rejection upon infusion has been used to justify the use of
unmatched allogeneic MSCs in animal models and clinical trials. However, upon
exposure to an inflammatory environment, expression of both MHC molecules
increases (30). Interestingly, glucocorticoids have been shown to reduce expression of
MHC molecules in many cell types (27, 29). Expression of class I and class 11 MHC
molecules, HLA-ABC and HLA-DR respectively, were examined to investigate
budesonide's impact on MSC's immunophenotype before and after IFN-y stimulation.
MSCs were exposed to vehicle or budesonide for 24 hours after which media was
changed to include IFN-y and the cells were cultured for an additional 48 hours prior to
antibody staining and flow cytometry analysis. Cells in the 'drug preconditioning' group
were exposed to budesonide only during the first 24 hours while cells in the 'drug
sustained' group were exposed to budesonide for the duration of the experiment (Fig.
2a). Figure 2b shows that MSC expression of HLA-ABC was reduced by over 50%
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Figure 1 (a) MSC were plated in 96 well plates (15,000 cells/well) treated with DMSO or
0.001-100uM budesonide and their metabolic activity was assessed by XTT at 24, 48,
and 72 hours. % cell condition (7,500 cells/well) used as control to show a reduction in
XTT signal when fewer cells are present. (b) MSCs were plated in 24 well plates(30,000 cells/well) treated with DMSO or 0.001-100uM budesonide. At 24, 48, and 72
hours after plating, cells were harvested, and viability was measured by staining with
Annexin V and propidium iodide. Staurosporine (STS) treatment for 1 and 3 hour was
used as a positive control for cell death. (c) Representative phase contrast images of
MSCs treated with budesonide for 48 hours show no change in morphology, density, or
adherence. (d) TUNEL staining for double stranded DNA breaks after 48 hour
budesonide exposure shows no increase in apoptosis. Stain control cells were treated
with DNase to induce DNA breaks to serve as a positive control for TUNEL stain. (DAPI,Blue; TUNEL, Green). (Bars are mean±SEM, 2-way ANOVA with Fishers LSD test, n=3,*p<0.05) Scale bar 100pm.
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for all doses of budesonide in both the precondition and drug sustained groups
(p<0.001). Following exposure to 100 pM budesonide, stimulation with IFN-y reduced
HLA-ABC expression by only -15% (not significant (NS), Fig. 2b, c). Budesonide
treatment did not result in any increase of HLA-DR expression in unstimulated
conditions or decrease in HLA-DR in stimulated conditions except for the 100 pM
treated group. Preconditioning with 100 pM budesonide reduced IFN-y induced HLA-DR
expression by 11 % (NS) while sustained exposure resulted in a 40% reduction
(p<0.001, Fig. 2.d,e).
MSC's immunosuppressive potential was evaluated following exposure to
budesonide through assessment of IDO protein content and activity. Following
treatment of MSCs with 1 pM budesonide for 24 hours, MSCs were additionally
exposed to 100 ng/ml IFN-y for 48 hours (Fig. 3a). MSCs were collected, lysed, and
IDO protein content was analyzed by western blot. Budesonide treatment alone did not
result in any increase in IDO protein content over untreated MSCs (Fig. 3b). IFN-y
stimulation resulted in increased IDO content in both untreated and budesonide treated
MSCs, with budesonide treated cells containing significantly more IDO than untreated
controls. To determine the extent to which budesonide could enhance MSC IDO
expression, IDO content of MSCs from multiple donors and passages was analyzed
with and without budesonide treatment. Enhancement in IDO expression following
budesonide exposure was observed in MSCs from multiple donors, regardless of the
baseline level of IDO expression (no budesonide treatment) for each donor (Fig. 3c). In
addition, high passage, P8 and P10, MSCs treated with budesonide expressed IDO at
levels greater or similar to untreated P5 MSCs (Fig. 3d). Interestingly, IDO expression
was most significantly enhanced when budesonide was continuously present versus
simply pretreated (Fig. 3e,f). To demonstrate the ability to enhance the
immunomodulatory potency of MSCs with poor immunosuppressive potential, donor
#7083, which had the lowest baseline IFN-y inducible IDO expression (no budesonide
treatment) of the three donors, was used for all subsequent experiments. As the
immunomodulatory function of IDO is dependent on its activity as an enzyme, an
enzymatic activity assay was performed. Specifically, MSCs were grown according to
the protocol depicted in Fig. 3a, collected, lysed to isolate IDO from the cytoplasm, and
130
a Drug Precondition
Drug Sustained
0hr 24 nrb u *es o n ' e
IFN-y
b Drug Precondition
4 No IFN-y 100ng/mi IFN-y
3x1$640
uio 24
0 0
nsndepMBdsodsM
BUduog d.andDrug Sustained
No IFN-M 100nglmI IFN-y
3-J 1640I64406 
.I
Budesonidk pM BudasonidesM
Drug Precondition
145 No IFN-y 100ng/ml IFN-y
I. 0 3.11 [4
6404 6
4440
924 9241
5 P 5I
udasondes oU udesonid pM
C Drug Precor dition
No IFN-y 100ng/ml IFN-y
.2 ACA .7 .2 4 A .CHLA. BC.A HLA.ABC-A
e
Drug Sustained
No IFN-y 100ng/mi IFN-y
HLA-ABC-A HLAABC-A
Drug Precondition
No IFN-y 100ng/mi IFN-y
HLADR A HLA-OR-A
Drug Sustained Drug Sustained
1405 No IFN-y 100nghmIIFN-y No IFN-y 100ng/mI IFN-y
84 
1 840
64()4 6.10
410 1
BUdKSonkdbsM BudesnbdeM HLADR-A HLADR-A
MIsotype 0 p M 0.01 I'm 100 pM 100 pA
Figure 2 (a) Timing of MSC exposure to budesonide and IFN-y in the DrugPrecondition and Drug Sustained groups. Flow cytometric analysis of (b,c) HLA-ABC
and (d,e) HLA-DR surface expression of MSCs. MSC were plated in 25 cm 2 flasks(100,000 MSC/flask) with media containing vehicle or budesonide and were either
stimulated with IFN-y or left unstimulated. MSC were then cultured an additional 48hours without budesonide (Drug Precondition) or with budesonide (Drug Sustained).(b,d) show mean fluorescence intensity (MFl) for each condition. (Bars are mean±SEM,One-way ANOVA with Bonferroni correction for multiple comparisons, n=3, *p<0.001
compared to untreated control). (c,e) show representative flow cytometry plots includingisotype controls.
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Figure 3. IDO expression is maximized following IFN-y and budesonide exposure. (a)
Timing of MSC exposure to budesonide and IFN-y. (b) Western blot of IDO protein
content measured from MSC exposed to 1 pM budesonide and 100 ng/ml IFN-y. P-actin
shown as loading control. (c) Western blot of IDO protein content measured from MSCs
harvested from three independent donors exposed to 1 pM budesonide and 100 ng/ml
IFN-y. P-actin shown as loading control. (d) P5, P8, and P10 MSCs were treated with
vehicle or budesonide for 24 hours and then additionally with 100 ng/ml IFN-y for 48
hours. Cell lysate was collected and analyzed for IDO content by western blot. (e)
Impact of IFN-y and budesonide on the enzymatic activity of IDO harvested from MSC(donor 7083) lysate measured by production of kynurenine. 5pg/ml rhIDO was used as
an internal control for the assay(right axis). (Bars are mean±SEM One-way ANOVA with
Tukey correction for multiple comparisons, n=3, *p<0.001). (f) Timing of MSC exposure
to budesonide and IFN-y. A 0 or 24 hour delay was introduced between preconditioning
and IFN-y exposure in the preconditioning group. (g) Western blot of IDO protein
content measured from MSCs exposed to (V) DMSO vehicle, or (P) preconditioned, or(C) continuously exposed to 1 pM budesonide. A 0 or 24 hour delay was introduced
between the 24 hour budesonide preconditioning and exposure to IFN-y. P-actin shown
as loading control.
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the quantity of L-kynurenine produced was measured by a colorimetric assay. Exposure
to budesonide had a dramatic effect on MSC's IDO activity. While IDO expression
naturally increases upon stimulation with IFN-y, additional conditioning by budesonide
resulted in an over 4-fold increase in IDO activity (Fig. 3g).
Mechanism of IDO augmentation
To begin to elucidate the mechanism of budesonide-mediated enhancement of
MSC IDO expression, we examined the timing and activation of intracellular pathways
likely to be involved. Elevated IDO levels were first detected by western blot 24 hours
after IFN-y exposure (Fig. 4 a,b), consistent with previous reports that show IFN-y
stimulates new transcription of IDO mRNA in MSCs (6). Furthermore, the effect does
not appear to be mediated through increased sensitivity to IFN-y, as the timing and
degree of Stat-1 phosphorylation between untreated (Fig. 4a) and budesonide treated
(Fig. 4b) MSCs were nearly identical. Next we examined if budesonide was exerting its
effect on IDO expression through the glucocorticoid receptor. Blocking the
glucocorticoid receptor with 2 pM of RU486 reversed budesonide's enhancing effect on
IDO expression back to baseline levels (Fig. 4c). This data suggests budesonide
mediated enhancement of IDO is dependent on the glucocorticoid receptor. Consistent
with this observation is the finding that treatment with either budesonide or
dexamethasone, both glucocorticoid steroids, results in similar enhancement in IDO
expression (Fig. 4d). Interestingly, the promoter region for the IDO gene does not
contain any known GREs. Thus, steroid enhancement of IDO is likely mediated through
up-regulation of a glucocorticoid responsive intermediary that enhances the
transcription of IDO. Therefore we looked for transcription factors known to bind the IDO
promoter that are also sensitive to glucocorticoid steroids. IDO has previously been
reported to be promoted by FOXO3 (17), a transcription factor which has recently been
shown to be a target of the glucocorticoid receptor (31). To determine FOXO3's role in
budesonide-mediated enhancement of MSC IDO, we performed siRNA knockdown
experiments. MSCs were transfected with FOXO3 siRNA or scramble siRNA as a
control and then treated with budesonide for 24 hours, after which cells were treated
with IFN-y. FOXO3 expression was measured 6 hours after IFN-y addition (preliminary
133
experiments revealed peak FOXO3 content at this time point) and IDO was measured
30 hours after IFN-y addition. Transfection of MSCs with FOXO3 siRNA resulted in
nearly complete inhibition of FOXO3 (Fig. 4e) and reverted budesonide treated MSC
IDO expression (Fig. 4f) and activity (Fig. 4g) back to the level of untreated MSCs.
Collectively this data suggests budesonide's effect on MSC IDO expression is mediated
by glucocorticoid induced expression of FOXO3 which then acts as a genomic enhancer
to augment the expression of IDO.
Establishing prolonged control of MSCs
We next sought to examine if we could prolong enhanced MSC IDO activity
without the need for continuous exposure to soluble budesonide. Glucocorticoid steroids
are commonly used clinically and potentially could be co-administered with MSCs,
however, their lack of specificity causes them to have numerous off-target effects that
can be detrimental to the overall health of a patient (32-34). Thus, developing a method
to control MSC phenotype without requiring co-administration of systemic glucocorticoid
steroids thereby minimizing systemic exposure is desirable. To achieve prolonged
control of MSC IDO activity we drew from our prior experience loading MSCs with drug
loaded poly(lactic-co-glycolic acid) (PLGA) microparticles. Previously we have shown
that 1 pm particles can be efficiently internalized into MSCs and remain stable for at
least 7-days during which time, small molecule drugs can be released to influence the
phenotype of cells (35, 36).
Budesonide microparticles -1 pm in diameter with low polydispersity were
formulated to control MSC IDO activity (Fig. 5a,b). Surface modification of the particles
with poly-L-Lysine resulted in a zeta potential of +10 mV (Fig. 5b), which we have
previously shown enhances particle uptake (35). Budesonide was extracted from the
particles and the drug loading (7.05%, Fig. 5b) and encapsulation efficiency (51.2%,
Fig. 5b) were determined by HPLC. 10 kDa molecular weight PLGA was used to
formulate the particles to ensure rapid release of the drug during the first week following
MSC particle modification. Release kinetic experiments were performed, revealing a
burst release of 20% of total drug in the first 12 hours followed by a continuous release,
with -80% of total drug released by day 10 (Fig. 5c). MSC internalization of particles
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Figure 4. Budesonide enhancement of IDO occurs through glucocorticoid receptor
mediated upregulation of FOXO3 and not increased sensitivity to IFN-y. MSCs were
treated with (a) vehicle only or (b) 1 pM budesonide for 24 hours and then additionally
exposed to 100 ng/ml IFN-y (continuous exposure to vehicle or budesonide). Lysates of
(a) untreated (vehicle only) MSCs and (b) 1 pM budesonide treated MSCs were
collected at 0, 1, 6, 12, and 24 hours after IFN-y exposure. To determine the timing of
IDO up-regulation IDO protein content was measured at each time point. To determine
if budesonide enhanced MSC sensitivity to IFN-y, the degree of Stat-1 phosphorylation
was measured as stat-1 phosphorylation is classically induced by IFN-y stimulation.
Ratio of pStat-1 to total Stat-1 is shown for each time point. (c) Inhibition of the
glucocorticoid receptor with RU486 reverts IDO levels back to baseline levels in
budesonide treated MSCs. (d) Western blot of IDO protein content measured from IFN-
y stimulated MSC exposed to DMSO vehicle, budesonide, or dexamethasone. To test
the dependence of enhanced IDO expression on FOXO3, siRNA knockdown was
performed. MSCs were transfected with FOXO3 siRNA or scrambled siRNA for 5 hours
and then treated with budesonide for 24 hours followed by IFN-y treatment. Cell lysates
were collected 6 and 30 hours following addition of IFN-y and analyzed for (e) FOXO3
and (f) IDO respectively. (g) Activity of IDO harvested from lysates of vehicle,
budesonide, budesonide/FOXO3 siRNA, and budesonide/scrambled siRNA treated
MSCs 48 hours after IFN-y stimulation. (Bars are mean±SEM, One-way ANOVA with
Tukey correction for multiple comparisons, n=3, *p<0.01).
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Figure 5. Sustained control of MSC phenotype. (a) Fluorescent image of Dil labeled
Budesonide PLGA microparticles(Scale bar 5 pm). (b) Physicochemical properties of
budesonide PLGA microparticles. (c) Release kinetics of budesonide from 2mg of PLGA
microparticles into PBS at 37*C. (d) MSC association with 1 pm, PLL coated particles
was assessed by flow cytometry (Representative plot). (e) Representative confocal
image of an MSC modified with 1 pm diameter PLGA particles (red) revealing particles
are predominately intracellular rather than membrane associated (membrane stained
Green, nuclei shown in Blue, scale bar 10 pm). (f) Particle modified MSC viability
examined by TUNEL staining. TUNEL stain shown in green with nuclei counterstained
with Hoechst (Blue). (bottom) Percent apoptotic cells (mean+SD TUNEL+/Hoechst+
nuclei, n=3) shown in each image (Scale bar 50 pm).
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Figure 6. Budesonide particles enhance MSC's therapetutic potential. (a) Timing of
MSC particle modification and exposure to IFN-y. MSCs were modified with particles
overnight, harvested and split into new flasks and then exposed to IFN-y for 48 hours.
(b) Western blot of IDO protein content measured from unmodified, Blank-Particle
modified, or BUD-Particle modified MSCs exposed to 100ng/ml IFN-y. P-actin shown as
loading control. (c) Impact of BUD-Particle modification on MSC IDO activity with and
without stimulation with 100ng/ml IFN-y. IDO activity measured by the production of L-
kynurenine from generated from MSC lysate incubated with tryptophan. 5pg/ml rhIDO
was used as an internal control for the assay(right axis). (Bars are mean±SEM, One-
way ANOVA with Tukey correction for multiple comparisons, n=3, *p<0.001).
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was optimized as previously described (35) by modulating the size and zeta-potential of
the particles. MSC association with 1 pm PLGA particles coated with poly-L-Lysine was
confirmed by flow cytometry showing nearly all MSCs associated with particles (Fig.
5d). Confocal imaging revealed PLGA particles were not merely associating with the
outer plasma membrane, but internalized (Fig. 5e). MSC's were engineered with BUD-
Particles without impacting cell viability (Fig. 5f).
To test if the intracellular release of budesonide from PLGA particles would work
similarly to soluble budesonide, we examined the expression and activity of IDO within
cell lysates. MSCs were modified with either BUD-PLGA or Blank-PLGA particles
overnight, allowed to rest 24 hours, and then stimulated with IFN-y for 48 hours, after
which cells were harvested for analysis (Fig. 6a). As with soluble budesonide, BUD-
PLGA particle modification significantly increased the content of IDO in MSC lysate (Fig.
6b). BUD-PLGA modified MSCs exhibited a 5X augmentation in IDO enzymatic activity
over Blank-PLGA modified and unmodified MSCs (Fig. 6c), an effect similar to what was
observed with soluble budesonide (Fig. 3g). In addition, when compared head to head,
BUD-PLGA particle modified MSCs expressed higher levels of IDO than MSCs simply
pretreated with soluble budesonide before IFN-y activation (Fig. 7a).
Enhanced suppression of inflammation in vitro
To test our hypothesis that enhanced IDO activity would lead to enhanced
immunosuppression, MSCs were co-cultured with CD3/CD28 Dynabead activated
PBMCs. BUD-Particle modified MSCs showed significantly enhanced suppression over
budesonide preconditioned MSCs, which showed no advantage over naTve MSCs (Fig.
7b). To determine the degree of BUD-Particle modified MSC enhancement over naive
MSCs, ratiometric MSC:PBMC co-cultures were established by fixing the number of
PBMCs in each well and varying the number of MSCs plated to achieve MSC:PBMC
ratios of 1:4, 1:8, or 1:16. Unmodified, Blank-Particle modified, and BUD-Particle
modified MSCs each suppressed PBMC proliferation in a cell-dose dependent manner.
However, BUD-Particle MSCs showed enhanced suppression of PBMCs at all ratios
tested as evidenced by reduced proliferation (Fig. 8c,d) and decreased IFN-y production
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Figure 7. (a) IDO content following 48 hours of IFN-y stimulation in untreated,
budesonide preconditioned, and budesonide-particle modified MSCs. P-actin shown as
loading control. (b) Bud-particle engineered MSCs exhibit enhanced suppression over
budesonide preconditioned MSCs. Quantification of MSC suppression of PBMCs after 5
day MSC:PBMC co-cultures. Data represents average of three experiments conducted
with independent PBMC donors. Un-stimulated control for each donor used to set
threshold for PBMC activation. (Bars are mean±SEM, Ordinary One-way ANOVA with
Tukey correction for multiple comparisons, n=3, *p<0.05)
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Figure 8. Engineered MSCs exhibit enhanced suppression. Gating and representative
flow cytometry plot of (a) unstimulated and (b) CD3+/CD28+ Dynabead stimulated
CFSE stained PBMCs (CFSE vs. Forward Scatter). (c) Representative CFSE vs forward
scatter flow cytometry plots of PBMCs harvested from 5 day MSC:PBMC co-cultures.
MSC:PBMC ratio and type of MSC particle modification are listed on each column and
row respectively. As PBMCs are activated and divide, CFSE is diluted 1:2, resulting in
discrete daughter generations that shift to the left with each cell division. (d)
Quantification of MSC suppression of PBMCs harvested from three independent
donors. Un-stimulated control for each donor used to set threshold for PBMC activation.
(e) IFN-y concentration measured from supernatant of MSC:PBMC co-cultures as
marker of PBMC activation. (f) Representative CFSE vs. forward scatter flow cytometry
plots of PBMCs harvested from 5 day MSC:PBMC co-cultures containing MSCs
preconditioned with IFN-y to stimulate IDO activity. MSC:PBMC ratio and type of MSC
particle modification are listed on each column and row respectively. (g) Quantification
of MSC suppression of PBMCs harvested from three independent donors. Un-
stimulated control for each donor used to set threshold for PBMC activation. (h) IFN-y
concentration measured from supernatant of preconditioned MSC:PBMC co-cultures as
marker of PBMC activation. Un-stimulated PBMC controls showed no detectable
secretion of IFN-y. (Bars are mean±SEM, Two-way ANOVA with Tukey correction for
multiple comparisons, n=3, *p<0.05).
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(Fig. 8e). Impressively, BUD-Particle MSC co-cultures at 1:8 and 1:16 ratios were as
effective at suppressing PBMC proliferation and IFN-y secretion as native MSCs at 1:4
and 1:8 ratios, respectively. In other words, twice as many unmodified MSCs are
required to achieve an equivalent in vitro suppressive effect as BUD-Particle MSCs.
As IDO activity is dependent on IFN-y stimulation, we hypothesized the effect
could be further accentuated by pre-activation of MSCs. Thus, the MSC:PBMC co-
cultures were repeated with MSCs preconditioned with IFN-y for 48 hours to stimulate
IDO expression prior to plating in the co-cultures. Pre-activation of MSC IDO
expression resulted in similar trends in unmodified MSCs, inferior suppression by Blank-
Particle MSCs, and further enhanced BUD-Particle MSCs ability to suppress PBMC
proliferation (Fig. 8f,g) and IFN-y secretion (Fig. 8h) compared to co-cultures with
unactivated MSCs.
Next we sought to examine the mechanism responsible for the enhanced
suppression. Soluble budesonide released from the MSCs did not appear to be
responsible, as PBMCs treated with 1 pM and 10 pM budesonide (no MSCs) were
activated to the same degree as untreated PBMCs (Fig. 9a). In order to determine if the
enhanced suppressive effect of BUD-Particle modified MSCs can be attributed to IDO
or that of other soluble factors, we used a widely used inhibitor of IDO, 1-methyl-DL-
tryptophan (1-MT) to inhibit IDO activity. MSC:PBMC co-cultures were repeated at a
MSC:PBMC ratio of 1:8 with or without the addition of 1 mM 1-MT. Inhibition of IDO with
1-MT completely abolished BUD-Particle MSCs inhibitory effect suggesting IDO is
significantly responsible for the enhanced immunomodulatory potency of BUD-Particle
MSCs (Fig. 9b).
Discussion
Herein we have elucidated the effect of budesonide on MSCs immunogenicity
and immunosuppressive properties. Budesonide treatment resulted in an over 4-fold
increase in IFN-y stimulated MSC IDO activity. Unlike other cell types such as
fibroblasts (28) and lymphocytes (37), MSC viability, metabolic activity, and morphology,
were not significantly impacted by exposure to a wide range of budesonide
concentrations. In addition to enhancement of MSC IDO activity, we also observed a
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reduction in MSC expression of HLA-ABC at all doses in unstimulated conditions and a
reduction in HLA-DR expression at high doses in IFN-y stimulated conditions. The
reduced expression of MHC molecules further minimizes the hypo-immunogenic
phenotype of native MSC, however, following IFN-y stimulation the level of HLA-ABC
and HLA-DR expression remains high, and is thus unlikely to significantly alter MSC
rejection in allogeneic transplant settings. In fact, previous attempts to shield MSCs
from allo-rejection through reduction of HLA-ABC expression required near complete
blockade of HLA-ABC presentation in both unstimulated and IFN-y stimulated
conditions by viral immunoevasins (38, 39). Overall, budesonide treatment maintained
MSCs proliferative capabilities while reducing MSC's immunophenotype and greatly
enhancing MSC's immunomodulatory potency through increased IDO activity. To our
knowledge, this is the first report of small molecule enhancement of IDO activity in
MSCs and the approach represents a significant opportunity to augment MSC-based
therapies.
Enhanced expression of IDO was shown to be dependent on both the
glucocorticoid receptor and FOXO3, as inhibition of either abrogated the effect. In
addition to the current report of FOXO3 enhancement of MSC immunosuppression,
enhanced FOXO3 expression has also recently been reported to be a marker of
tolerogenic dendritic cells (40, 41). FOXO3 expressing dendritic cells produce reduced
levels of IL-6 (40) and elevated levels of IDO (41). Inhibition of FOXO3 in tumor
associated dendritic cells results in decreased levels of IDO and enhanced anti-tumor
immune responses (41, 42). While these studies have examined the FOXO3-IDO
pathway in the context of pathology, we believe there is great potential to leverage the
tolerogenic effects to treat graft versus host disease, autoimmune conditions such as
Crohn's and multiple sclerosis, and prevent rejection of transplanted tissues.
As the enhanced therapeutic phenotype of MSCs was most prominent in cultures
continuously exposed to budesonide, we employed an engineering strategy to
continuously control MSCs. MSCs were engineered with budesonide loaded PLGA
particles that continuously release budesonide, resulting in a 5-fold enhancement in
IFN-y stimulated MSC IDO activity. BUD-Particle MSCs were shown to exhibit
enhanced immunosuppressive potency in PBMC co-culture assays in an IDO
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dependent manor. Inhibition of IDO with 1-MT led to abrogation of MSCs' suppressive
potential, implicating IDO as a primary mechanism of budesonide mediated MSC
enhancement. BUD-Particle engineered MSCs were twice as potent in suppressing
PBMC proliferation and IFN-y secretion, as determined from ratiometric co-culture
experiments. Enhancing the potency of a single MSC enables fewer MSCs to be
administered to achieve the same therapeutic effect and enables a single cell to exert a
significant impact on its microenvironment. In addition, this technique can be used to
augment the potency of MSCs harvested from different donors and tissues, eliminating
the need to select MSCs from only donors or tissues that have high native
immunosuppressive potential. Furthermore, as enhanced IDO activity has been shown
to lead to tolerance in the setting of pregnancy (18), solid organ transplant (43), and
tumor evasion (19), BUD-PLGA MSCs may be able to extend their therapeutic window
by promoting tolerance and evading immune clearance.
In the current study we have demonstrated the utility of BUD-Particle MSCs in in
vitro co-cultures. However, the potential benefits of an MSC therapeutic with enhanced
IDO expression could be far reaching. This strategy may be used to augment
therapeutic potency of MSC therapies by suppressing active inflammation and inducing
tolerance in the setting of GvHD, Crohn's disease, and transplant biology. In addition,
modified MSCs with enhanced IDO activity could also be applied to prevent bio-fouling
of orthopedic implants and other medical devices due to IDO's antimicrobial properties
(16).
We have previously shown intracellular PLGA particles can be used to influence
MSC differentiation (35) and track MSCs by MRI (36), and now we show that this
platform can be adapted to augment and control MSC's therapeutic potency. Further
studies are needed to demonstrate the ability of BUD-Particle MSCs to induce immune
tolerance in vivo and the long-term function and safety of the engineered therapy must
be evaluated.
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Methods
Culture of MSCs
Primary human MSCs were obtained from Texas A&M Health Science Center, College
of Medicine, Institute for Regenerative Medicine at Scott & White Hospital which has a
grant from NCRR of the NIH, Grant #P40RR017447 (Donors 7076, 7081, and 7083).
MSCs were maintained in cell-start (Invitrogen) coated flasks with StemPro MSC SFM
culture media (Invitrogen) supplemented with 1% (v/v) L-Glutamine (Invitrogen), and 1%
penicillin:streptomycin (Invitrogen). Cells were plated at a density of 6,000 cells/cm 2 and
were passaged when flasks reached 70-80% confluence. All experiments were
performed with passage 3-6 MSCs (Population doubling level between 4-8 from initial
plating) unless indicated otherwise.
Metabolic activity, viability, and morphology assays
Metabolic activity of MSCs was assessed by XTT (ATCC) following 24, 48, or 72 hour
exposure to budesonide. Briefly, 15,000 MSCs were plated in each well of a 96 well
plate in 100 pl of culture media containing DMSO vehicle and 0.001, 0.01, 0.1, 1, 10, or
100 pM budesonide. Cultures were maintained for 24, 48, or 72 hours in a humidified
culture chamber. Culture media with no cells and wells with half the starting cell density
were used as internal controls for each experiment. All conditions were explored in 5
wells for each experiment. To measure metabolic activity, 50 pl of activated XTT
reagent was prepared and added to each well per manufacturer's instructions. The plate
was incubated for 3 hours and read at 450 nm and 630 nm for reference. To determine
the morphology and viability of budesonide treated MSCs, 30,000 cells were plated into
each well of a 24 well plate with vehicle or 0.001-100 pM budesonide supplemented
culture media. Cells were grown for 24, 48, or 72 hours. Before harvest, 4 random fields
of each well were imaged at 1oX using an inverted phase contrast microscope to
capture cell morphology and differences in cell proliferation. To determine viability, cells
were then harvested with Accutase, washed, and re-suspended in 100 pl stain solution
containing 5 pl/ml FITC-Annexin-V and 1 pi propidium iodide (Invitrogen) and stained on
ice for 15 min. Cells were washed with 400 pl PBS, centrifuged, re-suspended in fresh
PBS and analyzed by an Accuri C6 flow cytometer. MSCs treated with staurosporine to
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induce cell death were used as a positive control for each experiment. TUNEL staining
of budesonide treated and particle modified MSCs was performed per manufacture's
instructions using a in situ cell death detection kit-fluorescein (Roche) to label double
strand DNA breaks indicative of apoptosis and counterstaining nuclei with Hoescht
(Invitrogen). Fixed, DNase treated MSCs (300 U/ml DNase, 1 mg/ml BSA, in 50 mM
TrisHCL for 10 min at room temperature) were used as a positive control for double
strand DNA breaks. ImageJ (NIH) was used to quantify the number of dual stained
nuclei, all conditions were performed in triplicate.
Flow Cytometry
Expression of MHC molecules on MSCs following 24 hour preconditioning or continuous
exposure to various doses of budesonide was determined using an Accuri C6 flow
cytometer. For each condition, MSCs were grown in T25 flasks, harvested with
Accutase, washed, and split for staining with either Alexa Fluor 488 anti-human HLA-
ABC and Alexa Fluor 647 anti-human HLA-DR or isotype controls. Cells were re-
suspended in antibody solution in PBS+1% BSA and stained on ice for 15 min. Cells
were washed with 400 pl PBS+1%BSA, centrifuged, and analyzed by flow cytometry.
Mean fluorescence intensity (MFI) was determined using CFlow software.
IDO Activity Assay
MSC cultures were grown to 80% confluence in T75 flasks. Cells were washed with
PBS, harvested with Accutase cell dissociation reagent (Invitrogen), centrifuged,
counted, and resuspended in 300 pl of ice cold PBS(without Ca2+/Mg 2+ ions) with 0.1%
(w/v) Triton X-100. Cell suspensions were lysed through triplicate freeze thaw cycles,
and briefly pulse sonicated using a probe sonicator with power output of 3W. Lysates
were centrifuged at 25000 rcf at 40C for 30 minutes. 250 ul of sample supernatant,
recombinant human IDO (rhIDO), or L-kynurenine standard were mixed in a 1:1 ratio
with 250 pl of IDO buffer (40 mM ascorbic acid, 20 pM methylene blue, 200 pg/ml
catalase, 800 pM L-tryptophan, in 50 mM MES buffer, pH 6.5). Samples were incubated
at 37'C for 45 min, followed by addition of 100 pl of tricholoracetic acid (30%, w/v) and
incubated at 52'C for 30 min. Samples were centrifuged at 2500 rcf for 10 min to
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remove proteins, and 100 pl of the resultant supernatant for each sample was added to
a 96 well plate (all samples and standards measured in duplicate). 100 pl of Ehrlich's
reagent (0.8% p-dimethylaminobenzaldehyde in glacial acetic acid) was added to each
well to induce a color change. Samples were incubated at room temperature for 10 min
and then read on a microplate reader at 490 nm. rhIDO was used as a positive control
in each assay and an internal L-kynurenine standard (8-5000 pM) was included to
determine kynurenine production of IDO from MSC lysate.
siRNA Transfection
T25 flasks were seeded with 166,000 MSCs and incubated overnight at 370 C. siRNA
transfection was performed as follows. 10 ul of Lipofectamine RNAiMAX transfection
reagent (Invitrogen) per sample was diluted into 0.5 ml of Opti-MEM media (Invitrogen),
and gently mixed. 20 pI of SignalSilence FOXO3 siRNA (Cell Signaling Technology,
#6302S) or scramble control siRNA (Cell Signaling Technology, #6201S ) per sample
was diluted into 0.5 ml of Opti-MEM media and gently mixed. Both solutions were
incubated at room temperature for five minutes. The solutions were then gently mixed
and incubated for twenty minutes at room temperature in the dark. During this time, the
cells were washed with PBS-/-. Following incubation, the PBS was removed, and 1 ml
of siRNA complex was added to each flask. The media of each flask was brought to 1.5
ml by adding 0.5 ml OPTIMEM media and the cells were incubated at 370 C in the dark
for 5 hours after which the media was replaced with full media.
Western Blots
MSC cell lysates were prepared by washing T25 plates with ice cold PBS three times to
remove media followed by addition of 200 pl ice cold RIPA buffer (10 pl/ml PMSF
solution, 10 pl/ml sodium orthovanadate, and 10 pl/ml protease inhibitor cocktail). Cells
were lifted using a cell scraper, collected in Eppendorf tubes, and incubated on ice for 5
min. Lysate was then clarified by centrifugation at 8000 rcf at 40C for 10 min. The
supernatant containing soluble protein was transferred to clean tubes and total protein
concentration was determined by microBCA (Thermo Scientific). Western blots were
performed using BioRad's Mini Protean Tetra Cell apparatus for the electrophoresis and
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transfer. Briefly, 10-20 pg of protein, mixed 1:1 with Laemmli Buffer were loaded into
each well of 10% Tris-HCI gels with Tris running buffer for SDS-PAGE. Proteins were
then transferred to a Polyvinyl difluoride membrane using the transfer apparatus
according to the BioRad protocol. Following transfer, the membrane was incubated with
5% BSA in TBST buffer overnight, washed with TBST and incubated with primary
antibodies (rabbit anti-IDO (12006S), rabbit anti-stat-1 (9172P), rabbit anti-pstat-1
(7649P), rabbit anti-FOXO3 (2497P), rabbit anti-p-actin (4970S), Cell Signaling).
Horseradish peroxidase conjugated anti-rabbit antibody (Cell Signaling, 7074S) was
used as a secondary and protein bands were visualized following incubation with
Amersham ECL Prime Detection Reagent (GE Healthcare) according to the
manufacturer's instructions. Beta actin staining was performed to determine relative
protein expressions and a Precision Plus Protein Dual Color Standard (Bio-Rad) was
used to determine the molecular weight of the bands. Western blot images were
analyzed and processed using ImageJ (NIH).
Budesonide Particle Formulation
PLGA particles were formulated using an oil-in-water single emulsion technique. 10 kDa
molecular weight 50:50 poly(lactic-co-glycolic acid) with a carboxylic acid end group
(inherent viscosity 0.15-0.25 dL/g) was obtained from Lactel Absorbable polymers. 50
mg of PLGA, 8 mg of budesonide, and 10 pl of Dil, were dissolved in 2 ml of
dichloromethane in a glass vial. After dissolving, PLGA:Drug solution was probe
sonicated for 30 seconds to thoroughly mix the drug within the polymer. The solution
was then added drop wise to 20 ml of filtered 1% (w/v) polyvinyl alcohol (80%
hydrolyzed, Sigma) on ice while homogenizing at 33,000 rpm using a Tissue Master
125 homogenizer (Omni International). After 2 min homogenization, particles
suspensions were gently stirred in a chemical hood for 4 hours to allow for evaporation
of solvent. Suspensions were then centrifuged, and washed with distilled water 3 times
before lyopholization and characterization. Blank particles were formed in parallel by
omitting the addition of budesonide in the above procedure. The zeta-potential of
particles was modified through adsorption of poly-l-lysine (PLL). Briefly, 6 mg/ml particle
suspensions were prepared in 100 pg/ml PLL solution in distilled water and gently
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agitated for 2 hours. Particles were then frozen for subsequent use. The hydrodynamic
diameter, polydispersity, and zeta potential of particles was measured in distilled water
using a Malvern Zetaziser ZS90. Averages from three separate samples are reported.
In addition, 40X fluorescence microscopy images were acquired to confirm the size and
polydispersity of the particle suspensions.
Budesonide Particle Loading and Release Kinetics
High pressure liquid chromatography (HPLC) was used to determine the drug loading,
encapsulation efficiency, and release kinetics of the budesonide microparticles. To
determine drug loading, 2-3 mg of particles were weighed into Eppendorf tubes, quickly
spun into a pellet, and swollen by addition of 500 pl methanol. Samples were agitated at
370C for 2 hours to allow for complete release of budesonide from the particles.
Samples were centrifuged to pellet PLGA, and supernatant was collected, filtered, and
analyzed by an Agilent 1100 series HPLC. An Agilent Zorbax Eclipse XDB-C1 8 column
(4 x 250 mm, 5 pm) was used with a mobile phase composed of 70:30 acetonitrile:0.1 %
acetic acid, 25 pl injection volume, and 1 ml/min flow rate. Budesonide was detected by
peak absorbance at 248 nm and quantified by comparison to internal standard curves.
Drug loading was calculated as the dry mass of drug per mg of PLGA particles.
Encapsulation efficiency was calculated as the ratio of encapsulated drug to total drug
added to formulate particles. All samples were prepared in triplicate. Release kinetics
were determined by suspending 2 mg of particles in 200 pl of PBS placed in a 2 inch
section of 6-8,000 molecular weight cut off dialysis bag (Spectra Labs). Dialysis bags
were submerged in 40 ml of PBS to simulate infinite sync conditions and agitated at
370C. At each time point, 1 ml of PBS was collected and replaced with fresh PBS.
Samples were frozen until HPLC analysis using the method as described above. All
samples were prepared in triplicate.
Particle Modification of MSCs
MSCs were cultured to 80% confluence prior to particle modification. PLL coated
budesonide or blank particles were thawed, briefly sonicated to break up particle
clumps, and suspended in 1% supplement StemPro culture media to make 10 ml of 0.1
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mg/ml particle media for each T75 flask. Flasks were modified at the end of the day and
incubated with particle media overnight. Following particle modification, MSCs were
washed three times with PBS, provided with fresh full supplement culture media and
allowed to rest for 24 hours before subsequent experimentation. To confirm particle
internalization, confocal microscopy was performed as previously described (35).
PBMC Isolation from whole blood
Fresh whole blood from 3 donors was obtained from Research Blood Components for
each experiment (Watertown, MA). Upon delivery, blood was diluted 1:1 with sterile
PBS-/- supplemented with 2% fetal bovine serum, layered on top of Ficoll-Paque
Premium (GE Healthcare), and centrifuged at 400 rcf with the brake off. The buffy coat
was collected and washed with PBS:FBS solution. PBMCs were counted and either
used immediately or frozen in freezing media (RPMI supplemented with 10% DMSO,
40% FBS, 1% Penicillin/Streptomycin, 1% L-Glut).
MSC:PBMC Co-cultures
The ratio of MSCs to PBMCs was established by adding 260,000 PBMCs and 65,000,
32,500, or 16,250 MSCs to each well of a 24-well plate. MSCs were particle modified
and allowed to rest a day before the co-culture experiments. Unmodified, blank-particle
modified, or bud-particle modified MSCs were plated in 24 well plates and allowed to
adhere. PBMCs labeled with a CellTrace CFSE Cell Proliferation Kit (Invitrogen)
according to the manufacturer's instructions. 260,000 PBMCs were then added to each
well. To stimulate PBMCs proliferation, 260,000 CD3+/CD28+ Dynabeads (StemCell
Technologies) were also added to each well. Total culture volume of each well was
standardized to 0.5 ml of RPMI supplemented with 10% FBS, 1% (v/v) L-Glutamine 1%
penicillin:streptomycin. PBMCs stimulated with Dynabeads but without MSCs were used
as an activated control and un-stimulated PBMCs grown without MSCs were used as an
un-activated control for each donor. Co-cultures were maintained for 5 days after which
the media from the wells (containing PBMCs) was collected and centrifuged to pellet the
PBMCs. The conditioned media was then collected for subsequent analysis. PBMC
pellets were re-suspended in PBS-/- containing 1% FBS and PBMC proliferation was
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assessed by flow cytometery. Un-stimulated PBMC controls were used to set the
threshold for PBMC activation for each donor. To inhibit IDO activity, the MSC:PBMC
co-cultures were repeated with or without the addition 1 mM of the enzymatic inhibitor 1-
methyl-DL-tryptophan (1-MT, Sigma) prepared in RPMI media. Data was analyzed
using Accuri's CFlow software. IFN-y content of co-culture supernatant was determined
using an ELISA MAX Deluxe Human IFN-y kit (Biolegend) by comparing to internal
standards according to manufacturer's instructions.
Statistical Analysis
All statistics were performed using Prism 6 (GraphPad). Two-way ANOVA's were
performed on data sets with two independent variables (dose and time or MSC group
and MSC:PBMC ratios) and one-way ANOVA was performed on data sets with a single
independent variable (effect of budesonide conditioning on MSC IDO activity). Fisher's
LSD test without correction for multiple comparisons was used when assessing effect of
budesonide doses on MSC metabolic activity and viability as the test has a higher Type
I error and would therefore highlight any potential negative impact of budesonide on
MSCs that would require further evaluation. Bonferroni correction for multiple
comparisons, which is a more conservative test than the Fisher's LSD method, was
used for the MHC expression data as all comparisons were made with respect to the
untreated control. For all other statistics, the mean of all groups were compared to all
other groups and thus, Tukey correction for multiple comparisons was used to minimize
Type I error.
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Appendix I Preface
This appendix complements Chapter 2 by providing a stand-alone version of our
work to track MSCs with intracellular iron oxide microparticles. In addition to controlling
cells phenotype, in this Appendix we demonstrate intracellular microparticles can be
used to track the location of MSCs. As both controlling cell phenotype and tracking cells
location are critical to developing improved cell based therapies, this work demonstates
the platform potential of the particle-in-cell technology for engineered cell-based
therapies. This appendix also extends the analysis of the effect of internalize
micoparticles on the phenotype of MSCs found in Chapter 2 to include in vitro
migration, in vivo homing, and in vivo transmigration.
This appendix is an adaptation of a peer-reviewed article published on July 12 ,2012 in
Nano Letters. Reprinted with permission, copyright 2013, American Chemical Society.
Xu C, Miranda-Nieves D, Ankrum J, Matthiesen ME, Phillips JA, Roes I, Wojtkiewicz
GR, Juneja V, Kultima JR, Zhao W, Vemula PK, Lin CP, Nahrendorf M, and Karp JM.
(2012). Tracking Mesenchymal Stem Cells with Iron Oxide Nanoparticle Loaded
Poly(lactide-co-glycolide) Microparticles. Nano Lett , 12(8), 4131-9.
Glossary of Terms
Relaxivity: Property of MR imaging that enables increased contrast.
Particle Dilution: Reduced number of particles per cell due to cell division.
Homing: Preferential collection of cells in specific tissues following systemic infusion
Transmigration: Passage of a cell out of a blood vessel and into the tissue beneath the
vessel wall.
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Appendix I: Tracking Mesenchymal Stem Cells with Iron
Oxide Nanoparticle Loaded Poly(lactide-co-glycolide)
Microparticles
Abstract
Monitoring the location, distribution and long-term engraftment of administered
cells is critical for demonstrating the success of a cell therapy. Among available
imaging-based cell tracking tools, magnetic resonance imaging (MRI) is advantageous
due to its non-invasiveness, deep penetration, and high spatial resolution. While
tracking cells in pre-clinical models via internalized MRI contrast agents (iron oxide
nanoparticles, 10-NPs) is a widely used method, 10-NPs suffer from low iron content per
particle, low uptake in non-phagocytotic cell types (e.g., mesenchymal stem cells,
MSCs), weak negative contrast, and decreased MRI signal due to cell proliferation and
cellular exocytosis. Herein, we demonstrate that internalization of 10-NP (10 nm) loaded
biodegradable poly(lactide-co-glycolide) microparticles (10:PLGA-MPs, 0.4-3pm) in
MSCs enhances MR parameters such as the r2 relaxivity (5-fold), residence time inside
the cells (3-fold) and R2 signal (2-fold) compared to lO-NPs alone. Intriguingly, in vitro
and in vivo experiments demonstrate that internalization of 10:PLGA-MPs in MSCs did
not compromise inherent cell properties such as viability, proliferation, migration and
their ability to home to sites of inflammation.
Introduction
Mesenchymal stem cells (or multipotent stromal cells, MSCs) hold great promise
for the treatment of multiple diseases and disorders including graft versus host
disease(1, 2), type I diabetes(3, 4), and myocardial infarction(5, 6). To develop effective
MSC therapies, it is essential in both experimental models and clinical trials to monitor
and understand the location, distribution and long-term engraftment of administrated
cells, preferably in a noninvasive manner. This will facilitate evaluation of treatment
efficacy; reveal optimal transplantation conditions including cell dosage, delivery route,
timing of injections; and ultimately improve patient treatment(7, 8).
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Recently, imaging techniques including optical imaging, radionuclide imaging and
magnetic resonance imaging (MRI), have been used for tracking transplanted MSCs(8,
9). However, they suffer from limitations. For example, optical imaging is limited by the
penetration ability of light, and radionuclide imaging suffers from the poor spatial
resolution and rapid decay of radioisotopes(1O). In comparison, MRI is an attractive tool
for longitudinal MSC monitoring of specific tissue locations in humans because of its
non-invasiveness, deep penetration, high spatial resolution (-100 pm) and the relatively
longer retention of MRI contrast agents in cells(11, 12).
Currently, the most widely used labeling agents for MRI tracking are iron oxide
(Fe 30 4) nanoparticles (lO-NPs) with core size ranging from 4 nm to 20 nm(13). Despite
their favorable biocompatibility, IO-NPs suffer from time-dependent decrease in MRI
signal due to cell proliferation and exocytosis of lO-NPs(14-16). When a cell
proliferates, particles (either NPs or MPs) are distributed evenly or unevenly between
two daughter cells. After a few cycles, only a fraction of cells contain particles and
become undetectable. However, if the signal from a single particle was strong enough
to be detected by MRI (e.g., polystyrene-based microparticles(10)), those cells
containing one or more particles should be detectable. Furthermore, exocytosis dilutes
particle concentration(17). Interestingly, the exocytosis process is dependent on particle
size(18); with larger particles exocytosed at a slower rate. Previously we have shown
that MSCs can efficiently internalize -1 micron sized biodegradable poly(lactide-co-
glycolide) microparticles (PLGA MPs) that are loaded with differentiation factors, and
the particles remain localized within the cell for several days(19). Combining these two
ideas, we hypothesized that a micron-sized particle with stronger MRI signal and
reduced exocytosis could address the dilution limitation of IO-NPs and enable improved
longitudinal tracking of MSCs.
Herein, we demonstrate that confinement of lO-NPs in micron-sized PLGA
particles (lO:PLGA-MPs) both enhances molar relaxivity of the Fe and localization
(through concentrating Fe in discreet locations) that increases the signal to noise ratio,
and leads to longer detectable time of labeled MSCs compared to IO-NPs. Furthermore,
the effects of lO:PLGA-MPs on MSC viability, proliferation, migration, and cell homing
ability have been investigated using a series of in vitro and in vivo models.
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Results and Discussion
Design of 10-NP encapsulated PLGA MPs for cell labeling
To evaluate the effect of size on particle retention time in cells, we labeled MSCs
with either fluorescent polystyrene NPs (50 nm) or polystyrene MPs (1 pm) (Bangs
Labs). Subsequently, fluorescent intensity of the labeled MSCs was monitored over two
weeks using flow cytometry (Fig. 1). When MSCs were labeled with NPs, fluorescent-
positive MSCs constituted 80% and 10% at day-1 and day-7, respectively. On the
contrary, at day-1 and day-7, 100% and 70% of the microparticle labeled MSCs
demonstrated positive fluorescent signals. After 14 days, only microparticle-labeled cells
showed fluorescence (>30% of the cells). This suggests that micron-sized particles are
retained within cells for the long term, which should permit prolonged cell tracking.
Thus, we further explored encapsulation of lO-NPs in biocompatible and biodegradable
PLGA MPs that can be internalized by cells as a potential strategy to improve cell
labeling with MRI contrast agents.
Fabrication and characterization of l0:PLGA-MPs
A schematic of the IO:PLGA-MPs fabrication method is described in Fig. 2A.
Oleic acid stabilized IO-NPs (10 nm core size and 25 nm hydrodynamic diameter, Fig.
2B) were encapsulated in PLGA (inherent viscosity: 0.55-0.75 dL/g with carboxyl end-
groups) using a single emulsion method(14). Scanning and transmission electron
microscope images (SEM and TEM, respectively) show that IO:PLGA-MPs were
spherical in shape an average size -0.8pm (Fig. 2B,C), and lO-NPs were encapsulated
within the core of PLGA-MPs (TEM, Fig. 2D). The amount of Fe loading was quantified
using Inductively Coupled Plasma Atomic Emission Spectroscopy (ICP-AES) after the
dissolution of lO:PLGA-MPs in 70% nitric acid. The lO:PLGA-MPs had Fe loading of
15.65±1.2 wt% (Fe 30 4 weight percentage of 21.61±1.7%). lO-NPs functionalized with
carboxy groups were utilized as a control for all experiments. Magnetic properties of
lO:PLGA-MPs were studied by a vibration sample magnetometer (VSM) (Fig. 3A). The
saturation magnetization (Ms) values of IO-NPs and lO:PLGA- MPs were found to be
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Figure 1: Continuous analysis of MSCs labeled with 50 nm polystyrene NPs or 1
polystyrene MPs with flow cytometry. (A) Percentage of fluorescent MSCs;
Fluorescent intensity of the fluorescent MSCs. (Adapted from (20))
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Figure 2. lO:PLGA-MPs preparation and internalization by MSCs: (A) Schematic
illustration of the preparation of lO:PLGA-MPs with single emulsion method. (B)
Hydrodynamic diameter of lO-NPs and lO:PLGA-MPs measured by dynamic light
scattering (C) SEM image of lO:PLGA-MPs. (D) TEM image of a representative
lO:PLGA-MP. (E) TEM image of lO:PLGA-MPs internalized in a MSC. (Adapted from(20))
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-40 emu/gram of iron, which is consistent with previous reports(21). The hysteresis
curve of 10:PLGA-MPs matches well with that of 10-NPs, which indicates that
encapsulation did not change the inherent superparamagnetic property of I0-NPs. The
magnetic properties were further examined with T2 relaxation rate (1/T 2) as a function of
iron concentration by a benchtop magnetic resonance relaxometer (Fig. 3B). The
magnetic relaxivity (r2) values were derived from the slope of the linear fit, which
revealed that the encapsulation of I0-NPs in PLGA matrix significantly increased r2 from
61.16 to 316.6 mM-1s' (-5-fold) compared to l0-NPs, which was the result of 10-NP
aggregation inside PLGA and thus their enhanced ability to decrease the transverse
relaxation time of protons in surrounding water (14, 22, 23). The increased magnetic
relaxivity enhances the hypointense signal. As shown in Fig. 3C, when dispersed in a
3% agarose hydrogel suspension, l0:PLGA-MPs provided higher negative contrast
(higher 1/T 2 or R2 value) than 10-NPs, as suggested by the pseudocolor in Fig. 3C. The
average R2 signal from lO:PLGA-MPs was approximately twice that of the signal
generated from IO-NPs.
To examine the potential for enhanced contrast of 10:PLGA-MPs in vivo,
suspensions of both I0-NPs and l0:PLGA-MPs in agarose gels (without cells) were
injected subcutaneously into the back of a healthy mouse (Fig. 4A). 60 minutes after
injection, the mouse was subjected to whole body multi-slice multi-echo T2 weighted
MRI. The collected images were reconstructed into a 3D 1/T 2 (R2 ) volumetric image
(Fig. 4B) through Amira-Visage Imaging software. Pseudocolor was applied to reveal
the contrast enhancement of particles. As shown in Fig. 4B, l0:PLGA-MPs generated a
stronger negative contrast than I0-NPs using two Fe concentrations (20 pg Fe/ml
(0.36mM) and 40 pg Fe/ml (0.71mM)). Under both conditions, the average R2 signal
from l0:PLGA-MPs was approximately twice that of the signal generated from l0-NPs.
Labeling MSCs with lO:PLGA-MPs
Given that positively charged particles typically show enhanced internalization
into the cells compared to negatively charged particles(24), the negatively charged 10-
NPs and MP, as measured by zeta potential (-30±lOmV and -2.7±1.0mV in PBS
accordingly), were coated with poly-L-lysine coating leading to a surface charge of
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Figure 3: Characterization of magnetic properties of particles prior to cellular
internalization: (A) Hysteresis loop and (B) 1/T 2 versus iron concentration for IO-NPs
and IO:PLGA-MPs measured at 300 K. Relaxivity values r2 were obtained from the
slope of the linear fit of the experimental data. (C) R2-weighted MRI images of 3%
agarose gels containing IO-NPs and lO:PLGA-MPs at iron concentrations of 0, 0.04,0.09, 0.13, 0.18, and 0.36mM. Pseudocolor was applied to reveal the R2 value (unit: Hz
or 1/s), as indicated by the scale bar. (Adapted from (20))
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Figure 4: Improved R2 contrast enhancement in vivo after PLGA encapsulation: A)Schematic illustration of the subcutaneous injection of 45 pL 3% agarose suspension of
either IO-NPs (left) or lO:PLGA-MPs (right) or at the iron concentration of 20 pg Fe/mi(0.36mM) and 40 pg Fe/ml (0.71 mM) on the back of the mouse. B) 3D reconstruction of
a mouse with the R2 map collected with a 4.7 T Bruker Pharmascan scanner and
calculated within the Osirix environment. Scale bar indicates the value of R2 (unit: 1/s orHz). (Adapted from (20))
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10±5.2 mV and 15.1±6.2 mV in PBS. To remove potential signal from free particles,
typically, IO:PLGA-MPs were incubated with MSCs for 12 hours at physiological
conditions, and then cells were detached by trypsinization and purified from free
particles with Ficoll-Paque.(25)
Particles were applied to cells while maintaining a constant Fe concentration (25,
50, 100 or 200 pg/mL) and the amount of Fe loaded into the cells was quantified. This
was achieved by digesting the cells and quantifying the Fe content via ICP-AES. The
maximum Fe loading/cell was attained at 100 pg/mL initial concentration (Fig. 5A).
Further increases in the initial Fe concentration did not enhance the final quantity of Fe
per cell. Interestingly, maximal Fe loading per cell was 20 and 80 pg Fe/cell for IO-NPs
and lO:PLGA-MPs, respectively. A significant 4-fold increase for Fe loading per cell
reveals the advantage of using MPs for internalization of iron oxide. Given that no
statistically significant difference was found in Fe loading between 50-100 pg/mL, to
minimize use of reagents further internalization experiments were performed using 50
pg/mL of Fe.
To assess changes in Fe content over time, following particle internalization and
subsequent purification from free particles, MSCs were plated in T25 plates for 28 days
(the labeling day was designated as day 1). The culture media was replaced every two
days for all samples and at each time point (day 1, 2, 4, 6, 12, and 28) MSCs were
collected for quantification of MSC the proliferation, Fe concentration, and MRI analysis
(by dispersing 200,000 MSCs in 1 mL 3% agarose gel). As shown in Fig. 5B, when
MSCs were labeled with lO-NPs, the iron concentration per MSC decreased to about
half of the initial value after 4 days. The iron concentration per cell was close to
background after 12 days, however, when MSCs were labeled with lO:PLGA-MPs,
within 6 days the concentration had decreased to half of its initial value and after 25
days, the iron concentration per cell was still significantly higher than background. The
combination of contrast enhancement, and increased cellular loading in MSCs of
lO:PLGA-MPs permitted us to visualize MSCs with MRI for at least 12 days (Fig. 5C),
while in the case of lO-NPs labeling there was minimal detectable signal after day 6. To
further confirm the MRI results and examine the stability of the internalized lO:PLGA-
MPs, we labeled MSCs with fluorescent lO:PLGA-MPs containing lipophilic
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Figure 5: Improved retention of 10 in MSCs after PLGA encapsulation: (A) Cellular Fe
content of MSCs after incubation with magnetic particles as a function of iron
concentration. (B) Change in cellular iron content per cell after initial labeling with 10-
NPs or l0:PLGA-MPs at the incubation concentration of 50pg Fe/ml. (C) R2-weightedMR images of 200,000 MSCs collected at different time points and suspended in 3%
agarose gels (4 x 4 mm 2 per square). (D) Fluorescent confocal image of MSCs 18 days
after labeling with l0:PLGA-MPs. The plasma membrane is stained green (DiO), the
nucleus is blue (DAPI) and the l0:PLGA-MPs are stained red (Dil). Scale bar 10pm.(Adapted from (20))
Figure 6. TEM images of MSCs after 12 hours labeling with (A) l0:PLGA-MPs and (B)
lO-NPs. White arrow: location of lO-NPs, Blue arrow: PLGA-MPs, Red arrow:
membrane of intracellular compartment. (Adapted from (20))
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carbocyanine dye (i.e. Dil), and examined the fluorescent signal with fluorescent
confocal microscopy. 18 days after labeling, we still observed the presence of lO:PLGA-
MPs in 15±5% MSCs (Fig. 5D), which revealed the potential of lO:PLGA-MPs for long-
term tracking of MSCs.
The location of internalized lO:PLGA-MPs and IO-NPs in MSCs after 12 hours
labeling was characterized using TEM. In both cases, particles were present in
intracellular compartments (Fig. 6). However, enhanced local density of IO-NPs was
observed when they were encapsulated within PLGA-MPs (Fig. 6A) whereas in the
absence of PLGA-MPs, lower density of IO-NPs was observed in a scattered manner
(Fig. 6B). This result suggests that the advantage of IO-NPs encapsulation in PLGA-
MPs may be enhanced contrast due to particle clustering(26).
lO:PLGA-MPs impact on MSCs
To investigate the potential negative impact on MSC phenotype, the viability,
proliferation and migration ability of MSC were examined following lO:PLGA-MPs
internalization using a series of in vitro and in vivo experiments. As shown in Fig. 7A,
there was no noticeable influence on cell viability for both types of magnetic particles
compared to native cells 24 hours following particle internalization. To assess the
potential impact on cell proliferation, MSCs were labeled with two types of magnetic
particles and studied for 12 days (Fig. 7B), during which confluence was reached
typically at day 9. Compared with the control, MSCs labeled with both types of magnetic
particles showed similar rates of proliferation. The number of MSCs tripled in 5 days.
The migration of MSCs in vitro was examined with a transwell assay. MSCs with
or without internalized particles in media with 1 % FBS were seeded on the insert, which
was placed in chambers receiving complete media (with 10% FBS). MSCs with or
without internalized particles showed similar adhesion on the insert 1 hr following cell
seeding (Fig. 8). Sixteen hours later, the migrated MSCs (bottom of filter) were stained
and counted. Similar to Huang's report(27), MSC modified with IO-NPs showed a
statistically significantly increased level of migration rate (-3x) (Fig. 7C,D&F). The
mechanism mediating this increase is not well understood. The encapsulation of IO-NPs
inside PLGA limited this effect. MSCs labeled with lO:PLGA-MPs showed similar
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Figure 8: MSCs on FluoroBlokTM 8.0 pm colored PET membrane 1 hour after seeding(images acquired of Phalloidin-FITC/DAPI double-stained cells from upside of
membranes) (A) unlabeled MSCs, (B) IO-NPs labeled MSCs, (C) lO:PLGA-MPs labeledMSCs. Scale bar is 100 pm. (Adapted from (20))
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migration through the 8 pm membrane as the unlabeled MSCs (Fig. 7C, E&F).
Homing of labeled MSCs in an inflamed ear model
The in vitro migration assay (Fig. 7C-F) revealed that internalization of lO:PLGA-
MPs does not impact MSC migration. Given that homing of systemically administered
MSCs can be influenced by factors not accounted for in our in vitro assay including
shear stress, immune system interference and endothelial barriers(28), we investigated
the influence of internalized lO:PLGA-MPs on MSCs ability to home in vivo to a distant
site of inflammation in an mouse model.
Previously, we examined the homing of systemically infused MSCs to a site of
inflammation in vivo with dynamic real-time intravital confocal microscopy, using
injection of lipo-polysaccharide (LPS) into the ear of a mouse(29). To facilitate cell
imaging, unlabeled MSCs and MSCs labeled with lO:PLGA-MPs (>97% labeling
efficiency) were treated with cell tracker dyes (DiD, Molecular Probes) and infused via
tail vein. After 24 hours, the ears were imaged with intravital confocal microscopy. As
we have previously shown, unmodified MSCs preferentially migrate to inflamed sites
(Fig. 9A&B). Similarly, lO:PLGA-MPs labeled MSCs exhibited a similar response (Fig.
9C&D). The number of cells at the site of inflammation was comparable between the
lO:PLGA-MPs labeled and unlabeled MSCs. Approximately 20-fold more cells per unit
volume were found in the inflamed ear (Fig. 9E) compared to non-inflamed (saline) ear.
In both cases, -1/3 MSCs had transmigrated outside the blood vessel into the ear
tissue, indicating that particle labeling did not impact transendothelial migration.
Collectively, these results reveal that labeling of MSCs with lO:PLGA-MPs does not
negatively impact MSC phenotype.
Conclusion
Herein, we demonstrated that MSC internalization of 10-NP (10 nm) loaded
biodegradable MPs (0.8 pm) can enhance MR parameters such as the relaxivity (5-
fold), residence time inside the cells (3-fold) and R2 signal (2-fold) compared to free 10-
NPs. Intriguingly, in vitro and in vivo experiments demonstrated that MSC internalization
of l0:PLGA-MPs did not compromise inherent cell properties such as viability,
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Inflamed ear
Saline T
T
Unlabeled MSCs lO:PLGA-MP labeled MSCs
Figure 9: (A-B) Representative images of homed unlabeled MSCs and (C-D)prelabeled with lO:PLGA-MPs in the (A,C) LPS ears and (B,D) saline ears.
signal indicates MSCs and red signal is from the blood vessels perfused with
Dextran, Bar = 100 pm. (E) Quantification of the MSCs in LPS and saline ears
experiment was repeated 3 times). (Adapted from (20))
169
E2.5x10-
2.Ox1O -
E 1.5x10*-
E
*1.xO-10
15.Ox10
0.0-
MSCs
Green
FITC-
(each
proliferation, migration and their ability to systemically home to sites of
inflammation.Thus, labeling cells with IO:PLGA-MPs may offer a potential opportunity
for longitudinal tracking of MSC or other cell types without compromising cell phenotype
including cell migration/homing ability.
Materials and Methods
Materials
All chemicals and solvents were of analytical grade from Sigma-Aldrich and were
used without further purification unless otherwise mentioned. IO-NPs coated with oleic
acid and water-soluble IO-NPs functionalized with carboxy groups were purchased from
Ocean Nanotech (AR).
Mesenchymal stem cell culture and characterization
Primary human MSCs were obtained from the Texas A&M Health Science
Center, College of Medicine, Institute for Regenerative Medicine at Scott & White
Hospital, which has a grant from NCRR of the NIH, Grant #P40RR017447. MSCs were
derived from healthy consenting donors and thoroughly characterized as previously
described.(30) MSCs were maintained in a-MEM expansion media (Invitrogen)
supplemented with 15% Fetal Bovine Serum (Atlanta Biologicals), 1% (v/v) L-Glutamine
(Invitrogen), and 1% penicillin:streptomycin solution (Invitrogen). Cells were cultured to
70-80% confluence before passaging. All experiments were performed using MSCs at
passage number 3-6, where cells expressed high levels of MSC markers CD90 and
CD29 (>99% cells), yet did not express hematopoietic markers CD34 or CD45 as
observed from flow cytometry analysis. Before cell experiments, MSCs were detached
with Trypsin 0.05% - EDTA 0.53mM (Gibco) and filtered with 40 pm Nylon Mesh (Fisher
Scientific)..
Animal welfare
BALB/C mouse (Charles River Laboratories, Wilmington, MA) were used for the
in vivo studies. All studies were in accordance with US National Institutes of Health
guidelines for care and use of animals under approval of the Institutional Animal Care
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and Use Committees of Massachusetts General Hospital (Protocol number
201 0N000064). All injections were performed under anesthesia, and all efforts were
made to minimize suffering. Animals were humanely sacrificed after experiments.
Fabrication of IO:PLGA-MPs
Particles were prepared by following the procedures developed by Nkansah et
al(14) with some minor modifications. Briefly, 10 mg Fe 3 0 4 NPs (10 nm, Ocean
Nanotech, AR) coated with oleic acid were mixed with 100 mg PLGA (acid terminated,
50:50, I.V.: 0.55-0.75 dL/g, Durect® Absorbables Durect Corporation) in 2 mL
chloroform. The organic phase was then added to 20 mL of a 3% (w/v) aqueous
solution of poly(vinyl alcohol) (MW: 90k, 80% hydrolyzed). To make the micronsized
particles, a homogenizer (Tissue Master 125, Omni International) was used to disperse
the organic phase into the aqueous phase (24,000 rpm for 2 min) in a 50 mL beaker.
The homogenized mixture was then stirred overnight in a chemical fume hood at room
temperature to allow for evaporation of chloroform. Finally, particles were isolated by
centrifugation at 7,500 rpm for 5 minutes, washed thrice with distilled water, frozen at -
80 0C and lyophilized for 2 days.
Characterization of lO:PLGA-MPs
TEM: The IO:PLGA-MPs were subject to dehydration using graded ethanol
(20%, 40%, 60%, 80%, 100%) and embedded in Epon 812 resin. Resin blocks were
sectioned using a microtome and imaged with JEOL 200CX (80kV).
SEM: The IO:PLGA-MPs were deposited on silica wafers and coated with 10 nm
gold. Then the PLGA-particle morphology was visualized via SEM (JEOL 6320 at 5kV).
Iron quantification: Iron content of particles was determined using ICP (HORIBA
JOBINYVON, model: Activa) after digestion in 70 % nitric acid.
Hydrodynamic diameter quantification: The hydrodynamic diameter and
polydispersity of particles were collected by Malvern Zetasizer Nano ZS90 in water by
averaging 3 runs.
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Hysteresis loop measurement: Samples were examined with a magnetometer
(DMS Model 880 VSM vintage) at 37 0C. The measurements were normalized for the
grams of iron in each sample, verified through ICP.
Relaxivity measurement (r2) with benchtop relaxmeter: The Fe concentration of
samples was quantified with ICP first. Then five solutions with different Fe
concentrations were prepared and placed in NMR tubes. T2 was measured in the
Minispec Mq-20 (Bruker Optik GmbH, Germany). r2 was derived by extracting the slope
from the plot of 1/T2 versus Fe concentration (mM).
Sample preparation for MRI: The particles were diluted to different
concentrations (0, 5, 10, 15, 20, and 40 pg Fe/mL) in PBS and mixed with equivalent
volume of 6% agarose-gel solution to obtain a final agarose concentration of 3%.
Subsequently, the mixture was pipetted into a 3% agarose-gel-made plate. Pipetting
was gently performed to avoid air bubbles. After 12 hours, MRI samples were imaged
using a 4.7 T Bruker Pharmascan scanner at 370C.
In-vivo MRI of lO:PLGA-MP: A BALB/C mouse (Charles River Laboratories,
Wilmington, MA) was used for the in vivo studies. Mice were anesthetized using
ketamine/xylazine first. Then 45pL 3% agarose gels containing either IO-NPs or
lO:PLGA-MPs with 20 and 40 pg Fe/ml were subcutaneously injected on the back of the
mouse. After one hour the mice were euthanized and multi-slice multi-echo T2 (TR =
2800 ms, 4 averages, 128x128x16 matrix size, 0.432 mm x 0.312 mm x 1 mm voxel
size) scanning was performed with effective echo times of 8.68, 17.36, 26.04, 34.72,
43.40, 52.08, 60.76, 69.44, 78.12, 86.80, 95.48, 104.16, 112.84, 121.52, 130.20, and
138.88 ms on the mouse with a 4.7 T Bruker Pharmascan scanner along with a RARE
T2 sequence (TR= 2000 ms, effective TE = 36.0, 256x256x16 matrix size, 0.216 mm x
0.156 mm x 1 mm voxel size) ms, 8 averages). Amira (Visage Imaging) was used for
the 3D reconstructions, which utilized the T2 maps calculated within the Osirix
environment.
MSCs labeling with lO:PLGA-MPs
Particles were incubated with Poly-L-lysine (0.01%) for 40 minutes at room
temperature in PBS. Then, the complex was added to cells in a-MEM expansion media
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supplemented with 1% FBS, 1% (v/v) L-Glutamine, and 1% penicillin:streptomycin
solution for 12 hours. Cells were then permitted to recover in fresh media (15% FBS).
For experimentation, labeled cells were washed twice with PBS, trypsinized, centrifuged
with Ficoll-Paque (GE Healthcare), re-dispersed and counted in PBS.
Labeling efficiency of MSCs with lO:PLGA-MPs: to facilitate the identification of particles
internalized within MSCs, we incorporated the fluorescent dye, Dil during the
preparation of lO:PLGA-MPs. Then MSCs were labeled with the fluorescent lO:PLGA-
MPs and analyzed with flow cytometry.
Fe quantification in MSCs: For a typical sample, 0.1 mL of cell suspension was
digested overnight using 0.3 mL concentrated nitric acid (-70%) and 0.1 mL hydrogen
peroxide (30%). Samples were then diluted to a volume of 10 mL with deionized water,
yielding a final nitric acid concentration of 2%. Iron concentration was determined with
ICP.
MRI sample preparation: Agar wells were prepared using a 3% agar solution
heated in a water bath until fully dissolved and poured into a PDMS mold. MSCs
suspension samples were mixed with agar powder to a concentration of 3% and heated.
Once the agar was fully dissolved, samples were transferred into an agar well and
allowed to set. MRI samples were imaged using a Bruker 4.7 T MRI scanner.
TEM: MSCs were labeled with IO-NPs or IO:PLGA-MPs (50 pg Fe/mL) for 12
hours, and then washed twice with PBS. MSCs were fixed in phosphate-buffered
Karnofsky's solution followed by staining with 2% osmium tetroxide at 41C overnight,
and dehydration using graded ethanol and embedded in Epon 812 resin. Resin blocks
were sectioned using a microtome, doubly stained with uranyl acetate and lead
hydroxide, and imaged with JEOL 200CX (80kV).
Influence of magnetic particle labeling on MSC properties
Viability study: 200,000 MSCs were seeded in T25 flasks 24 hours before the
experiment. Poly-L-lysine coated lO-NPs or lO:PLGA-MPs dispersed in serum free
media were added to the plates and incubated for 24 hours at 370C. Unmodified MSCs
were treated with serum free media in the same way. Then, the cells were permitted to
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recover in fresh media (15% FBS) for 30 minutes before being collected with 1X trypsin.
Finally, the collected cells were counted. Each condition was performed in triplicate.
Proliferation assessment: 2 million MSCs were labeled with magnetic particles (l0-NPs
or l0:PLGA-MPs) as described above and sub-cultured in T25 flasks. At each time point
(day 1, 3, 6, 9, 12), MSCs in three flasks were trypsinized and counted.
Transwell migration assay: In a 24- well transwell plate (FluoroBlok m 8.0 pm
colored PET membrane, BD), complete medium with 10% FBS was added into the
(bottom) wells. 30,000 MSCs labeled with particles and purified with Ficoll-Paque were
seeded into the insert in media containing 1% FBS. After 16 hours of incubation at 5%
C02 and 370C, inserts were washed twice with PBS, fixed in 4% paraformadehyde for
15 minutes, stained in 0.5% Phalloidin-FITC (Sigmal-Aldrich) for 10 minutes, and
counted.
In-vivo MSC homing
Cell preparation: 18 hours prior to injection, MSCs were labeled with l0:PLGA-
MPs as described above. 2 hours before injection, serum-free medium was replaced
with 15% FBS containing MEM-a for 30 min. Then cells were trypsinized, centrifuged,
and re-suspended at 2x10 6 cells/mL in PBS. DiD stock (Invitrogen Inc.) was diluted to
20 pM in PBS. Equivalent volumes of cells and DiD solution were mixed together and
incubated for 20 minutes at room temperature in the dark. Then, the labeled MSCs were
centrifuged and washed twice with PBS. Finally, MSCs were passed through a 40pm
cell strainer, and re-suspended at 107 cell/mL in PBS.
Animals: BALB/C mice (Charles River Laboratories, Wilmington, MA) were
anesthetized using ketamine/xylazine and the hair around the base of both ears was
trimmed with scissors. To assess the potential for l0:PLGA-MP loaded MSCs to
preferentially home to a site of inflammation, we utilized a model where 24 hours prior to
cell infusion, inflammation was induced through injection of 30pg of E. coli
lipopolysaccharide (LPS, Sigma, St. Louis, MO) in 30 pL of saline into the base of the
left ear, whereas the right ear received 30pL 0.9% of saline as a control. 1 x 106 MSCs
suspended in 100 pL PBS (pH 7.4) were injected retro-orbitally 24 hours post LPS
injection. For delineation of vasculature during imaging, -100 pL of 2 mg/mL FITC-
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dextran (2 x 106 kDa; Sigma, St. Louis, MO) was injected retro-orbitally just prior to
imaging.
Dynamic real-time intravital confocal microscopy. Homing of unmodified and
modified MSCs to the skin was imaged noninvasively (in real time) using a custom-built
video-rate laser-scanning confocal microscope designed specifically for live animal
imaging(31). To image the vasculature and surrounding tissue, we positioned the
mouse's ear on a coverslip (with index matching gels) and obtained high-resolution
images with cellular details through the intact mouse skin at depths of up to 250 pm.
The laser beams were focused onto the sample (mouse ear skin) using a 60X, 1.2NA
water immersion objective lens (Olympus, Center Valley, PA). DiD-labeled MSCs were
excited with a 635 nm continuous-wave (CW) laser (Coherent, Inc., Santa Clara, CA)
and detected through a 695 nm ± 27.5 nm band pass filter (Omega Optical, Brattleboro,
VT). FITC-dextran was excited with a 491 nm CW laser (Cobalt, Stockholm, Sweden)
and detected through a 520 ± 20 nm bandpass filter (Semrock, Inc., Rochester, NY).
For static images, 15 frames were averaged from the live video mode to improve the
signal to noise ratio. The total number of "homed" cells from each MSC population
within the mouse ear was quantified from the z-stacks acquired. For publication
purposes, the contrast and brightness of the images were changed using ImageJ
software.
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Appendix II Preface
In this Appendix I discuss an additional project I was heavily involved in
throughout the duration of my PhD involving biomimicry of the North American
porcupine quill to develop novel medical devices. While the primary focus of this thesis
is on the development of improved cell-based therapies, I have also always had an
interest in medical devices. While these topics may seem divergent, as a biomedical
engineer I find them quite similar. Both involve first acquiring a deep understanding of a
natural system (MSCs or porcupine quills) and then using that newly acquired
knowledge and the tools of engineering to solve important problems in medicine.
This appendix is an adaptation of a peer-reviewed article published on December 26,
2012 in Proceedings of the National Academy of Sciences. Reprinted with Permission.
Cho WK, Ankrum J, Guo D, Chester SA, Yang SY, Kashyap A, Campbell GA, Wood RJ,
Rijal RK, Karnik R, Langer R, Karp JM. (2012). Microstructured barbs on the North
American porcupine quill enable easy tissue penetration and difficult removal.
Proceedings of the National Academy of Sciences, 109(52), 21289-94.
Glossary of Terms
Quill: Modified hair of porcupine used for self defense and display
Barb: 100 micron sized backward facing scale found at the tip of quills
Stress Concentration: Zone of high stress caused by local geometry that is prone to
fracture before the bulk medium.
Puncture: Initial breaking of a surface barrier
Penetration: Movement into a medium following puncture.
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Appendix I: Microstructured Barbs on the North American
Porcupine Quill Enable Easy Tissue Penetration and Difficult
Removal
Abstract
North American porcupines are well known for their specialized hairs, or quills
that feature microscopic backwards-facing deployable barbs that are used in self-
defense. Herein we show that the natural quill's geometry enables easy penetration and
high tissue adhesion where the barbs specifically contribute to adhesion and
unexpectedly, dramatically reduce the force required to penetrate tissue. Reduced
penetration force is achieved by topography that appears to create stress
concentrations along regions of the quill where the cross sectional diameter grows
rapidly, facilitating cutting of the tissue. Barbs located near the first geometrical
transition zone exhibit the most substantial impact on minimizing the force required for
penetration. Barbs at the tip of the quill independently exhibit the greatest impact on
tissue adhesion force and the cooperation between barbs in the 0-2 mm and 2-4 mm
regions appears critical to enhance tissue adhesion force. The dual functions of barbs
were reproduced with replica molded synthetic polyurethane quills. These findings
should serve as the basis for the development of bio-inspired devices such as tissue
adhesives or needles, trocars, and vascular tunnelers where minimizing the penetration
force is important to prevent collateral damage.
Introduction
The North American porcupine has -30,000 quills on the dorsal surface(1) that
are released when a predator contacts the porcupine. In contrast to other mammals
such as the African porcupine, hedgehog, and echidna that have smooth spines, each
quill tip contains microscopic backward facing barbs (1-4). It has been well documented
that it is difficult to remove porcupine quills once the quills are lodged within tissue
(typically through both skin and muscle)(1, 3). However, the forces involved in
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penetration and pull-out have yet to be described and a comprehensive mechanism
remains elusive.
Results and Discussion
North American porcupine quills (Fig. 1A) have two distinct regions. The conical
black tip contains a layer of microscopic backward facing barbs on its surface (Fig. 1B),
while the cylindrical white base contains smooth scale-like structures (Fig. 1C). As
shown in Fig. 1D, barbs overlap slightly and have dimensions ranging from 100-120 mm
in length, with a maximum width of 35-45 mm. There is 1-5 mm space between the tip
of each barb and the shaft of the quill. The size of the barbs becomes larger farther from
the apex of the tip (Fig. 1E). Since the length of the barbed region varies (Fig. 2), we
standardized tests by only using quills with a barbed region of 4 mm.
Fig. 1 F shows the results of penetration-retraction tests including a barbless
control quill whose barbs were carefully removed by gentle sanding to avoid altering the
diameter of quill (Fig 3). The force required for penetration into tissue was defined as
the penetration force and the maximum force required to remove the quill with respect
to baseline was defined as pull-out force. Surprisingly, Fig. 1 F shows that the quill with
barbs required 54% less penetration force compared to the barbless quill. Regarding
pull-out force, quills with and without barbs required 0.44±0.06 N and 0.11±0.02 N,
respectively, and the barbed quill required less work of penetration and higher work of
removal (Fig. 1G). Also, the barbed quill requires significantly less force and work to
penetrate into tissue, compared to an 18 gauge hypodermic needle, which has a
diameter of 1.161±0.114 mm, similar to the diameter of a porcupine quill (1.262±0.003
mm) (Figs. 1G).
As an additional control for the presence of barbs, we performed penetration-
retraction tests using the naturally barbless African porcupine quills (Fig. 1F). The work
of penetration and work of removal were 2.13±0.04 mJ and 0.22±0.06 mJ, respectively
(Figs. 1F and G). The profile of the force versus extension plot for the African quill
exhibited a similar profile to the barbless North American quill. Thus, barbs appear
essential for both reducing penetration force and generating tissue adhesion.
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Force (N) Force (N) Penetration (mJ) Removal (mJ)
Barbed 0.33 0.08 0.44 0.06 1.08 ± 0.37 1.73 ± 0.41Quill
Quill 0.71 ± 0.09' 0.11 ± 0.02* 2.41 ± 0.28* 0.28 * 0.03
18 Gauge 0.59 0.11* 0.04 0.006 2.75 ± 0.70* 0.10 O.2Needle
African
Porcupine 0.65 0.01 0.06 0.01* 2.13 ± 0.04' 0.22 ± o.of'Quill
Figure 1. Geometrical features of the North American porcupine quill and analysis of
the penetration and removal forces with muscle tissue. (A) North American porcupine
quill. (B, C) FE-SEM images showing the microstructure of the quill tip and base,
respectively. (D) Fluorescence image enables visual delineation of the geometry of
single barbs. (E) FE-SEM image showing the microstructure of the tip of the porcupine
quill. (F) Representative force versus extension plots show puncture, penetration, and
removal of barbed, barbless, and African porcupine quills from muscle tissue (see Fig.
12 for experimental set-up). Inset shows micron-level topography of the three quills.
Scale bars represent 100 mm. Red arrows indicate resistance as the barbed quill is
removed from the tissue (not observed for others). (G) Summary of experimental values
obtained from penetration/removal of barbed quill, barbless quill, 18 gauge needle, and
African porcupine quill (Mean ± standard deviation, n=5). Each mean is compared to
every other mean using one-way ANOVA with Tukey's Honestly Significant Difference
post-hoc analysis to correct multiple comparisons at 95% confidence interval by using
GraphPad Prism 6 (*p<0.05, compared to barbed quill and tp<0.05, compared to
barbless quill). (Adapted from (5))
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Figure 2. Barbed regions vary between 4-10mm in length. (A) Representative quills with
different lengths of barbed regions where the length is typically in the range of 3-5 mm.(B) Optical microscopic image confirms the length of a quill with a 4 mm barbed region.(C) Sequential FE-SEM images of a single quill show the transition from functional
barbs to a smooth surface containing barbs that have yet to emerge (i.e. those that
cannot yet engage tissue). (Adapted from (5))
Figure 3. Sanding of quills removes barbs but does not substantially alter the quill
morphology or size. FE-SEM images show (A) the barbed quill with 4 mm-barbed region
and (B) the barbless quill after removal of the barbs by sanding. Gentle sanding didn't
significantly change the diameter of quill. Specifically, while sanding of barbs led to a
3-7% reduction in diameter for the first 0-2 mm from the apex of tip, sanding of other
regions showed -1 % reduction. (Adapted from (5))
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Figure 4. Finite element analysis shows that the tissue is primarily stretched and
deformed near the barbs. (A-B) Strain field distribution in skin tissue when a barbless
quill or two-barbed is penetrated into tissue, respectively. The Young's modulus of both
quills was set at 3.25 GPa for finite element analysis. LE refers to for Logarithmic (L)
strain (E) and represents true strain. 75% refers to the averaging threshold of the
extrapolated results to achieve a smooth colored contour map. (C) Geometry of two-
barbed quill with the dimensions of a single barb and the distance between two barbs
indicated. The simplified geometry is based on the middle point of 4 mm barbed region
of natural quill. (D) Finite element modeling of the quill penetration into skin tissue
shows compressive stresses (in MPa) from the tissue acting on the quill at a distance
from the quill tip. This is the stress state following a 10 mm-penetration into the skin
tissue. S means stress and S1 1 refers to the stress vector on the plane normal to "91" in
the "1" direction. 75% refers to the averaging threshold of the extrapolated results to
achieve a smooth colored contour map. (Adapted from (5))
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Figure 5. Barbs reduce tissue damage and facilitate penetration into tissue. (A, B)
Representative histological images of tissue samples that were penetrated with barbed
and barbless quills, respectively, showing significantly less damage induced by the
barbed quills (n=5). The scale bar represents 200 mm. (C, D) Micro-computed
tomography (Micro-CT) images present the penetrated (C) barbed and (D) barbless
quills within tissue. Both quills were penetrated into tissue with an applied force of 0.2 N.
The red dashed arrows indicate the penetrating depth of quill. The scale bar bepresents
1 mm. (E) Mean penetrating depth of barbed and barbless quills observed in micro-CT
images (n=3). (Adapted from (5))
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During the penetration process, tissue initially deforms under the advancing quill
tip until a critical load leads to tissue puncture (6, 7). At the critical load, the quill tip
initiates a crack that expands the hole circumferentially through stretching and tearing
tissue fibers, permitting the quill to penetrate into tissue. The rupture of the tissue
surface occurs via a planar mode I crack ahead of the tip, and the crack faces are
wedged open by the advancing quill similar to what has been described for needles (8,
9). The work of penetration is the energy absorbed by the tissue during the penetration
process and includes the energy required to deform and tear the tissue upon
penetration (10). The barbed quill requires less work of penetration (Fig. 1G) while
minimizing tissue damage. Stress concentrations generated by the barbs during
penetration likely stretches or tears tissue fibers locally at the interface of the quill.
To visualize the effect of barbs on penetration, we examined the strain
distribution in tissue using finite element analysis (FEA) for a barbless quill and a
simplified two-barbed quill (Figs. 4A and B). Values for the geometry and material
properties of the quill and tissue for FEA were experimentally derived (Fig. 4C). The
analysis revealed that tissue is primarily stretched and deformed by high stress
concentrations near the barbs. The local stress concentrations likely reduce the need to
deform the entire circumference of tissue surrounding the quill, consequently reducing
the penetration force. The concept of stress concentration has been used to design
blades and knives, albeit at a much larger scale than what is utilized by porcupine quills.
Compared to straight blades, serrated blades require less work to cut tissue by
localizing strain at points on the tips of the teeth of the blade. The strain concentration
causes the tissue to fail with a lower input force (11). Consequently, serrated blades
provide cleaner cuts with minimal deformation of the tissue (11).
While porcupine quill barbs are relatively small compared to the jagged edge of a
serrated knife, we observed a cleaner interface between tissue and barbed quills
compared to barbless quills upon histological analysis of the tract left by quills after
penetration (Figs. 5A and B). This result suggests that the tissue absorbs less energy
and is damaged less during penetration by a barbed quill. Furthermore, when 0.2N was
applied to barbed and barbless quills, the barbed quills advanced significantly deeper
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Figure 6. The reduced penetration force of the natural porcupine quill
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in synthetic polyurethane quills. (A, B) FE-SEM images show the barbless and barbed
synthetic PU quills. The scale bar represents 100 mm. (C) The forces required to
penetrate the PU quills into muscle tissue to 4 mm-depth (Experimental details in Fig.
12B). The mean values are shown with standard deviation (n=5, student t-test at the
level of 95% significance). The box plot whiskers are set to ± 1.2 standard deviations.(D) Representative force versus extension plots from the penetration-retraction tests of
the natural quill and replica molded PU quills performed in muscle tissue. (E) Fabricated
quill-mimetic needle. (F) The forces required to penetrate the fabricated
barbed/barbless needles into a model of human skin. The data shows the mean
penetration force with standard deviation (n=3, each needle was used at least 4 times,
student t-test at the level of 95% significance). The two "X"s in box plots of (C) and (F)
indicate 1st and 99th percentiles. (Adapted from (5))
Figure 7. Selective ablation of
barbs is achieved by gentle
sanding. (A-H) Representative
optical micrographic images
confirm the barbed region for
eight quills that have been
sanded to obtain barbed regions
of specific length. Inset in (C)
shows the enlarged images for 1
mm barbed region. (Adapted
from (5))
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into muscle (4.19±0.39 mm) than barbless quills (2.50±0.33 mm) (Figs. 5C-E) as
measured by micro-computed tomography (micro-CT).
To investigate the role of barb deflection in the reduction of penetration force, we
reproduced quills with non-deployable barbs using replica molding that reproduces the
surface topography of the quill. We fabricated both barbless and barbed (non-
deployable) polyurethane (PU) quills by replica molding (Figs. 6A and B). While the
penetration force for insertion of barbless PU quills to a depth of 4 mm was 0.046 +
0.010 N, the barbed PU quill required 35% less force, 0.030 ± 0.006 N (Fig. 6C).
Additionally, the penetration force of natural barbed quills with muscle tissue was 0.043
± 0.013 N (Fig. 6D), which was not significantly different from that of the PU barbed
quill. Although the barbs of the PU quill cannot bend, the PU quill includes the same
topography (i.e. barbs) creating stress concentrations during penetration into the tissue.
Therefore, the experimental results with the fabricated PU quills support that stress
concentration at barbs helps to reduce the penetration force of the natural porcupine
quill. As barbs and muscle tissue fibers are on the same length scale (-50-100 mm),
(12) the stress concentrations at barbs can potentially stretch tissue fibers locally. To
apply this phenomenon to the development of a medical needle to achieve reduced
penetration force (see SI text), we fabricated a prototypic hypodermic needle with
microscopic barbs. The PU-barbed needle showed 80% less penetration force
compared to the PU barbless needle (Figs. 6E and F).
Upon penetration of a quill into tissue, tensile and compressive 'zones' arise in
the surrounding tissue. The quill has three geometrical transition zones as shown in Fig.
8A. FEA shows that tissue compression occurs tangential to the quill from the first
transition zone, which is -3 mm from the apex of tip with a maximum at the second
transition zone (Fig. 4D). This suggests that barbs closest to the first transition zone
may experience the greatest interaction with tissue. To understand the interaction and
contribution of each region of the barbed tip, we isolated individual regions of quill tips
via sanding (Fig. 7, Fig 8B). Compared to the barbless quill, the penetration force does
not decrease if only the first 1 or 2 mm of barbed region at the tip of the quill is included
(quills 3 and 4). However, when barbs in the 2-3 mm region are included, the
penetration force significantly decreases. Quill 6, which has barbs only in the 2-4 mm
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Figure 8. Barbs within a 4 mm barbed region at the apex of the quill work independently
to minimize penetration force and cooperatively to maximize pull-out from tissue. (A)
Dimensional analysis of the porcupine quill through length scale measurements of
natural quills (mean ± standard deviation, n=5). In terms of curvature, there are three
transition points. L and W indicate length and width, respectively. (B, C) Penetration and
pull-out forces were obtained with the prepared quills via sanding to isolate the
contribution of barbs within different regions (see Fig. 7) (mean ± standard deviation,
n=5). The penetrating depth for all experiments was 10 mm (see Figure 12A for the
experimental set-up). Cartoons depict quills prepared with specific lengths of barbs
obtained through ablation with sand paper. The blue color indicates the barbed region
and the white color indicates the barbless region. The penetration and pull-out forces of
the prepared quills are compared to those of the barbless quill (quill 1). The difference in
force is defined as Aj (Aj = penetration (or pull-out) force of qui/l j-penetration (or pull-
out) force of quill i)). (D) Summarized work of penetration and work of removal obtained
through penetration-retraction tests with muscle tissue (mean ± standard deviation,
n=5). All are compared to quill 1 (*p<0.05, one-way ANOVA Fisher's Least Significant
Difference post-hoc analysis at 95% confidence interval by using GraphPad Prism 6).(Adapted from (5))
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region, resulted in a significant reduction of penetration force, -0.26 N. Additionally, the
2-3 mm (quill 7) and 3-4 mm (quill 8) barbed regions independently reduce the
penetration force compared to the barbless quill (quill 1). Therefore it appears the 2-4
mm barbed region close to the first transition zone is most critical for reducing the
penetration force.
The presence of barbs contributes 0.33 N of pull-out force (comparing quills with
a 4 mm barbed region to barbless quills (A12 = 0.33)). The 1-3 mm barbed region had
less impact on pull-out force compared to the 1 mm region at the tip (Comparing quill 3
with 5). Comparing the pull-out forces between quill 5 and 2 (A52 = 0.14) suggests that
the 1 mm region near the transition zone (at the base) is likely critical. However, the
presence of barbs solely in the 2-4 mm region (quill 6) or in the 2-3 mm region (quill 7)
did not substantially increase pull-out force compared to the barbless quill. Furthermore,
barbs in the 3-4 mm region alone did not increase the pull-out force. This data suggests
that barbs in different regions likely work cooperatively. Cooperativity is further
supported by the lack of additive effects (A14 +A160A 12 and A15+A180A12). Taken
together, the first 1 mm barbed region of tip independently makes the greatest impact
on pull-out force, and the cooperation between 0-2 mm and 2-4 mm regions increases
the force. Cooperativity may be a function of barb overlap where increased compressive
force from tissue on barbs near the transition zone impacts barbs closer to the tip. Or
barbs near the tip may experience different stresses due to the cutting of tissue by the
more proximal barbs. Figure 8D shows the summary of work of removal for all quill
preparations. Together these data suggest that the quill achieves adhesion by a
mechanism that is more complex than simply hooking tissue fibers.
To examine how barbs generate mechanical adhesion, we investigated quill
removal from both fibrous tissue and a non-fibrous control (Fig. 9). Tissue fibers
interlock under the barbs, suggesting barbs may be deployed or bent during removal
from tissue. We postulated that such deployment of the barbs could increase tissue
adhesion by projecting barbs radially away from the quill (thus increasing the apparent
quill diameter) to significantly increase frictional resistance and promote further
mechanical interlocking with tissue. The ability of deployment or bending of barbs to
contribute to tissue adhesion was further tested with porcine skin, which has similar
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mechanical properties to human skin (13, 14). The deployment or bending of barbs was
observed following penetration-retraction tests with significant residual tissue adhered to
the quill (Figs. 1OA-D). The pull-out force for porcine skin was 2.36 ± 0.83 N (Fig. 1OE)
while the work of removal was 2.34 ± 0.68 mJ. Interestingly, we observed a direct
correlation between the pull-out force and the number of bent barbs following removal of
the quill from skin (Figs. 1OF-l) and significantly greater work is required to remove a
natural quill from muscle tissue compared to a PU barbed quill (Fig. 6D). Natural quill
with deployable barbs requires 0.144 ± 0.048 mJ for removal, compared to 0.053 ±
0.023 mJ for non-deployable PU-barbed quill. The PU-barbed quill produces the
maximum force after 2 mm of pull-out and then disengages the tissue completely at 4
mm of pull-out. However, natural quill drags tissue for a relatively long displacement
generating peak-adhesion after it has been pulled beyond 4 mm. The natural quill is
able to stretch tissue maximally during removal by using the bending of barbs, which
increases engagement with tissue fibers. The non-deployable barbs of the PU quill,
however, pull tissue and cut as the quill is removed.
Reproducing the strong tissue adhesion property of the porcupine quill would be
useful for the development of mechanically interlocking tissue adhesives. As a proof of
concept, we fabricated a prototypic quill-mimetic patch that has a hexagonal array of 7
replica molded PU quills (Fig. 1 1A). While the barbless PU quill patch showed minimal
pull-out resistance (0.063 ± 0.033 N), the barbed PU quill patch achieved significantly
greater tissue adhesion (0.219 ± 0.059 N, Fig. 11 B). The work of removal for the barbed
quill patch was >30x that of the barbless quill patch (Fig. 11 B). As observed in figure
11C, the barbed quill array achieved significant interlocking with tissue whereas the
barbless quill array achieved minimal interaction with tissue and thus could be easily
removed. Although current barbed array systems have shown tissue adhesion, all of
them feature initially deployed barbs that require high penetration force and cause
tissue damage during penetration (15, 16). The quill-mimetic patch is unique in that it
can both easily penetrate tissue and achieve high tissue adhesion.
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characteristic FE-SEM images following removal of a barbed quill following a 4 mm
penetration depth into tissue (For the FE-SEM image of the quill prior to penetration into
tissue, see Fig. 1 B). Residual tissue was present along the length of the barbs and
under the barbs as indicated with white arrows. Scale bar represents 50 mm. (C)
Representative force-extension curves show penetration and pull-out forces that were
obtained with fibrous muscle tissue and a density matched non-fibrous model tissue
fabricated from gelatin gel (n=5). (Adapted from (5))
A svaww Tw C E
4 ,.
B Te D Extenelon (mm)
Fore (N) Removal (mJ)
f 1.823 1.622
9 2.469 2.643
h 3.771 2.O4
Figure 10. Generation of mechanical adhesion by microstructured barbs. (A, B)
Representative optical and fluorescent images of porcupine quills before and after
removal from porcine skin. Fluorescence images are useful to delineate the boundaries
of individual barbs and are obtained by merging several images taken at different focal
planes along the Z-axis. The scale bar represents 100 mm. (C, D) FE-SEM micrographs
following removal of quills from porcine skin. Residual tissue is indicated by blue arrows.
Red arrows in figures indicate bending of barbs during pull-out. (E) A representative
force versus extension plot for a penetrating depth of 4 mm where puncture typically
occurs following tissue compression of 1-2 mm (n=5). (F-H) Images of quills following
removal from porcine skin are useful to examine the heterogeneity of tissue interactions
and to establish the relationship between the bending of barbs and relative level of
tissue adhesion summarized in the table (/). The scale bar in each image represents
100 mm. See Figure 12A for the experimental set-up for the tests with porcine skin.(Adapted from (5))
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Figure 11. A prototypic quill-mimetic patch as a mechanically interlocking tissue
adhesive. (A) The digital photograph shows the fabricated quill-mimetic patch, which
consists of 7 PU barbless or barbed quills. (B) The tissue adhesion forces obtained from
barbless and barbed PU quill patches (n=5, student t-test at the level of 95%
significance). The box plot whiskers are set to ± 1.2 standard deviations. The two "X"s in
box plot indicate 1st and 99th percentiles. (C) Shows the quill-mimetic patches
interacting with muscle tissue during the retraction process from muscle tissue.(Adapted from (5))
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Conclusions
Herein we report how the North American porcupine quill displays a unique
geometry that serves two polar opposite functions. Barbs on quills enable easy
penetration into tissue and strong tissue adhesion during removal through the presence
of backwards facing deployable barbs. Similar to how biomimicry of cockleburs inspired
the development of Velcro* hook-and-loop fastener (17) and gecko is inspiring the
development of tape-based tissue adhesives (18, 19), these findings should serve as
the basis for the bio-inspired development of new devices including needles for easy
penetration with compliant substrates such as tissue or microneedles where effective
insertion without deformation (buckling) is required (20). Mimicking the porcupine quill
should be useful for biomedical applications including local anesthesia, abscess
drainage, vascular tunneling, and trocar placement in addition to the development of
mechanically interlocking tissue adhesives.
Materials and Methods
Materials
North American (specifically, Pacific Northwest) porcupine quills and African
porcupine quills were purchased from Minute Bear Trading, USA. Fluorescein (sodium
salt, dye content -70%, Aldrich), rhodamine B (dye content -90%, Sigma-Aldrich),
ethanol (ACS reagent, 99.5%, 200 proof, Sigma-Aldrich), formalin solution (neutral
buffered, 10%, Sigma), Sylgard* 184 silicone elastomer kit (Dow Corning, Corp., USA),
UV-curable polyurethane acrylate (Minuta Tech., Korea), Irgacure 2959 (Ciba Specialty
Chemicals Corporation), 18 gauge, 19 gauge, and 25 gauge needles (Becton Dickinson
Company), artificial human skin (SynDaverTM Labs), muscle tissue of domesticated fowl
(Shaw's, Inc.), gelatin powder (DifcoTM, BD), sand paper (3M wetordry sandpaper
413Q 400 and Norton MultiSandTM, 60), cyanoacrylate glue (Loctite 495, Loctite
Corp.), industrial razor blades (surgical carbon steel, single edged No. 9, VWR),
polyether ether ketone (PEEK) hex nuts (Small Parts), silicone rubber film with backing
adhesive (McMaster-Carr), pin mount stubs (25.4 mm in diameter, 9.5 mm in height,
and 3.2 mm in pin diameter, Ted Pella, Inc.), 5 min and 60 min epoxy glues (ITW
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Performance Polymers) were used as received. The fresh porcine skin was purchased
from a local butcher shop.
Penetration-retraction Tests with Muscle Tissue and Gelatin Gel.
Penetration-retraction tests were performed with the mechanical tester (Model
5540, Instron Corporation). Only quills with a barbed region of 4 mm in length were
selected for testing, as measured with a millimeter ruler and a dissecting optical
microscope (SZ-6 PLUS, Cambridge Instruments). The muscle tissue was cut into
specimens with 3-4 cm width, 2-3 cm length, and 4-5 mm thickness using a razor blade.
The tissue specimens were mounted within the lower grips at the base of the
mechanical tester. During fixation, care was taken not to excessively compress the
tissue. After the specimen was fixed between the grips, the exposed excess tissue over
the grips was cut with a blade, generating a flat tissue surface (Fig. 12A). The explanted
muscle tissue was static, aside from when it was compressed during penetration
followed by elastic relaxation as insertion force was removed. The quill was fixed
between the upper grips and the tip adjusted to contact the tissue surface. The quill was
penetrated into the muscle tissue to the desired depth, typically 10 mm, at a rate of 1
mm/sec and was pulled out at a rate of 0.033 mm/sec to study how the barbs function
during removal from tissue. For the duration of all experiments, the tissue was kept
moist with phosphate buffered saline. Each quill was used for a single measurement.
For details of experiment with gelatin gel as a non-fibrous tissue control, please see SI
text.
Preparation of the Stained Quills for Visualization during Adhesive Measurements
Porcupine quills were immersed into 0.01% aqueous fluorescein or rhodamine B
solution. After 1 h, quills were removed from the staining solution and washed thoroughly
with water. The stained quills were dried overnight before use.
Penetration-retraction Tests with Porcine Skin
Fresh porcine skin was cut into specimens with 3-4 cm width and 3 cm length
using a razor blade. For adhesive measurements, porcupine quills were inserted into
porcine skin, vertically aligned within the lower grips, with a penetrating depth of 4 mm.
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Figure 12. Cartoon depicting the apparatus used for penetration-retraction tests. (A)
set-up for the test with muscle tissue, which was under compression. (B) set-up for the
test with muscle tissue without compression. The muscle tissue in (B) was cut to fit
exactly with the available space within the lower platform. Purple and orange colorsindicate the porcupine quill and muscle tissue, respectively. Set-up (A) was utilized
when we penetrated the porcupine quill into muscle tissue to a depth up to 10 mm. Asthe thickness of muscle tissue was <10 mm, we rotated the tissue vertically within thelower grips to allow penetration in the transverse direction. Set-up (B) was used to
adequately compare data from the tests with gelatin gel and muscle tissue. This
comparison was useful to examine how barbs generate mechanical adhesion withtissue by examining quills following retrieval. To minimize any movement of muscle
tissue, which was not under compression, we used thicker muscle tissue (i.e. chickenbreast). Since the quill was consistently covered by tissue when 10 mm was used as apenetrating depth, obscuring observation of barbs, a penetrating depth of 4 mm was
used. The penetrating depth of all tests with set-up (B) was 4 mm. The test with porcine
skin was performed with the set-up (A) as the skin was <10 mm thick. Furthermore, to
study mechanisms of tissue adhesion with porcine skin, 4 mm was used as apenetrating depth. (note: we utilized set-up (A) for generating the data in Figures 1, 8,
and 10. We used set-up (B) for the data in Figures 5, 6, 9, and 11. It is important to
consider that the differences in models impacted the force profiles and puncture andpenetration forces. In set-up (A), quill removal from tissue did not extend beyond zero inthe force-extension curve. In set-up (B) where tissue was not in compression (likely
mimicking how quills penetrate tissue in nature), the quill is pulled beyond 0 when it is
removed from tissue). (Adapted from (5))
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The remainder of the test followed the procedure previously described for muscle
tissue.
Surface Characterization of the Quills
The microstructures of the porcupine quills before and after penetration-retraction
tests were examined with field-emission scanning electron microscope (FE-SEM, JEOL
5910) following a 30 nm-thick gold sputter coating. Light and fluorescence images were
obtained with a Nikon Eclipse TE-2000-U microscope (Nikon Digital Sight DS-QiMC
camera, Japan). The length of barbed region of each quill was examined with a
dissecting optical microscope (SZ-6 PLUS, Cambridge Instruments) and optical digital
images were obtained (IXY Digital, Canon, Japan).
Histological Analysis
The porcupine quill was penetrated into muscle tissue at a rate of 1 mm/sec until
the force reached 0.2 N. The sample was then fixed by immersing it into 10% buffered
formalin for 24 h. The fixed sample was washed with water and stored in 70% ethanol
prior to embedding in paraffin. The sample was then dehydrated with 95% and 100%
ethanol solutions and embedded in paraffin (Thermo Electron Shandon Excelsior tissue
processor). 5-,im sections of embedded samples were obtained with a rotary microtome
(Thermo Scientific Shandon Finesse ME+). Sections were stained with haematoxylin
and eosin, cover-slipped with a xylene-based mounting medium, and the prepared
slides were examined with a Nikon Eclipse TE-2000-U microscope (Nikon Digital Sight
DS-QiMC camera, Japan).
Micro-Computed Tomography (Micro-CT)
The porcupine quill was penetrated into muscle tissue at a rate of 1 mm/sec until
the force reached 0.2 N. The sample was then fixed by immersing it into 10% buffered
formalin for 24 h. The fixed sample was washed with water and dehydrated. For each
25%, 50%, 75%, and 100% ethanol solutions, the sample was incubated for 30 min.
The sample was then evaluated using a microtomographic imaging system (eXplore CT
120, Gamma Medica, Northridge, California). CT slices of the sample were acquired by
using 1200 views with 25- xm isotropic voxels, a tube voltage of 80 kVp, 32 mA current,
and 100 ms exposure time. The sample images were obtained to include the entire
region of the quill and tissue. Images were reconstructed, filtered, and a specimen-
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specific threshold was applied. The penetrating depth of the porcupine quill within tissue
was computed by using a direct three-dimensional approach that does not rely on
assumptions regarding the underlying structure.
Fabrication of Polyurethane (PU) Quills and Quill-mimetic Needles
Poly(dimethylsiloxane) (PDMS) pre-polymer was prepared by mixing the base
material and curing agent in a 10:1 ratio. After vigorous mixing and degassing, PDMS
molds of natural barbed and barbless quills were prepared by thermal curing at 70 'C
overnight. To make quill-mimetic needle, a 25 gauge needle was inserted into the quill's
base. After curing PDMS, the quill and needle were removed to produce PDMS molds.
The polyurethane acrylate, which was mixed with 0.1% photo-initiator, was added into
the PDMS molds. To fabricate a quill-mimetic needle, a 25 gauge needle was again
inserted into the mold at this stage allowing the polyurethane to bond to the needle. The
samples were placed in a vacuum desiccator in the dark to degas the samples for 1-2
hours. The samples were then cured under UV (254 nm) for 90 min and removed from
the molds.
Measurement of Penetration Force of PU Quills and Needles with Tissue
A thick section of muscle tissue was prepared to fit with the available space
between the lower grips of mechanical tester. The prepared tissue was placed between
the grips without compression. The PU quill was fixed between the upper grips of
mechanical tester and the tip adjusted to contact the tissue surface. The quill was
penetrated into the muscle tissue to the desired depth, 4 mm, at a rate of 1 mm/sec. For
the duration of all experiments, the tissue was kept moist with phosphate buffered
saline. Each quill was used for a single measurement. The mean penetration force was
measured from n=5 different samples.
The penetration force of quill-mimetic PU needle was examined with artificial skin
(SynDaver Labs) that mimics the property of human skin. The fabricated PU needle was
connected with a force gauge (Model FGV-5XY, Nidec-Shimpo Corp., Japan), and
inserted manually into the skin tissue. The force gauge reads the required penetration
force. Each needle was used at least 4 times. The mean penetration force was obtained
from n=3 different samples.
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Fabrication of a Quill-mimetic Patch with a Hexagonal Array of PU Quills
The tip (5 mm-length) of natural quills was replicated with a hex nut base and
arranged in a hexagonal array with a silicone backing layer using 60 min epoxy glue.
Following generation of PDMS molds of barbed or barbless quills, we followed the same
procedure descried previously to produce replica molded PU quills. The 7 PU
barbed/barbless samples were then assembled with silicone backing layer. The hex
base of PU quills allowed for simple alignment of a hexagonal array. To ensure that the
array was stable, another backing layer was attached to the assembled sample using 5
min epoxy glue. All PU quills within the patch were perpendicular to the backing layer.
Measurement of Tissue Adhesion Force of Quill-mimetic Patch
A modification of ASTM F2258-05 was used to measure the tissue adhesion
force of quill-mimetic patches. A flat section of muscle tissue was affixed using
cyanoacrylate glue to test fixtures (i.e. pin mount stub with diameter of 25.4 mm). The
prepared tissue sample was mounted within the lower grips at the base of the
mechanical tester. The quill-mimetic patch was glued onto another fixture, and the
prepared patch was fixed between the upper grips of mechanical tester. The tips of
quills within the patch were adjusted to contact the tissue surface. The patch was
penetrated into the muscle tissue to a depth of 4 mm at a rate of 1 mm/sec and was
pulled out at a rate of 0.033 mm/sec to study how the barbs function during removal
from tissue. For the duration of all experiments, the tissue was kept moist with
phosphate buffered saline. The mean tissue adhesion force was measured from n=5
different samples.
Finite Element Analysis (FEA)
For the finite element simulation, we employed a two-dimensional approximation
of the geometry. We model the quill and barbs as a linear elastic material with Young's
modulus E = 3.25 GPa and Poisson's ratio v = 0.4 as determined from uniaxial tension
experiments of quill tips. The porcine skin is modeled as a non-linear incompressible
material using the inverse Langevin model (21, 22) with an initial shear modulus t=
0.165 MPa and locking stretch kL = 1.81. Please see the details in SI text.
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